PMC:1283364 / 48153-62158 JSON TXT

Annnotations TAB JSON ListView MergeView

craft-sa-dev

Id	Subject	Object	Predicate	Lexical cue
T10541	11-13	PRP	denotes	We
T10542	14-21	VBP	denotes	present
T10543	22-23	DT	denotes	a
T10544	34-39	NN	denotes	model
T10545	24-27	JJ	denotes	new
T10546	28-33	NN	denotes	mouse
T10547	40-43	IN	denotes	for
T10548	44-46	NN	denotes	AD
T10549	47-51	WDT	denotes	that
T10550	56-64	VBN	denotes	designed
T10551	52-55	VBD	denotes	was
T10552	65-67	TO	denotes	to
T10553	68-72	VB	denotes	test
T10554	73-76	DT	denotes	the
T10555	77-89	NNS	denotes	consequences
T10556	90-92	IN	denotes	of
T10557	93-103	VBG	denotes	inhibiting
T10558	104-106	NN	denotes	Aβ
T10559	107-117	NN	denotes	production
T10560	118-123	IN	denotes	after
T10561	124-127	DT	denotes	the
T10562	128-133	NN	denotes	onset
T10563	134-136	IN	denotes	of
T10564	137-144	NN	denotes	amyloid
T10565	145-154	NN	denotes	pathology
T10566	154-155	.	denotes	.
T10567	155-310	sentence	denotes	New lines of transgenic mice were developed for this study that express high levels of APPswe/ind under the control of a tetracycline-responsive promoter.
T10568	156-159	JJ	denotes	New
T10569	160-165	NNS	denotes	lines
T10570	190-199	VBN	denotes	developed
T10571	166-168	IN	denotes	of
T10572	169-179	JJ	denotes	transgenic
T10573	180-184	NNS	denotes	mice
T10574	185-189	VBD	denotes	were
T10575	200-203	IN	denotes	for
T10576	204-208	DT	denotes	this
T10577	209-214	NN	denotes	study
T10578	215-219	WDT	denotes	that
T10579	220-227	VBP	denotes	express
T10580	228-232	JJ	denotes	high
T10581	233-239	NNS	denotes	levels
T10582	240-242	IN	denotes	of
T10583	243-249	NN	denotes	APPswe
T10584	250-253	NN	denotes	ind
T10585	249-250	HYPH	denotes	/
T10586	254-259	IN	denotes	under
T10587	260-263	DT	denotes	the
T10588	264-271	NN	denotes	control
T10589	272-274	IN	denotes	of
T10590	275-276	DT	denotes	a
T10591	301-309	NN	denotes	promoter
T10592	277-289	NN	denotes	tetracycline
T10593	290-300	JJ	denotes	responsive
T10594	289-290	HYPH	denotes	-
T10595	309-310	.	denotes	.
T10596	310-508	sentence	denotes	We demonstrate that treatment with dox suppresses steady-state levels of both APPswe/ind and its C-terminal fragments, indicating that the mutant proteins have a relatively short half-life in vivo.
T10597	311-313	PRP	denotes	We
T10598	314-325	VBP	denotes	demonstrate
T10599	326-330	IN	denotes	that
T10600	350-360	VBZ	denotes	suppresses
T10601	331-340	NN	denotes	treatment
T10602	341-345	IN	denotes	with
T10603	346-349	NN	denotes	dox
T10604	361-367	JJ	denotes	steady
T10605	368-373	NN	denotes	state
T10606	367-368	HYPH	denotes	-
T10607	374-380	NNS	denotes	levels
T10608	381-383	IN	denotes	of
T10609	384-388	CC	denotes	both
T10610	396-399	NN	denotes	ind
T10611	389-395	NN	denotes	APPswe
T10612	395-396	HYPH	denotes	/
T10613	400-403	CC	denotes	and
T10614	404-407	PRP$	denotes	its
T10615	419-428	NNS	denotes	fragments
T10616	408-409	NN	denotes	C
T10617	409-410	HYPH	denotes	-
T10618	410-418	JJ	denotes	terminal
T10619	428-430	,	denotes	,
T10620	430-440	VBG	denotes	indicating
T10621	441-445	IN	denotes	that
T10622	466-470	VBP	denotes	have
T10623	446-449	DT	denotes	the
T10624	457-465	NN	denotes	proteins
T10625	450-456	NN	denotes	mutant
T10626	471-472	DT	denotes	a
T10627	495-499	NN	denotes	life
T10628	473-483	RB	denotes	relatively
T10629	484-489	JJ	denotes	short
T10630	490-494	NN	denotes	half
T10631	494-495	HYPH	denotes	-
T10632	500-502	FW	denotes	in
T10633	503-507	FW	denotes	vivo
T10634	507-508	.	denotes	.
T10635	508-688	sentence	denotes	Transgenic expression of APPswe/ind and consequent overproduction of Aβ42 cause early-onset amyloid deposition in untreated mice, in which deposits appear as early as 2 mo of age.
T10636	509-519	JJ	denotes	Transgenic
T10637	520-530	NN	denotes	expression
T10638	583-588	VBP	denotes	cause
T10639	531-533	IN	denotes	of
T10640	534-540	NN	denotes	APPswe
T10641	541-544	NN	denotes	ind
T10642	540-541	HYPH	denotes	/
T10643	545-548	CC	denotes	and
T10644	549-559	JJ	denotes	consequent
T10645	560-574	NN	denotes	overproduction
T10646	575-577	IN	denotes	of
T10647	578-582	NN	denotes	Aβ42
T10648	589-594	JJ	denotes	early
T10649	595-600	NN	denotes	onset
T10650	594-595	HYPH	denotes	-
T10651	609-619	NN	denotes	deposition
T10652	601-608	NN	denotes	amyloid
T10653	620-622	IN	denotes	in
T10654	623-632	JJ	denotes	untreated
T10655	633-637	NNS	denotes	mice
T10656	637-639	,	denotes	,
T10657	639-641	IN	denotes	in
T10658	657-663	VBP	denotes	appear
T10659	642-647	WDT	denotes	which
T10660	648-656	NNS	denotes	deposits
T10661	664-666	RB	denotes	as
T10662	667-672	RB	denotes	early
T10663	673-675	IN	denotes	as
T10664	676-677	CD	denotes	2
T10665	678-680	NN	denotes	mo
T10666	681-683	IN	denotes	of
T10667	684-687	NN	denotes	age
T10668	687-688	.	denotes	.
T10669	688-837	sentence	denotes	Amyloid burden worsens significantly with age, and by 9 mo, the hippocampus and cortex of untreated mice are largely filled with aggregated peptide.
T10670	689-696	NN	denotes	Amyloid
T10671	697-703	NN	denotes	burden
T10672	704-711	VBZ	denotes	worsens
T10673	712-725	RB	denotes	significantly
T10674	726-730	IN	denotes	with
T10675	731-734	NN	denotes	age
T10676	734-736	,	denotes	,
T10677	736-739	CC	denotes	and
T10678	740-742	IN	denotes	by
T10679	806-812	VBN	denotes	filled
T10680	743-744	CD	denotes	9
T10681	745-747	NN	denotes	mo
T10682	747-749	,	denotes	,
T10683	749-752	DT	denotes	the
T10684	753-764	NN	denotes	hippocampus
T10685	765-768	CC	denotes	and
T10686	769-775	NN	denotes	cortex
T10687	776-778	IN	denotes	of
T10688	779-788	JJ	denotes	untreated
T10689	789-793	NNS	denotes	mice
T10690	794-797	VBP	denotes	are
T10691	798-805	RB	denotes	largely
T10692	813-817	IN	denotes	with
T10693	818-828	VBN	denotes	aggregated
T10694	829-836	NN	denotes	peptide
T10695	836-837	.	denotes	.
T10696	837-950	sentence	denotes	We find that suppression of transgenic APP by more than 95% abruptly halts the progression of amyloid pathology.
T10697	838-840	PRP	denotes	We
T10698	841-845	VBP	denotes	find
T10699	846-850	IN	denotes	that
T10700	907-912	VBZ	denotes	halts
T10701	851-862	NN	denotes	suppression
T10702	863-865	IN	denotes	of
T10703	866-876	JJ	denotes	transgenic
T10704	877-880	NN	denotes	APP
T10705	881-883	IN	denotes	by
T10706	884-888	JJR	denotes	more
T10707	894-896	CD	denotes	95
T10708	889-893	IN	denotes	than
T10709	896-897	NN	denotes	%
T10710	898-906	RB	denotes	abruptly
T10711	913-916	DT	denotes	the
T10712	917-928	NN	denotes	progression
T10713	929-931	IN	denotes	of
T10714	932-939	NN	denotes	amyloid
T10715	940-949	NN	denotes	pathology
T10716	949-950	.	denotes	.
T10717	950-1143	sentence	denotes	Importantly, this outcome occurs in animals already harboring considerable amyloid pathology, a situation similar to what might be expected in patients to be treated with secretase inhibitors.
T10718	951-962	RB	denotes	Importantly
T10719	977-983	VBZ	denotes	occurs
T10720	962-964	,	denotes	,
T10721	964-968	DT	denotes	this
T10722	969-976	NN	denotes	outcome
T10723	984-986	IN	denotes	in
T10724	987-994	NNS	denotes	animals
T10725	995-1002	RB	denotes	already
T10726	1003-1012	VBG	denotes	harboring
T10727	1013-1025	JJ	denotes	considerable
T10728	1034-1043	NN	denotes	pathology
T10729	1026-1033	NN	denotes	amyloid
T10730	1043-1045	,	denotes	,
T10731	1045-1046	DT	denotes	a
T10732	1047-1056	NN	denotes	situation
T10733	1057-1064	JJ	denotes	similar
T10734	1065-1067	IN	denotes	to
T10735	1068-1072	WP	denotes	what
T10736	1082-1090	VBN	denotes	expected
T10737	1073-1078	MD	denotes	might
T10738	1079-1081	VB	denotes	be
T10739	1091-1093	IN	denotes	in
T10740	1094-1102	NNS	denotes	patients
T10741	1103-1105	TO	denotes	to
T10742	1109-1116	VBN	denotes	treated
T10743	1106-1108	VB	denotes	be
T10744	1117-1121	IN	denotes	with
T10745	1122-1131	NN	denotes	secretase
T10746	1132-1142	NNS	denotes	inhibitors
T10747	1142-1143	.	denotes	.
T10748	1143-1316	sentence	denotes	Somewhat unexpectedly, we observe no appreciable clearance of deposited amyloid even following periods of transgene suppression equal to the time taken for plaques to form.
T10749	1144-1152	RB	denotes	Somewhat
T10750	1153-1165	RB	denotes	unexpectedly
T10751	1170-1177	VBP	denotes	observe
T10752	1165-1167	,	denotes	,
T10753	1167-1169	PRP	denotes	we
T10754	1178-1180	DT	denotes	no
T10755	1193-1202	NN	denotes	clearance
T10756	1181-1192	JJ	denotes	appreciable
T10757	1203-1205	IN	denotes	of
T10758	1206-1215	VBN	denotes	deposited
T10759	1216-1223	NN	denotes	amyloid
T10760	1224-1228	RB	denotes	even
T10761	1229-1238	VBG	denotes	following
T10762	1239-1246	NNS	denotes	periods
T10763	1247-1249	IN	denotes	of
T10764	1250-1259	NN	denotes	transgene
T10765	1260-1271	NN	denotes	suppression
T10766	1272-1277	JJ	denotes	equal
T10767	1278-1280	IN	denotes	to
T10768	1281-1284	DT	denotes	the
T10769	1285-1289	NN	denotes	time
T10770	1290-1295	VBN	denotes	taken
T10771	1296-1299	IN	denotes	for
T10772	1311-1315	VB	denotes	form
T10773	1300-1307	NNS	denotes	plaques
T10774	1308-1310	TO	denotes	to
T10775	1315-1316	.	denotes	.
T10776	1316-1534	sentence	denotes	This latter finding indicates that compared to other disease-associated protein aggregates such as mutant huntingtin, which clear in less than 3 mo [32], the disaggregation of extracellular amyloid is relatively slow.
T10777	1317-1321	DT	denotes	This
T10778	1329-1336	NN	denotes	finding
T10779	1322-1328	JJ	denotes	latter
T10780	1337-1346	VBZ	denotes	indicates
T10781	1347-1351	IN	denotes	that
T10782	1515-1517	VBZ	denotes	is
T10783	1352-1360	VBN	denotes	compared
T10784	1361-1363	IN	denotes	to
T10785	1364-1369	JJ	denotes	other
T10786	1397-1407	NNS	denotes	aggregates
T10787	1370-1377	NN	denotes	disease
T10788	1378-1388	VBN	denotes	associated
T10789	1377-1378	HYPH	denotes	-
T10790	1389-1396	NN	denotes	protein
T10791	1408-1412	JJ	denotes	such
T10792	1413-1415	IN	denotes	as
T10793	1416-1422	NN	denotes	mutant
T10794	1423-1433	NN	denotes	huntingtin
T10795	1433-1435	,	denotes	,
T10796	1435-1440	WDT	denotes	which
T10797	1441-1446	VBP	denotes	clear
T10798	1447-1449	IN	denotes	in
T10799	1450-1454	JJR	denotes	less
T10800	1460-1461	CD	denotes	3
T10801	1455-1459	IN	denotes	than
T10802	1462-1464	NN	denotes	mo
T10803	1465-1466	-LRB-	denotes	[
T10804	1466-1468	CD	denotes	32
T10805	1468-1469	-RRB-	denotes	]
T10806	1469-1471	,	denotes	,
T10807	1471-1474	DT	denotes	the
T10808	1475-1489	NN	denotes	disaggregation
T10809	1490-1492	IN	denotes	of
T10810	1493-1506	JJ	denotes	extracellular
T10811	1507-1514	NN	denotes	amyloid
T10812	1518-1528	RB	denotes	relatively
T10813	1529-1533	JJ	denotes	slow
T10814	1533-1534	.	denotes	.
T10815	1534-1705	sentence	denotes	Notably, pharmaceutical γ-secretase inhibitors published to date show less strict regulation of Aβ production following chronic administration than we have attained here.
T10816	1535-1542	RB	denotes	Notably
T10817	1600-1604	VBP	denotes	show
T10818	1542-1544	,	denotes	,
T10819	1544-1558	JJ	denotes	pharmaceutical
T10820	1571-1581	NNS	denotes	inhibitors
T10821	1559-1560	SYM	denotes	γ
T10822	1561-1570	NN	denotes	secretase
T10823	1560-1561	HYPH	denotes	-
T10824	1582-1591	VBN	denotes	published
T10825	1592-1594	IN	denotes	to
T10826	1595-1599	NN	denotes	date
T10827	1605-1609	RBR	denotes	less
T10828	1610-1616	JJ	denotes	strict
T10829	1617-1627	NN	denotes	regulation
T10830	1628-1630	IN	denotes	of
T10831	1631-1633	NN	denotes	Aβ
T10832	1634-1644	NN	denotes	production
T10833	1645-1654	VBG	denotes	following
T10834	1655-1662	JJ	denotes	chronic
T10835	1663-1677	NN	denotes	administration
T10836	1678-1682	IN	denotes	than
T10837	1691-1699	VBN	denotes	attained
T10838	1683-1685	PRP	denotes	we
T10839	1686-1690	VBP	denotes	have
T10840	1700-1704	RB	denotes	here
T10841	1704-1705	.	denotes	.
T10842	1705-1915	sentence	denotes	Two independent compounds tested in Tg2576 [33] and TgCRND8 [34] transgenic mice show no more than 85% suppression of Aβ40 levels, and where measured, even less suppression of Aβ42 (approximately 60%) [35,36].
T10843	1706-1709	CD	denotes	Two
T10844	1722-1731	NNS	denotes	compounds
T10845	1710-1721	JJ	denotes	independent
T10846	1787-1791	VBP	denotes	show
T10847	1732-1738	VBN	denotes	tested
T10848	1739-1741	IN	denotes	in
T10849	1742-1748	NN	denotes	Tg2576
T10850	1771-1781	JJ	denotes	transgenic
T10851	1749-1750	-LRB-	denotes	[
T10852	1750-1752	CD	denotes	33
T10853	1752-1753	-RRB-	denotes	]
T10854	1754-1757	CC	denotes	and
T10855	1758-1765	NN	denotes	TgCRND8
T10856	1766-1767	-LRB-	denotes	[
T10857	1767-1769	CD	denotes	34
T10858	1769-1770	-RRB-	denotes	]
T10859	1782-1786	NNS	denotes	mice
T10860	1792-1794	RB	denotes	no
T10861	1805-1807	CD	denotes	85
T10862	1795-1799	JJR	denotes	more
T10863	1800-1804	IN	denotes	than
T10864	1807-1808	NN	denotes	%
T10865	1809-1820	NN	denotes	suppression
T10866	1821-1823	IN	denotes	of
T10867	1824-1828	NN	denotes	Aβ40
T10868	1829-1835	NNS	denotes	levels
T10869	1835-1837	,	denotes	,
T10870	1837-1840	CC	denotes	and
T10871	1841-1846	WRB	denotes	where
T10872	1847-1855	VBN	denotes	measured
T10873	1867-1878	NN	denotes	suppression
T10874	1855-1857	,	denotes	,
T10875	1857-1861	RB	denotes	even
T10876	1862-1866	JJR	denotes	less
T10877	1879-1881	IN	denotes	of
T10878	1882-1886	NN	denotes	Aβ42
T10879	1887-1888	-LRB-	denotes	(
T10880	1904-1905	NN	denotes	%
T10881	1888-1901	RB	denotes	approximately
T10882	1902-1904	CD	denotes	60
T10883	1905-1906	-RRB-	denotes	)
T10884	1907-1908	-LRB-	denotes	[
T10885	1911-1913	CD	denotes	36
T10886	1908-1910	CD	denotes	35
T10887	1910-1911	,	denotes	,
T10888	1913-1914	-RRB-	denotes	]
T10889	1914-1915	.	denotes	.
T10890	1915-2187	sentence	denotes	Thus, even after accounting for the much higher APP expression levels in our mice than in the Tg2576 and TgCRND8 lines, we have achieved better absolute suppression of Aβ production with the tet-off system than is currently possible with published γ-secretase inhibitors.
T10891	1916-1920	RB	denotes	Thus
T10892	2044-2052	VBN	denotes	achieved
T10893	1920-1922	,	denotes	,
T10894	1922-1926	RB	denotes	even
T10895	1927-1932	IN	denotes	after
T10896	1933-1943	VBG	denotes	accounting
T10897	1944-1947	IN	denotes	for
T10898	1948-1951	DT	denotes	the
T10899	1979-1985	NNS	denotes	levels
T10900	1952-1956	RB	denotes	much
T10901	1957-1963	JJR	denotes	higher
T10902	1964-1967	NN	denotes	APP
T10903	1968-1978	NN	denotes	expression
T10904	1986-1988	IN	denotes	in
T10905	1989-1992	PRP$	denotes	our
T10906	1993-1997	NNS	denotes	mice
T10907	1998-2002	IN	denotes	than
T10908	2003-2005	IN	denotes	in
T10909	2006-2009	DT	denotes	the
T10910	2029-2034	NNS	denotes	lines
T10911	2010-2016	NN	denotes	Tg2576
T10912	2017-2020	CC	denotes	and
T10913	2021-2028	NN	denotes	TgCRND8
T10914	2034-2036	,	denotes	,
T10915	2036-2038	PRP	denotes	we
T10916	2039-2043	VBP	denotes	have
T10917	2053-2059	RBR	denotes	better
T10918	2069-2080	NN	denotes	suppression
T10919	2060-2068	JJ	denotes	absolute
T10920	2081-2083	IN	denotes	of
T10921	2084-2086	NN	denotes	Aβ
T10922	2087-2097	NN	denotes	production
T10923	2098-2102	IN	denotes	with
T10924	2103-2106	DT	denotes	the
T10925	2115-2121	NN	denotes	system
T10926	2107-2110	NN	denotes	tet
T10927	2111-2114	NN	denotes	off
T10928	2110-2111	HYPH	denotes	-
T10929	2122-2126	IN	denotes	than
T10930	2127-2129	VBZ	denotes	is
T10931	2130-2139	RB	denotes	currently
T10932	2140-2148	JJ	denotes	possible
T10933	2149-2153	IN	denotes	with
T10934	2154-2163	VBN	denotes	published
T10935	2176-2186	NNS	denotes	inhibitors
T10936	2164-2165	SYM	denotes	γ
T10937	2166-2175	NN	denotes	secretase
T10938	2165-2166	HYPH	denotes	-
T10939	2186-2187	.	denotes	.
T10940	2187-2419	sentence	denotes	Since even the most advanced future pharmaceutical agents are unlikely to attain more complete control of Aβ production than achieved here, this system provides a salient test of therapeutic intervention with Aβ-lowering compounds.
T10941	2188-2193	IN	denotes	Since
T10942	2246-2249	VBP	denotes	are
T10943	2194-2198	RB	denotes	even
T10944	2239-2245	NNS	denotes	agents
T10945	2199-2202	DT	denotes	the
T10946	2203-2207	RBS	denotes	most
T10947	2208-2216	JJ	denotes	advanced
T10948	2217-2223	JJ	denotes	future
T10949	2224-2238	JJ	denotes	pharmaceutical
T10950	2340-2348	VBZ	denotes	provides
T10951	2250-2258	JJ	denotes	unlikely
T10952	2259-2261	TO	denotes	to
T10953	2262-2268	VB	denotes	attain
T10954	2269-2273	RBR	denotes	more
T10955	2274-2282	JJ	denotes	complete
T10956	2283-2290	NN	denotes	control
T10957	2291-2293	IN	denotes	of
T10958	2294-2296	NN	denotes	Aβ
T10959	2297-2307	NN	denotes	production
T10960	2308-2312	IN	denotes	than
T10961	2313-2321	VBN	denotes	achieved
T10962	2322-2326	RB	denotes	here
T10963	2326-2328	,	denotes	,
T10964	2328-2332	DT	denotes	this
T10965	2333-2339	NN	denotes	system
T10966	2349-2350	DT	denotes	a
T10967	2359-2363	NN	denotes	test
T10968	2351-2358	JJ	denotes	salient
T10969	2364-2366	IN	denotes	of
T10970	2367-2378	JJ	denotes	therapeutic
T10971	2379-2391	NN	denotes	intervention
T10972	2392-2396	IN	denotes	with
T10973	2397-2399	NN	denotes	Aβ
T10974	2400-2408	VBG	denotes	lowering
T10975	2399-2400	HYPH	denotes	-
T10976	2409-2418	NNS	denotes	compounds
T10977	2418-2419	.	denotes	.
T10978	2419-2607	sentence	denotes	Although the progression of amyloid deposition was sharply arrested by this approach, we found that a substantial amyloid burden remained even after long periods of transgene suppression.
T10979	2420-2428	IN	denotes	Although
T10980	2479-2487	VBN	denotes	arrested
T10981	2429-2432	DT	denotes	the
T10982	2433-2444	NN	denotes	progression
T10983	2445-2447	IN	denotes	of
T10984	2448-2455	NN	denotes	amyloid
T10985	2456-2466	NN	denotes	deposition
T10986	2467-2470	VBD	denotes	was
T10987	2471-2478	RB	denotes	sharply
T10988	2509-2514	VBD	denotes	found
T10989	2488-2490	IN	denotes	by
T10990	2491-2495	DT	denotes	this
T10991	2496-2504	NN	denotes	approach
T10992	2504-2506	,	denotes	,
T10993	2506-2508	PRP	denotes	we
T10994	2515-2519	IN	denotes	that
T10995	2549-2557	VBD	denotes	remained
T10996	2520-2521	DT	denotes	a
T10997	2542-2548	NN	denotes	burden
T10998	2522-2533	JJ	denotes	substantial
T10999	2534-2541	NN	denotes	amyloid
T11000	2558-2562	RB	denotes	even
T11001	2563-2568	IN	denotes	after
T11002	2569-2573	JJ	denotes	long
T11003	2574-2581	NNS	denotes	periods
T11004	2582-2584	IN	denotes	of
T11005	2585-2594	NN	denotes	transgene
T11006	2595-2606	NN	denotes	suppression
T11007	2606-2607	.	denotes	.
T11008	2607-2766	sentence	denotes	We examined a small number of animals after 12 mo of dox treatment (beginning at 6 mo of age), and found that amyloid deposits were still relatively abundant.
T11009	2608-2610	PRP	denotes	We
T11010	2611-2619	VBD	denotes	examined
T11011	2620-2621	DT	denotes	a
T11012	2628-2634	NN	denotes	number
T11013	2622-2627	JJ	denotes	small
T11014	2635-2637	IN	denotes	of
T11015	2638-2645	NNS	denotes	animals
T11016	2646-2651	IN	denotes	after
T11017	2652-2654	CD	denotes	12
T11018	2655-2657	NN	denotes	mo
T11019	2658-2660	IN	denotes	of
T11020	2661-2664	NN	denotes	dox
T11021	2665-2674	NN	denotes	treatment
T11022	2675-2676	-LRB-	denotes	(
T11023	2676-2685	VBG	denotes	beginning
T11024	2686-2688	IN	denotes	at
T11025	2689-2690	CD	denotes	6
T11026	2691-2693	NN	denotes	mo
T11027	2694-2696	IN	denotes	of
T11028	2697-2700	NN	denotes	age
T11029	2700-2701	-RRB-	denotes	)
T11030	2701-2703	,	denotes	,
T11031	2703-2706	CC	denotes	and
T11032	2707-2712	VBD	denotes	found
T11033	2713-2717	IN	denotes	that
T11034	2735-2739	VBD	denotes	were
T11035	2718-2725	NN	denotes	amyloid
T11036	2726-2734	NNS	denotes	deposits
T11037	2740-2745	RB	denotes	still
T11038	2746-2756	RB	denotes	relatively
T11039	2757-2765	JJ	denotes	abundant
T11040	2765-2766	.	denotes	.
T11041	2766-2810	sentence	denotes	Longer-term treatments are now in progress.
T11042	2767-2773	JJ	denotes	Longer
T11043	2774-2778	NN	denotes	term
T11044	2773-2774	HYPH	denotes	-
T11045	2779-2789	NNS	denotes	treatments
T11046	2790-2793	VBP	denotes	are
T11047	2794-2797	RB	denotes	now
T11048	2798-2800	IN	denotes	in
T11049	2801-2809	NN	denotes	progress
T11050	2809-2810	.	denotes	.
T11051	2810-3113	sentence	denotes	At the latest treatment interval analyzed by ELISA, animals administered dox for 6 mo showed elevated levels of PBS-soluble Aβ (see Figure 5) that could be interpreted as an indication that the plaques are slowly releasing peptide (or oligomeric Aβ) into the soluble pool and might eventually dissolve.
T11052	2811-2813	IN	denotes	At
T11053	2897-2903	VBD	denotes	showed
T11054	2814-2817	DT	denotes	the
T11055	2835-2843	NN	denotes	interval
T11056	2818-2824	JJS	denotes	latest
T11057	2825-2834	NN	denotes	treatment
T11058	2844-2852	VBN	denotes	analyzed
T11059	2853-2855	IN	denotes	by
T11060	2856-2861	NN	denotes	ELISA
T11061	2861-2863	,	denotes	,
T11062	2863-2870	NNS	denotes	animals
T11063	2871-2883	VBN	denotes	administered
T11064	2884-2887	NN	denotes	dox
T11065	2888-2891	IN	denotes	for
T11066	2892-2893	CD	denotes	6
T11067	2894-2896	NN	denotes	mo
T11068	2904-2912	VBN	denotes	elevated
T11069	2913-2919	NNS	denotes	levels
T11070	2920-2922	IN	denotes	of
T11071	2923-2926	NN	denotes	PBS
T11072	2927-2934	JJ	denotes	soluble
T11073	2926-2927	HYPH	denotes	-
T11074	2935-2937	NN	denotes	Aβ
T11075	2938-2939	-LRB-	denotes	(
T11076	2939-2942	VB	denotes	see
T11077	2943-2949	NN	denotes	Figure
T11078	2950-2951	CD	denotes	5
T11079	2951-2952	-RRB-	denotes	)
T11080	2953-2957	WDT	denotes	that
T11081	2967-2978	VBN	denotes	interpreted
T11082	2958-2963	MD	denotes	could
T11083	2964-2966	VB	denotes	be
T11084	2979-2981	IN	denotes	as
T11085	2982-2984	DT	denotes	an
T11086	2985-2995	NN	denotes	indication
T11087	2996-3000	IN	denotes	that
T11088	3024-3033	VBG	denotes	releasing
T11089	3001-3004	DT	denotes	the
T11090	3005-3012	NNS	denotes	plaques
T11091	3013-3016	VBP	denotes	are
T11092	3017-3023	RB	denotes	slowly
T11093	3034-3041	NN	denotes	peptide
T11094	3042-3043	-LRB-	denotes	(
T11095	3043-3045	CC	denotes	or
T11096	3046-3056	JJ	denotes	oligomeric
T11097	3057-3059	NN	denotes	Aβ
T11098	3059-3060	-RRB-	denotes	)
T11099	3061-3065	IN	denotes	into
T11100	3066-3069	DT	denotes	the
T11101	3078-3082	NN	denotes	pool
T11102	3070-3077	JJ	denotes	soluble
T11103	3083-3086	CC	denotes	and
T11104	3087-3092	MD	denotes	might
T11105	3104-3112	VB	denotes	dissolve
T11106	3093-3103	RB	denotes	eventually
T11107	3112-3113	.	denotes	.
T11108	3113-3318	sentence	denotes	Whether inhibiting Aβ production longer than 6 (or 12) mo may ultimately result in clearance of amyloid is under investigation; unfortunately, the life span of the model eventually limits this experiment.
T11109	3114-3121	IN	denotes	Whether
T11110	3187-3193	VB	denotes	result
T11111	3122-3132	VBG	denotes	inhibiting
T11112	3133-3135	NN	denotes	Aβ
T11113	3136-3146	NN	denotes	production
T11114	3147-3153	RBR	denotes	longer
T11115	3154-3158	IN	denotes	than
T11116	3159-3160	CD	denotes	6
T11117	3169-3171	NN	denotes	mo
T11118	3161-3162	-LRB-	denotes	(
T11119	3162-3164	CC	denotes	or
T11120	3165-3167	CD	denotes	12
T11121	3167-3168	-RRB-	denotes	)
T11122	3172-3175	MD	denotes	may
T11123	3176-3186	RB	denotes	ultimately
T11124	3218-3220	VBZ	denotes	is
T11125	3194-3196	IN	denotes	in
T11126	3197-3206	NN	denotes	clearance
T11127	3207-3209	IN	denotes	of
T11128	3210-3217	NN	denotes	amyloid
T11129	3295-3301	VBZ	denotes	limits
T11130	3221-3226	IN	denotes	under
T11131	3227-3240	NN	denotes	investigation
T11132	3240-3241	:	denotes	;
T11133	3242-3255	RB	denotes	unfortunately
T11134	3255-3257	,	denotes	,
T11135	3257-3260	DT	denotes	the
T11136	3266-3270	NN	denotes	span
T11137	3261-3265	NN	denotes	life
T11138	3271-3273	IN	denotes	of
T11139	3274-3277	DT	denotes	the
T11140	3278-3283	NN	denotes	model
T11141	3284-3294	RB	denotes	eventually
T11142	3302-3306	DT	denotes	this
T11143	3307-3317	NN	denotes	experiment
T11144	3317-3318	.	denotes	.
T11145	3318-3442	sentence	denotes	Therapeutics used in humans will have considerably more time to act than is possible within the life span of rodent models.
T11146	3319-3331	NNS	denotes	Therapeutics
T11147	3352-3356	VB	denotes	have
T11148	3332-3336	VBN	denotes	used
T11149	3337-3339	IN	denotes	in
T11150	3340-3346	NNS	denotes	humans
T11151	3347-3351	MD	denotes	will
T11152	3357-3369	RB	denotes	considerably
T11153	3370-3374	JJR	denotes	more
T11154	3375-3379	NN	denotes	time
T11155	3380-3382	TO	denotes	to
T11156	3383-3386	VB	denotes	act
T11157	3387-3391	IN	denotes	than
T11158	3392-3394	VBZ	denotes	is
T11159	3395-3403	JJ	denotes	possible
T11160	3404-3410	IN	denotes	within
T11161	3411-3414	DT	denotes	the
T11162	3420-3424	NN	denotes	span
T11163	3415-3419	NN	denotes	life
T11164	3425-3427	IN	denotes	of
T11165	3428-3434	NN	denotes	rodent
T11166	3435-3441	NNS	denotes	models
T11167	3441-3442	.	denotes	.
T11168	3442-3532	sentence	denotes	Long-term treatments would certainly be possible and could be a key to effective therapy.
T11169	3443-3447	JJ	denotes	Long
T11170	3448-3452	NN	denotes	term
T11171	3447-3448	HYPH	denotes	-
T11172	3453-3463	NNS	denotes	treatments
T11173	3480-3482	VB	denotes	be
T11174	3464-3469	MD	denotes	would
T11175	3470-3479	RB	denotes	certainly
T11176	3483-3491	JJ	denotes	possible
T11177	3492-3495	CC	denotes	and
T11178	3496-3501	MD	denotes	could
T11179	3502-3504	VB	denotes	be
T11180	3505-3506	DT	denotes	a
T11181	3507-3510	NN	denotes	key
T11182	3511-3513	IN	denotes	to
T11183	3514-3523	JJ	denotes	effective
T11184	3524-3531	NN	denotes	therapy
T11185	3531-3532	.	denotes	.
T11186	3532-3829	sentence	denotes	Overall, however, we interpret our findings as evidence that AD therapies that significantly lower the production of Aβ (by either inhibiting secretase activity or inhibiting APP expression) may not quickly reverse preexisting pathology, but should effectively halt further deposition of amyloid.
T11187	3533-3540	RB	denotes	Overall
T11188	3554-3563	VBP	denotes	interpret
T11189	3540-3542	,	denotes	,
T11190	3542-3549	RB	denotes	however
T11191	3549-3551	,	denotes	,
T11192	3551-3553	PRP	denotes	we
T11193	3564-3567	PRP$	denotes	our
T11194	3568-3576	NNS	denotes	findings
T11195	3577-3579	IN	denotes	as
T11196	3580-3588	NN	denotes	evidence
T11197	3589-3593	IN	denotes	that
T11198	3740-3747	VB	denotes	reverse
T11199	3594-3596	NN	denotes	AD
T11200	3597-3606	NNS	denotes	therapies
T11201	3607-3611	WDT	denotes	that
T11202	3626-3631	VBP	denotes	lower
T11203	3612-3625	RB	denotes	significantly
T11204	3632-3635	DT	denotes	the
T11205	3636-3646	NN	denotes	production
T11206	3647-3649	IN	denotes	of
T11207	3650-3652	NN	denotes	Aβ
T11208	3653-3654	-LRB-	denotes	(
T11209	3654-3656	IN	denotes	by
T11210	3657-3663	CC	denotes	either
T11211	3664-3674	VBG	denotes	inhibiting
T11212	3675-3684	NN	denotes	secretase
T11213	3685-3693	NN	denotes	activity
T11214	3694-3696	CC	denotes	or
T11215	3697-3707	VBG	denotes	inhibiting
T11216	3708-3711	NN	denotes	APP
T11217	3712-3722	NN	denotes	expression
T11218	3722-3723	-RRB-	denotes	)
T11219	3724-3727	MD	denotes	may
T11220	3728-3731	RB	denotes	not
T11221	3732-3739	RB	denotes	quickly
T11222	3748-3759	JJ	denotes	preexisting
T11223	3760-3769	NN	denotes	pathology
T11224	3769-3771	,	denotes	,
T11225	3771-3774	CC	denotes	but
T11226	3775-3781	MD	denotes	should
T11227	3794-3798	VB	denotes	halt
T11228	3782-3793	RB	denotes	effectively
T11229	3799-3806	JJ	denotes	further
T11230	3807-3817	NN	denotes	deposition
T11231	3818-3820	IN	denotes	of
T11232	3821-3828	NN	denotes	amyloid
T11233	3828-3829	.	denotes	.
T11234	3829-4147	sentence	denotes	In interpreting our study, it should be remembered that the earliest plaques to appear in these mice, like other APP transgenics harboring the Swedish mutation [27], are predominantly fibrillar deposits, which may be less tractable than the diffuse aggregates thought to come first in the course of the human disease.
T11235	3830-3832	IN	denotes	In
T11236	3870-3880	VBN	denotes	remembered
T11237	3833-3845	VBG	denotes	interpreting
T11238	3846-3849	PRP$	denotes	our
T11239	3850-3855	NN	denotes	study
T11240	3855-3857	,	denotes	,
T11241	3857-3859	PRP	denotes	it
T11242	3860-3866	MD	denotes	should
T11243	3867-3869	VB	denotes	be
T11244	3881-3885	IN	denotes	that
T11245	3996-3999	VBP	denotes	are
T11246	3886-3889	DT	denotes	the
T11247	3899-3906	NNS	denotes	plaques
T11248	3890-3898	JJS	denotes	earliest
T11249	3907-3909	TO	denotes	to
T11250	3910-3916	VB	denotes	appear
T11251	3917-3919	IN	denotes	in
T11252	3920-3925	DT	denotes	these
T11253	3926-3930	NNS	denotes	mice
T11254	3930-3932	,	denotes	,
T11255	3932-3936	IN	denotes	like
T11256	3937-3942	JJ	denotes	other
T11257	3947-3958	NNS	denotes	transgenics
T11258	3943-3946	NN	denotes	APP
T11259	3959-3968	VBG	denotes	harboring
T11260	3969-3972	DT	denotes	the
T11261	3981-3989	NN	denotes	mutation
T11262	3973-3980	JJ	denotes	Swedish
T11263	3990-3991	-LRB-	denotes	[
T11264	3991-3993	CD	denotes	27
T11265	3993-3994	-RRB-	denotes	]
T11266	3994-3996	,	denotes	,
T11267	4000-4013	RB	denotes	predominantly
T11268	4014-4023	JJ	denotes	fibrillar
T11269	4024-4032	NNS	denotes	deposits
T11270	4032-4034	,	denotes	,
T11271	4034-4039	WDT	denotes	which
T11272	4044-4046	VB	denotes	be
T11273	4040-4043	MD	denotes	may
T11274	4047-4051	RBR	denotes	less
T11275	4052-4061	JJ	denotes	tractable
T11276	4062-4066	IN	denotes	than
T11277	4067-4070	DT	denotes	the
T11278	4079-4089	NNS	denotes	aggregates
T11279	4071-4078	JJ	denotes	diffuse
T11280	4090-4097	VBN	denotes	thought
T11281	4098-4100	TO	denotes	to
T11282	4101-4105	VB	denotes	come
T11283	4106-4111	RB	denotes	first
T11284	4112-4114	IN	denotes	in
T11285	4115-4118	DT	denotes	the
T11286	4119-4125	NN	denotes	course
T11287	4126-4128	IN	denotes	of
T11288	4129-4132	DT	denotes	the
T11289	4139-4146	NN	denotes	disease
T11290	4133-4138	JJ	denotes	human
T11291	4146-4147	.	denotes	.
T11292	4147-4308	sentence	denotes	However, our data suggest that once diffuse deposits are formed in these mice, they are no more easily cleared in our system than cored plaques (see Figure S4).
T11293	4148-4155	RB	denotes	However
T11294	4166-4173	VBP	denotes	suggest
T11295	4155-4157	,	denotes	,
T11296	4157-4160	PRP$	denotes	our
T11297	4161-4165	NNS	denotes	data
T11298	4174-4178	IN	denotes	that
T11299	4251-4258	VBN	denotes	cleared
T11300	4179-4183	IN	denotes	once
T11301	4205-4211	VBN	denotes	formed
T11302	4184-4191	JJ	denotes	diffuse
T11303	4192-4200	NNS	denotes	deposits
T11304	4201-4204	VBP	denotes	are
T11305	4212-4214	IN	denotes	in
T11306	4215-4220	DT	denotes	these
T11307	4221-4225	NNS	denotes	mice
T11308	4225-4227	,	denotes	,
T11309	4227-4231	PRP	denotes	they
T11310	4232-4235	VBP	denotes	are
T11311	4236-4238	RB	denotes	no
T11312	4239-4243	RBR	denotes	more
T11313	4244-4250	RB	denotes	easily
T11314	4259-4261	IN	denotes	in
T11315	4262-4265	PRP$	denotes	our
T11316	4266-4272	NN	denotes	system
T11317	4273-4277	IN	denotes	than
T11318	4278-4283	VBN	denotes	cored
T11319	4284-4291	NNS	denotes	plaques
T11320	4292-4293	-LRB-	denotes	(
T11321	4293-4296	VB	denotes	see
T11322	4297-4303	NN	denotes	Figure
T11323	4304-4306	NN	denotes	S4
T11324	4306-4307	-RRB-	denotes	)
T11325	4307-4308	.	denotes	.
T11326	4308-4484	sentence	denotes	An additional consideration we recognize is that a small amount of transgene expression continues in the presence of dox and that endogenous mouse Aβ continues to be produced.
T11327	4309-4311	DT	denotes	An
T11328	4323-4336	NN	denotes	consideration
T11329	4312-4322	JJ	denotes	additional
T11330	4350-4352	VBZ	denotes	is
T11331	4337-4339	PRP	denotes	we
T11332	4340-4349	VBP	denotes	recognize
T11333	4353-4357	IN	denotes	that
T11334	4397-4406	VBZ	denotes	continues
T11335	4358-4359	DT	denotes	a
T11336	4366-4372	NN	denotes	amount
T11337	4360-4365	JJ	denotes	small
T11338	4373-4375	IN	denotes	of
T11339	4376-4385	NN	denotes	transgene
T11340	4386-4396	NN	denotes	expression
T11341	4407-4409	IN	denotes	in
T11342	4410-4413	DT	denotes	the
T11343	4414-4422	NN	denotes	presence
T11344	4423-4425	IN	denotes	of
T11345	4426-4429	NN	denotes	dox
T11346	4430-4433	CC	denotes	and
T11347	4434-4438	IN	denotes	that
T11348	4459-4468	VBZ	denotes	continues
T11349	4439-4449	JJ	denotes	endogenous
T11350	4456-4458	NN	denotes	Aβ
T11351	4450-4455	NN	denotes	mouse
T11352	4469-4471	TO	denotes	to
T11353	4475-4483	VBN	denotes	produced
T11354	4472-4474	VB	denotes	be
T11355	4483-4484	.	denotes	.
T11356	4484-4629	sentence	denotes	It is possible that the combined low levels of endogenous mouse Aβ and nonsuppressed human peptide are sufficient to maintain existing deposits.
T11357	4485-4487	PRP	denotes	It
T11358	4488-4490	VBZ	denotes	is
T11359	4491-4499	JJ	denotes	possible
T11360	4500-4504	IN	denotes	that
T11361	4584-4587	VBP	denotes	are
T11362	4505-4508	DT	denotes	the
T11363	4522-4528	NNS	denotes	levels
T11364	4509-4517	VBN	denotes	combined
T11365	4518-4521	JJ	denotes	low
T11366	4529-4531	IN	denotes	of
T11367	4532-4542	JJ	denotes	endogenous
T11368	4549-4551	NN	denotes	Aβ
T11369	4543-4548	NN	denotes	mouse
T11370	4576-4583	NN	denotes	peptide
T11371	4552-4555	CC	denotes	and
T11372	4556-4569	JJ	denotes	nonsuppressed
T11373	4570-4575	JJ	denotes	human
T11374	4588-4598	JJ	denotes	sufficient
T11375	4599-4601	TO	denotes	to
T11376	4602-4610	VB	denotes	maintain
T11377	4611-4619	VBG	denotes	existing
T11378	4620-4628	NNS	denotes	deposits
T11379	4628-4629	.	denotes	.
T11380	4629-4834	sentence	denotes	However, these low levels of peptide are not sufficient to induce new amyloid formation, as CaMKIIα-tTA × tetAPPswe/ind mice raised on dox for up to a year do not develop amyloid lesions (data not shown).
T11381	4630-4637	RB	denotes	However
T11382	4667-4670	VBP	denotes	are
T11383	4637-4639	,	denotes	,
T11384	4639-4644	DT	denotes	these
T11385	4649-4655	NNS	denotes	levels
T11386	4645-4648	JJ	denotes	low
T11387	4656-4658	IN	denotes	of
T11388	4659-4666	NN	denotes	peptide
T11389	4671-4674	RB	denotes	not
T11390	4675-4685	JJ	denotes	sufficient
T11391	4686-4688	TO	denotes	to
T11392	4689-4695	VB	denotes	induce
T11393	4696-4699	JJ	denotes	new
T11394	4708-4717	NN	denotes	formation
T11395	4700-4707	NN	denotes	amyloid
T11396	4717-4719	,	denotes	,
T11397	4719-4721	IN	denotes	as
T11398	4793-4800	VB	denotes	develop
T11399	4722-4729	NN	denotes	CaMKIIα
T11400	4746-4749	NN	denotes	ind
T11401	4729-4730	HYPH	denotes	-
T11402	4730-4733	NN	denotes	tTA
T11403	4734-4735	SYM	denotes	×
T11404	4736-4745	NN	denotes	tetAPPswe
T11405	4745-4746	HYPH	denotes	/
T11406	4750-4754	NNS	denotes	mice
T11407	4755-4761	VBN	denotes	raised
T11408	4762-4764	IN	denotes	on
T11409	4765-4768	NN	denotes	dox
T11410	4769-4772	IN	denotes	for
T11411	4773-4775	IN	denotes	up
T11412	4779-4780	DT	denotes	a
T11413	4776-4778	IN	denotes	to
T11414	4781-4785	NN	denotes	year
T11415	4786-4788	VBP	denotes	do
T11416	4789-4792	RB	denotes	not
T11417	4801-4808	NN	denotes	amyloid
T11418	4809-4816	NNS	denotes	lesions
T11419	4817-4818	-LRB-	denotes	(
T11420	4827-4832	VBN	denotes	shown
T11421	4818-4822	NNS	denotes	data
T11422	4823-4826	RB	denotes	not
T11423	4832-4833	-RRB-	denotes	)
T11424	4833-4834	.	denotes	.
T11425	4834-5014	sentence	denotes	It is also clear that in this genetic system, we have raised the production of Aβ to levels not found in humans to accelerate pathology into an experimentally feasible time frame.
T11426	4835-4837	PRP	denotes	It
T11427	4838-4840	VBZ	denotes	is
T11428	4841-4845	RB	denotes	also
T11429	4846-4851	JJ	denotes	clear
T11430	4852-4856	IN	denotes	that
T11431	4889-4895	VBN	denotes	raised
T11432	4857-4859	IN	denotes	in
T11433	4860-4864	DT	denotes	this
T11434	4873-4879	NN	denotes	system
T11435	4865-4872	JJ	denotes	genetic
T11436	4879-4881	,	denotes	,
T11437	4881-4883	PRP	denotes	we
T11438	4884-4888	VBP	denotes	have
T11439	4896-4899	DT	denotes	the
T11440	4900-4910	NN	denotes	production
T11441	4911-4913	IN	denotes	of
T11442	4914-4916	NN	denotes	Aβ
T11443	4917-4919	IN	denotes	to
T11444	4920-4926	NNS	denotes	levels
T11445	4927-4930	RB	denotes	not
T11446	4931-4936	VBN	denotes	found
T11447	4937-4939	IN	denotes	in
T11448	4940-4946	NNS	denotes	humans
T11449	4947-4949	TO	denotes	to
T11450	4950-4960	VB	denotes	accelerate
T11451	4961-4970	NN	denotes	pathology
T11452	4971-4975	IN	denotes	into
T11453	4976-4978	DT	denotes	an
T11454	5008-5013	NN	denotes	frame
T11455	4979-4993	RB	denotes	experimentally
T11456	4994-5002	JJ	denotes	feasible
T11457	5003-5007	NN	denotes	time
T11458	5013-5014	.	denotes	.
T11459	5014-5273	sentence	denotes	This system allowed us to create an approximately 20-fold differential between APP/Aβ synthetic rates before and after treatment, yet the in vivo equilibrium between aggregated and disaggregated states of Aβ still favored the maintenance of amyloid deposits.
T11460	5015-5019	DT	denotes	This
T11461	5020-5026	NN	denotes	system
T11462	5027-5034	VBD	denotes	allowed
T11463	5229-5236	VBD	denotes	favored
T11464	5035-5037	PRP	denotes	us
T11465	5041-5047	VB	denotes	create
T11466	5038-5040	TO	denotes	to
T11467	5048-5050	DT	denotes	an
T11468	5073-5085	NN	denotes	differential
T11469	5051-5064	RB	denotes	approximately
T11470	5065-5072	JJ	denotes	20-fold
T11471	5086-5093	IN	denotes	between
T11472	5094-5097	NN	denotes	APP
T11473	5098-5100	NN	denotes	Aβ
T11474	5097-5098	HYPH	denotes	/
T11475	5111-5116	NNS	denotes	rates
T11476	5101-5110	JJ	denotes	synthetic
T11477	5117-5123	IN	denotes	before
T11478	5124-5127	CC	denotes	and
T11479	5128-5133	IN	denotes	after
T11480	5134-5143	NN	denotes	treatment
T11481	5143-5145	,	denotes	,
T11482	5145-5148	RB	denotes	yet
T11483	5149-5152	DT	denotes	the
T11484	5161-5172	NN	denotes	equilibrium
T11485	5153-5155	FW	denotes	in
T11486	5156-5160	FW	denotes	vivo
T11487	5173-5180	IN	denotes	between
T11488	5181-5191	VBN	denotes	aggregated
T11489	5210-5216	NNS	denotes	states
T11490	5192-5195	CC	denotes	and
T11491	5196-5209	VBN	denotes	disaggregated
T11492	5217-5219	IN	denotes	of
T11493	5220-5222	NN	denotes	Aβ
T11494	5223-5228	RB	denotes	still
T11495	5237-5240	DT	denotes	the
T11496	5241-5252	NN	denotes	maintenance
T11497	5253-5255	IN	denotes	of
T11498	5256-5263	NN	denotes	amyloid
T11499	5264-5272	NNS	denotes	deposits
T11500	5272-5273	.	denotes	.
T11501	5273-5414	sentence	denotes	In our opinion, it seems unlikely that amyloid deposits in human brain would be inherently any less stable than those formed in mouse brain.
T11502	5274-5276	IN	denotes	In
T11503	5293-5298	VBZ	denotes	seems
T11504	5277-5280	PRP$	denotes	our
T11505	5281-5288	NN	denotes	opinion
T11506	5288-5290	,	denotes	,
T11507	5290-5292	PRP	denotes	it
T11508	5299-5307	JJ	denotes	unlikely
T11509	5308-5312	IN	denotes	that
T11510	5351-5353	VB	denotes	be
T11511	5313-5320	NN	denotes	amyloid
T11512	5321-5329	NNS	denotes	deposits
T11513	5330-5332	IN	denotes	in
T11514	5333-5338	JJ	denotes	human
T11515	5339-5344	NN	denotes	brain
T11516	5345-5350	MD	denotes	would
T11517	5354-5364	RB	denotes	inherently
T11518	5365-5368	DT	denotes	any
T11519	5374-5380	JJ	denotes	stable
T11520	5369-5373	RBR	denotes	less
T11521	5381-5385	IN	denotes	than
T11522	5386-5391	DT	denotes	those
T11523	5392-5398	VBN	denotes	formed
T11524	5399-5401	IN	denotes	in
T11525	5402-5407	NN	denotes	mouse
T11526	5408-5413	NN	denotes	brain
T11527	5413-5414	.	denotes	.
T11528	5414-5554	sentence	denotes	However, the human brain may harbor clearance mechanisms not shared by mice that would allow more efficient removal of preexisting amyloid.
T11529	5415-5422	RB	denotes	However
T11530	5444-5450	VB	denotes	harbor
T11531	5422-5424	,	denotes	,
T11532	5424-5427	DT	denotes	the
T11533	5434-5439	NN	denotes	brain
T11534	5428-5433	JJ	denotes	human
T11535	5440-5443	MD	denotes	may
T11536	5451-5460	NN	denotes	clearance
T11537	5461-5471	NNS	denotes	mechanisms
T11538	5472-5475	RB	denotes	not
T11539	5476-5482	VBN	denotes	shared
T11540	5483-5485	IN	denotes	by
T11541	5486-5490	NNS	denotes	mice
T11542	5491-5495	WDT	denotes	that
T11543	5502-5507	VB	denotes	allow
T11544	5496-5501	MD	denotes	would
T11545	5508-5512	RBR	denotes	more
T11546	5513-5522	JJ	denotes	efficient
T11547	5523-5530	NN	denotes	removal
T11548	5531-5533	IN	denotes	of
T11549	5534-5545	VBG	denotes	preexisting
T11550	5546-5553	NN	denotes	amyloid
T11551	5553-5554	.	denotes	.
T11552	5554-5709	sentence	denotes	One potential mechanism by which amyloid may be more efficiently removed in the human disease than in the mouse models is through microglial phagocytosis.
T11553	5555-5558	CD	denotes	One
T11554	5569-5578	NN	denotes	mechanism
T11555	5559-5568	JJ	denotes	potential
T11556	5674-5676	VBZ	denotes	is
T11557	5579-5581	IN	denotes	by
T11558	5620-5627	VBN	denotes	removed
T11559	5582-5587	WDT	denotes	which
T11560	5588-5595	NN	denotes	amyloid
T11561	5596-5599	MD	denotes	may
T11562	5600-5602	VB	denotes	be
T11563	5603-5607	RBR	denotes	more
T11564	5608-5619	RB	denotes	efficiently
T11565	5628-5630	IN	denotes	in
T11566	5631-5634	DT	denotes	the
T11567	5641-5648	NN	denotes	disease
T11568	5635-5640	JJ	denotes	human
T11569	5649-5653	IN	denotes	than
T11570	5654-5656	IN	denotes	in
T11571	5657-5660	DT	denotes	the
T11572	5667-5673	NNS	denotes	models
T11573	5661-5666	NN	denotes	mouse
T11574	5677-5684	IN	denotes	through
T11575	5685-5695	JJ	denotes	microglial
T11576	5696-5708	NN	denotes	phagocytosis
T11577	5708-5709	.	denotes	.
T11578	5709-5850	sentence	denotes	Resident microglia in transgenic mouse models localize to tissue surrounding plaques but show little evidence of amyloid engulfment [37–40].
T11579	5710-5718	JJ	denotes	Resident
T11580	5719-5728	NNS	denotes	microglia
T11581	5756-5764	VBP	denotes	localize
T11582	5729-5731	IN	denotes	in
T11583	5732-5742	JJ	denotes	transgenic
T11584	5749-5755	NNS	denotes	models
T11585	5743-5748	NN	denotes	mouse
T11586	5765-5767	IN	denotes	to
T11587	5768-5774	NN	denotes	tissue
T11588	5775-5786	VBG	denotes	surrounding
T11589	5787-5794	NNS	denotes	plaques
T11590	5795-5798	CC	denotes	but
T11591	5799-5803	VBP	denotes	show
T11592	5804-5810	JJ	denotes	little
T11593	5811-5819	NN	denotes	evidence
T11594	5820-5822	IN	denotes	of
T11595	5823-5830	NN	denotes	amyloid
T11596	5831-5841	NN	denotes	engulfment
T11597	5842-5843	-LRB-	denotes	[
T11598	5843-5845	CD	denotes	37
T11599	5845-5846	SYM	denotes	–
T11600	5846-5848	CD	denotes	40
T11601	5848-5849	-RRB-	denotes	]
T11602	5849-5850	.	denotes	.
T11603	5850-6008	sentence	denotes	In contrast, microglia surrounding amyloid plaques in human brain show a much higher state of activation with greater expression of complement receptor [40].
T11604	5851-5853	IN	denotes	In
T11605	5917-5921	VBP	denotes	show
T11606	5854-5862	NN	denotes	contrast
T11607	5862-5864	,	denotes	,
T11608	5864-5873	NNS	denotes	microglia
T11609	5874-5885	VBG	denotes	surrounding
T11610	5886-5893	NN	denotes	amyloid
T11611	5894-5901	NNS	denotes	plaques
T11612	5902-5904	IN	denotes	in
T11613	5905-5910	JJ	denotes	human
T11614	5911-5916	NN	denotes	brain
T11615	5922-5923	DT	denotes	a
T11616	5936-5941	NN	denotes	state
T11617	5924-5928	RB	denotes	much
T11618	5929-5935	JJR	denotes	higher
T11619	5942-5944	IN	denotes	of
T11620	5945-5955	NN	denotes	activation
T11621	5956-5960	IN	denotes	with
T11622	5961-5968	JJR	denotes	greater
T11623	5969-5979	NN	denotes	expression
T11624	5980-5982	IN	denotes	of
T11625	5983-5993	NN	denotes	complement
T11626	5994-6002	NN	denotes	receptor
T11627	6003-6004	-LRB-	denotes	[
T11628	6004-6006	CD	denotes	40
T11629	6006-6007	-RRB-	denotes	]
T11630	6007-6008	.	denotes	.
T11631	6008-6121	sentence	denotes	Thus, the role of microglia in amyloid metabolism is minor in transgenic models compared to the human condition.
T11632	6009-6013	RB	denotes	Thus
T11633	6059-6061	VBZ	denotes	is
T11634	6013-6015	,	denotes	,
T11635	6015-6018	DT	denotes	the
T11636	6019-6023	NN	denotes	role
T11637	6024-6026	IN	denotes	of
T11638	6027-6036	NNS	denotes	microglia
T11639	6037-6039	IN	denotes	in
T11640	6040-6047	NN	denotes	amyloid
T11641	6048-6058	NN	denotes	metabolism
T11642	6062-6067	JJ	denotes	minor
T11643	6068-6070	IN	denotes	in
T11644	6071-6081	JJ	denotes	transgenic
T11645	6082-6088	NNS	denotes	models
T11646	6089-6097	VBN	denotes	compared
T11647	6098-6100	IN	denotes	to
T11648	6101-6104	DT	denotes	the
T11649	6111-6120	NN	denotes	condition
T11650	6105-6110	JJ	denotes	human
T11651	6120-6121	.	denotes	.
T11652	6121-6412	sentence	denotes	Somewhat paradoxically, several studies further demonstrate that treatment with anti-inflammatory drugs to reduce microglial activation actually lowers amyloid load in APP transgenic mice, suggesting a role for mouse microglia in the formation and maintenance of amyloid aggregates [41–43].
T11653	6122-6130	RB	denotes	Somewhat
T11654	6131-6144	RB	denotes	paradoxically
T11655	6170-6181	VBP	denotes	demonstrate
T11656	6144-6146	,	denotes	,
T11657	6146-6153	JJ	denotes	several
T11658	6154-6161	NNS	denotes	studies
T11659	6162-6169	RB	denotes	further
T11660	6182-6186	IN	denotes	that
T11661	6267-6273	VBZ	denotes	lowers
T11662	6187-6196	NN	denotes	treatment
T11663	6197-6201	IN	denotes	with
T11664	6202-6219	JJ	denotes	anti-inflammatory
T11665	6220-6225	NNS	denotes	drugs
T11666	6226-6228	TO	denotes	to
T11667	6229-6235	VB	denotes	reduce
T11668	6236-6246	JJ	denotes	microglial
T11669	6247-6257	NN	denotes	activation
T11670	6258-6266	RB	denotes	actually
T11671	6274-6281	NN	denotes	amyloid
T11672	6282-6286	NN	denotes	load
T11673	6287-6289	IN	denotes	in
T11674	6290-6293	NN	denotes	APP
T11675	6294-6304	JJ	denotes	transgenic
T11676	6305-6309	NNS	denotes	mice
T11677	6309-6311	,	denotes	,
T11678	6311-6321	VBG	denotes	suggesting
T11679	6322-6323	DT	denotes	a
T11680	6324-6328	NN	denotes	role
T11681	6329-6332	IN	denotes	for
T11682	6333-6338	NN	denotes	mouse
T11683	6339-6348	NNS	denotes	microglia
T11684	6349-6351	IN	denotes	in
T11685	6352-6355	DT	denotes	the
T11686	6356-6365	NN	denotes	formation
T11687	6366-6369	CC	denotes	and
T11688	6370-6381	NN	denotes	maintenance
T11689	6382-6384	IN	denotes	of
T11690	6385-6392	NN	denotes	amyloid
T11691	6393-6403	NNS	denotes	aggregates
T11692	6404-6405	-LRB-	denotes	[
T11693	6405-6407	CD	denotes	41
T11694	6407-6408	SYM	denotes	–
T11695	6408-6410	CD	denotes	43
T11696	6410-6411	-RRB-	denotes	]
T11697	6411-6412	.	denotes	.
T11698	6412-6548	sentence	denotes	However, this outcome may be alternatively explained by direct effects of many anti-inflammatory drugs on γ-secretase cleavage [44–47].
T11699	6413-6420	RB	denotes	However
T11700	6456-6465	VBN	denotes	explained
T11701	6420-6422	,	denotes	,
T11702	6422-6426	DT	denotes	this
T11703	6427-6434	NN	denotes	outcome
T11704	6435-6438	MD	denotes	may
T11705	6439-6441	VB	denotes	be
T11706	6442-6455	RB	denotes	alternatively
T11707	6466-6468	IN	denotes	by
T11708	6469-6475	JJ	denotes	direct
T11709	6476-6483	NNS	denotes	effects
T11710	6484-6486	IN	denotes	of
T11711	6487-6491	JJ	denotes	many
T11712	6510-6515	NNS	denotes	drugs
T11713	6492-6509	JJ	denotes	anti-inflammatory
T11714	6516-6518	IN	denotes	on
T11715	6519-6520	SYM	denotes	γ
T11716	6521-6530	NN	denotes	secretase
T11717	6520-6521	HYPH	denotes	-
T11718	6531-6539	NN	denotes	cleavage
T11719	6540-6541	-LRB-	denotes	[
T11720	6541-6543	CD	denotes	44
T11721	6543-6544	SYM	denotes	–
T11722	6544-6546	CD	denotes	47
T11723	6546-6547	-RRB-	denotes	]
T11724	6547-6548	.	denotes	.
T11725	6548-6839	sentence	denotes	Nonetheless, the role of microglia in both the human condition and the mouse models is poorly understood, and differences in microglial reactivity between the two could lead to significantly faster amyloid clearance in the brains of patients with AD than we observe in the tet-off APP mice.
T11726	6549-6560	RB	denotes	Nonetheless
T11727	6633-6635	VBZ	denotes	is
T11728	6560-6562	,	denotes	,
T11729	6562-6565	DT	denotes	the
T11730	6566-6570	NN	denotes	role
T11731	6571-6573	IN	denotes	of
T11732	6574-6583	NNS	denotes	microglia
T11733	6584-6586	IN	denotes	in
T11734	6587-6591	CC	denotes	both
T11735	6602-6611	NN	denotes	condition
T11736	6592-6595	DT	denotes	the
T11737	6596-6601	JJ	denotes	human
T11738	6612-6615	CC	denotes	and
T11739	6616-6619	DT	denotes	the
T11740	6626-6632	NNS	denotes	models
T11741	6620-6625	NN	denotes	mouse
T11742	6636-6642	RB	denotes	poorly
T11743	6643-6653	VBN	denotes	understood
T11744	6653-6655	,	denotes	,
T11745	6655-6658	CC	denotes	and
T11746	6659-6670	NNS	denotes	differences
T11747	6718-6722	VB	denotes	lead
T11748	6671-6673	IN	denotes	in
T11749	6674-6684	JJ	denotes	microglial
T11750	6685-6695	NN	denotes	reactivity
T11751	6696-6703	IN	denotes	between
T11752	6704-6707	DT	denotes	the
T11753	6708-6711	CD	denotes	two
T11754	6712-6717	MD	denotes	could
T11755	6723-6725	IN	denotes	to
T11756	6726-6739	RB	denotes	significantly
T11757	6740-6746	JJR	denotes	faster
T11758	6755-6764	NN	denotes	clearance
T11759	6747-6754	NN	denotes	amyloid
T11760	6765-6767	IN	denotes	in
T11761	6768-6771	DT	denotes	the
T11762	6772-6778	NNS	denotes	brains
T11763	6779-6781	IN	denotes	of
T11764	6782-6790	NNS	denotes	patients
T11765	6791-6795	IN	denotes	with
T11766	6796-6798	NN	denotes	AD
T11767	6799-6803	IN	denotes	than
T11768	6807-6814	VBP	denotes	observe
T11769	6804-6806	PRP	denotes	we
T11770	6815-6817	IN	denotes	in
T11771	6818-6821	DT	denotes	the
T11772	6834-6838	NNS	denotes	mice
T11773	6822-6825	NN	denotes	tet
T11774	6826-6829	NN	denotes	off
T11775	6825-6826	HYPH	denotes	-
T11776	6830-6833	NN	denotes	APP
T11777	6838-6839	.	denotes	.
T11778	6839-7038	sentence	denotes	Given the relatively minor role played by microglia in other mouse models of amyloidosis, we think it unlikely that these cells have influenced the rate of amyloid clearance in the tet-off APP mice.
T11779	6840-6845	VBN	denotes	Given
T11780	6933-6938	VBP	denotes	think
T11781	6846-6849	DT	denotes	the
T11782	6867-6871	NN	denotes	role
T11783	6850-6860	RB	denotes	relatively
T11784	6861-6866	JJ	denotes	minor
T11785	6872-6878	VBN	denotes	played
T11786	6879-6881	IN	denotes	by
T11787	6882-6891	NNS	denotes	microglia
T11788	6892-6894	IN	denotes	in
T11789	6895-6900	JJ	denotes	other
T11790	6907-6913	NNS	denotes	models
T11791	6901-6906	NN	denotes	mouse
T11792	6914-6916	IN	denotes	of
T11793	6917-6928	NN	denotes	amyloidosis
T11794	6928-6930	,	denotes	,
T11795	6930-6932	PRP	denotes	we
T11796	6939-6941	PRP	denotes	it
T11797	6942-6950	JJ	denotes	unlikely
T11798	6951-6955	IN	denotes	that
T11799	6973-6983	VBN	denotes	influenced
T11800	6956-6961	DT	denotes	these
T11801	6962-6967	NNS	denotes	cells
T11802	6968-6972	VBP	denotes	have
T11803	6984-6987	DT	denotes	the
T11804	6988-6992	NN	denotes	rate
T11805	6993-6995	IN	denotes	of
T11806	6996-7003	NN	denotes	amyloid
T11807	7004-7013	NN	denotes	clearance
T11808	7014-7016	IN	denotes	in
T11809	7017-7020	DT	denotes	the
T11810	7033-7037	NNS	denotes	mice
T11811	7021-7024	NN	denotes	tet
T11812	7025-7028	NN	denotes	off
T11813	7024-7025	HYPH	denotes	-
T11814	7029-7032	NN	denotes	APP
T11815	7037-7038	.	denotes	.
T11816	7038-7176	sentence	denotes	Even so, we considered the possibility that chronic dox treatment may have altered the activation state of microglia in our treated mice.
T11817	7039-7043	RB	denotes	Even
T11818	7044-7046	RB	denotes	so
T11819	7051-7061	VBD	denotes	considered
T11820	7046-7048	,	denotes	,
T11821	7048-7050	PRP	denotes	we
T11822	7062-7065	DT	denotes	the
T11823	7066-7077	NN	denotes	possibility
T11824	7078-7082	IN	denotes	that
T11825	7114-7121	VBN	denotes	altered
T11826	7083-7090	JJ	denotes	chronic
T11827	7095-7104	NN	denotes	treatment
T11828	7091-7094	NN	denotes	dox
T11829	7105-7108	MD	denotes	may
T11830	7109-7113	VB	denotes	have
T11831	7122-7125	DT	denotes	the
T11832	7137-7142	NN	denotes	state
T11833	7126-7136	NN	denotes	activation
T11834	7143-7145	IN	denotes	of
T11835	7146-7155	NNS	denotes	microglia
T11836	7156-7158	IN	denotes	in
T11837	7159-7162	PRP$	denotes	our
T11838	7171-7175	NNS	denotes	mice
T11839	7163-7170	VBN	denotes	treated
T11840	7175-7176	.	denotes	.
T11841	7176-7299	sentence	denotes	Dox is structurally similar to minocycline, a reported anti-inflammatory drug and inhibitor of microglial activation [48].
T11842	7177-7180	NN	denotes	Dox
T11843	7181-7183	VBZ	denotes	is
T11844	7184-7196	RB	denotes	structurally
T11845	7197-7204	JJ	denotes	similar
T11846	7205-7207	IN	denotes	to
T11847	7208-7219	NN	denotes	minocycline
T11848	7219-7221	,	denotes	,
T11849	7221-7222	DT	denotes	a
T11850	7250-7254	NN	denotes	drug
T11851	7223-7231	VBN	denotes	reported
T11852	7232-7249	JJ	denotes	anti-inflammatory
T11853	7255-7258	CC	denotes	and
T11854	7259-7268	NN	denotes	inhibitor
T11855	7269-7271	IN	denotes	of
T11856	7272-7282	JJ	denotes	microglial
T11857	7283-7293	NN	denotes	activation
T11858	7294-7295	-LRB-	denotes	[
T11859	7295-7297	CD	denotes	48
T11860	7297-7298	-RRB-	denotes	]
T11861	7298-7299	.	denotes	.
T11862	7299-7489	sentence	denotes	However, if dox does have anti-inflammatory activity, then, based on previous studies with other anti-inflammatories, we would have expected to find less amyloid in the dox-treated animals.
T11863	7300-7307	RB	denotes	However
T11864	7432-7440	VBN	denotes	expected
T11865	7307-7309	,	denotes	,
T11866	7309-7311	IN	denotes	if
T11867	7321-7325	VB	denotes	have
T11868	7312-7315	NN	denotes	dox
T11869	7316-7320	VBZ	denotes	does
T11870	7326-7343	JJ	denotes	anti-inflammatory
T11871	7344-7352	NN	denotes	activity
T11872	7352-7354	,	denotes	,
T11873	7354-7358	RB	denotes	then
T11874	7358-7360	,	denotes	,
T11875	7360-7365	VBN	denotes	based
T11876	7366-7368	IN	denotes	on
T11877	7369-7377	JJ	denotes	previous
T11878	7378-7385	NNS	denotes	studies
T11879	7386-7390	IN	denotes	with
T11880	7391-7396	JJ	denotes	other
T11881	7397-7416	NNS	denotes	anti-inflammatories
T11882	7416-7418	,	denotes	,
T11883	7418-7420	PRP	denotes	we
T11884	7421-7426	MD	denotes	would
T11885	7427-7431	VB	denotes	have
T11886	7441-7443	TO	denotes	to
T11887	7444-7448	VB	denotes	find
T11888	7449-7453	RBR	denotes	less
T11889	7454-7461	NN	denotes	amyloid
T11890	7462-7464	IN	denotes	in
T11891	7465-7468	DT	denotes	the
T11892	7481-7488	NNS	denotes	animals
T11893	7469-7472	NN	denotes	dox
T11894	7473-7480	VBN	denotes	treated
T11895	7472-7473	HYPH	denotes	-
T11896	7488-7489	.	denotes	.
T11897	7489-7521	sentence	denotes	Clearly, that was not the case.
T11898	7490-7497	RB	denotes	Clearly
T11899	7504-7507	VBD	denotes	was
T11900	7497-7499	,	denotes	,
T11901	7499-7503	DT	denotes	that
T11902	7508-7511	RB	denotes	not
T11903	7512-7515	DT	denotes	the
T11904	7516-7520	NN	denotes	case
T11905	7520-7521	.	denotes	.
T11906	7521-7815	sentence	denotes	While it is possible that dox acts in some other way to slow amyloid clearance, data from multiple studies demonstrate that microglial responses are normally weak in the mouse AD models [37–40], and thus it is doubtful that dox-mediated microglial inhibition affected the outcome of our study.
T11907	7522-7527	IN	denotes	While
T11908	7531-7533	VBZ	denotes	is
T11909	7528-7530	PRP	denotes	it
T11910	7629-7640	VBP	denotes	demonstrate
T11911	7534-7542	JJ	denotes	possible
T11912	7543-7547	IN	denotes	that
T11913	7552-7556	VBZ	denotes	acts
T11914	7548-7551	NN	denotes	dox
T11915	7557-7559	IN	denotes	in
T11916	7560-7564	DT	denotes	some
T11917	7571-7574	NN	denotes	way
T11918	7565-7570	JJ	denotes	other
T11919	7575-7577	TO	denotes	to
T11920	7578-7582	VB	denotes	slow
T11921	7583-7590	NN	denotes	amyloid
T11922	7591-7600	NN	denotes	clearance
T11923	7600-7602	,	denotes	,
T11924	7602-7606	NNS	denotes	data
T11925	7607-7611	IN	denotes	from
T11926	7612-7620	JJ	denotes	multiple
T11927	7621-7628	NNS	denotes	studies
T11928	7641-7645	IN	denotes	that
T11929	7667-7670	VBP	denotes	are
T11930	7646-7656	JJ	denotes	microglial
T11931	7657-7666	NNS	denotes	responses
T11932	7671-7679	RB	denotes	normally
T11933	7680-7684	JJ	denotes	weak
T11934	7685-7687	IN	denotes	in
T11935	7688-7691	DT	denotes	the
T11936	7701-7707	NNS	denotes	models
T11937	7692-7697	NN	denotes	mouse
T11938	7698-7700	NN	denotes	AD
T11939	7708-7709	-LRB-	denotes	[
T11940	7709-7711	CD	denotes	37
T11941	7711-7712	SYM	denotes	–
T11942	7712-7714	CD	denotes	40
T11943	7714-7715	-RRB-	denotes	]
T11944	7715-7717	,	denotes	,
T11945	7717-7720	CC	denotes	and
T11946	7721-7725	RB	denotes	thus
T11947	7729-7731	VBZ	denotes	is
T11948	7726-7728	PRP	denotes	it
T11949	7732-7740	JJ	denotes	doubtful
T11950	7741-7745	IN	denotes	that
T11951	7781-7789	VBD	denotes	affected
T11952	7746-7749	NN	denotes	dox
T11953	7750-7758	VBN	denotes	mediated
T11954	7749-7750	HYPH	denotes	-
T11955	7770-7780	NN	denotes	inhibition
T11956	7759-7769	JJ	denotes	microglial
T11957	7790-7793	DT	denotes	the
T11958	7794-7801	NN	denotes	outcome
T11959	7802-7804	IN	denotes	of
T11960	7805-7808	PRP$	denotes	our
T11961	7809-7814	NN	denotes	study
T11962	7814-7815	.	denotes	.
T11963	7815-7997	sentence	denotes	The persistence and stability of amyloid deposits in our system is unexpected given the speed with which Aβ aggregates are cleared in other mouse models of therapeutic intervention.
T11964	7816-7819	DT	denotes	The
T11965	7820-7831	NN	denotes	persistence
T11966	7880-7882	VBZ	denotes	is
T11967	7832-7835	CC	denotes	and
T11968	7836-7845	NN	denotes	stability
T11969	7846-7848	IN	denotes	of
T11970	7849-7856	NN	denotes	amyloid
T11971	7857-7865	NNS	denotes	deposits
T11972	7866-7868	IN	denotes	in
T11973	7869-7872	PRP$	denotes	our
T11974	7873-7879	NN	denotes	system
T11975	7883-7893	JJ	denotes	unexpected
T11976	7894-7899	VBN	denotes	given
T11977	7900-7903	DT	denotes	the
T11978	7904-7909	NN	denotes	speed
T11979	7910-7914	IN	denotes	with
T11980	7939-7946	VBN	denotes	cleared
T11981	7915-7920	WDT	denotes	which
T11982	7921-7923	NN	denotes	Aβ
T11983	7924-7934	NNS	denotes	aggregates
T11984	7935-7938	VBP	denotes	are
T11985	7947-7949	IN	denotes	in
T11986	7950-7955	JJ	denotes	other
T11987	7962-7968	NNS	denotes	models
T11988	7956-7961	NN	denotes	mouse
T11989	7969-7971	IN	denotes	of
T11990	7972-7983	JJ	denotes	therapeutic
T11991	7984-7996	NN	denotes	intervention
T11992	7996-7997	.	denotes	.
T11993	7997-8141	sentence	denotes	Anti-Aβ antibodies injected directly into the brain have been shown to eliminate amyloid deposits in as little as 1 wk after treatment [49–51].
T11994	7998-8005	JJ	denotes	Anti-Aβ
T11995	8006-8016	NNS	denotes	antibodies
T11996	8060-8065	VBN	denotes	shown
T11997	8017-8025	VBN	denotes	injected
T11998	8026-8034	RB	denotes	directly
T11999	8035-8039	IN	denotes	into
T12000	8040-8043	DT	denotes	the
T12001	8044-8049	NN	denotes	brain
T12002	8050-8054	VBP	denotes	have
T12003	8055-8059	VBN	denotes	been
T12004	8066-8068	TO	denotes	to
T12005	8069-8078	VB	denotes	eliminate
T12006	8079-8086	NN	denotes	amyloid
T12007	8087-8095	NNS	denotes	deposits
T12008	8096-8098	IN	denotes	in
T12009	8099-8101	RB	denotes	as
T12010	8112-8113	CD	denotes	1
T12011	8102-8108	JJ	denotes	little
T12012	8109-8111	IN	denotes	as
T12013	8114-8116	NN	denotes	wk
T12014	8117-8122	IN	denotes	after
T12015	8123-8132	NN	denotes	treatment
T12016	8133-8134	-LRB-	denotes	[
T12017	8134-8136	CD	denotes	49
T12018	8136-8137	SYM	denotes	–
T12019	8137-8139	CD	denotes	51
T12020	8139-8140	-RRB-	denotes	]
T12021	8140-8141	.	denotes	.
T12022	8141-8358	sentence	denotes	Peripheral antibody injection decreases amyloid load more broadly, and although it does not appear to act as quickly as local injection, can significantly reduce amyloid load within 2 mo of initial treatment [52,53].
T12023	8142-8152	JJ	denotes	Peripheral
T12024	8162-8171	NN	denotes	injection
T12025	8153-8161	NN	denotes	antibody
T12026	8172-8181	VBZ	denotes	decreases
T12027	8182-8189	NN	denotes	amyloid
T12028	8190-8194	NN	denotes	load
T12029	8195-8199	RBR	denotes	more
T12030	8200-8207	RB	denotes	broadly
T12031	8207-8209	,	denotes	,
T12032	8209-8212	CC	denotes	and
T12033	8213-8221	IN	denotes	although
T12034	8234-8240	VB	denotes	appear
T12035	8222-8224	PRP	denotes	it
T12036	8225-8229	VBZ	denotes	does
T12037	8230-8233	RB	denotes	not
T12038	8297-8303	VB	denotes	reduce
T12039	8241-8243	TO	denotes	to
T12040	8244-8247	VB	denotes	act
T12041	8248-8250	RB	denotes	as
T12042	8251-8258	RB	denotes	quickly
T12043	8259-8261	IN	denotes	as
T12044	8262-8267	JJ	denotes	local
T12045	8268-8277	NN	denotes	injection
T12046	8277-8279	,	denotes	,
T12047	8279-8282	MD	denotes	can
T12048	8283-8296	RB	denotes	significantly
T12049	8304-8311	NN	denotes	amyloid
T12050	8312-8316	NN	denotes	load
T12051	8317-8323	IN	denotes	within
T12052	8324-8325	CD	denotes	2
T12053	8326-8328	NN	denotes	mo
T12054	8329-8331	IN	denotes	of
T12055	8332-8339	JJ	denotes	initial
T12056	8340-8349	NN	denotes	treatment
T12057	8350-8351	-LRB-	denotes	[
T12058	8354-8356	CD	denotes	53
T12059	8351-8353	CD	denotes	52
T12060	8353-8354	,	denotes	,
T12061	8356-8357	-RRB-	denotes	]
T12062	8357-8358	.	denotes	.
T12063	8358-8527	sentence	denotes	More recently, an alternative approach has shown that lentiviral transfer of neprilysin can also reduce the number of aggregates in the area of the injection site [54].
T12064	8359-8363	RBR	denotes	More
T12065	8364-8372	RB	denotes	recently
T12066	8402-8407	VBN	denotes	shown
T12067	8372-8374	,	denotes	,
T12068	8374-8376	DT	denotes	an
T12069	8389-8397	NN	denotes	approach
T12070	8377-8388	JJ	denotes	alternative
T12071	8398-8401	VBZ	denotes	has
T12072	8408-8412	IN	denotes	that
T12073	8456-8462	VB	denotes	reduce
T12074	8413-8423	JJ	denotes	lentiviral
T12075	8424-8432	NN	denotes	transfer
T12076	8433-8435	IN	denotes	of
T12077	8436-8446	NN	denotes	neprilysin
T12078	8447-8450	MD	denotes	can
T12079	8451-8455	RB	denotes	also
T12080	8463-8466	DT	denotes	the
T12081	8467-8473	NN	denotes	number
T12082	8474-8476	IN	denotes	of
T12083	8477-8487	NNS	denotes	aggregates
T12084	8488-8490	IN	denotes	in
T12085	8491-8494	DT	denotes	the
T12086	8495-8499	NN	denotes	area
T12087	8500-8502	IN	denotes	of
T12088	8503-8506	DT	denotes	the
T12089	8517-8521	NN	denotes	site
T12090	8507-8516	NN	denotes	injection
T12091	8522-8523	-LRB-	denotes	[
T12092	8523-8525	CD	denotes	54
T12093	8525-8526	-RRB-	denotes	]
T12094	8526-8527	.	denotes	.
T12095	8527-8737	sentence	denotes	Careful study of the mechanism behind several of the antibody-mediated therapies has suggested that activated microglia play an important role in the removal of fibrillar plaques after immunization [50,52,55].
T12096	8528-8535	JJ	denotes	Careful
T12097	8536-8541	NN	denotes	study
T12098	8613-8622	VBN	denotes	suggested
T12099	8542-8544	IN	denotes	of
T12100	8545-8548	DT	denotes	the
T12101	8549-8558	NN	denotes	mechanism
T12102	8559-8565	IN	denotes	behind
T12103	8566-8573	JJ	denotes	several
T12104	8574-8576	IN	denotes	of
T12105	8577-8580	DT	denotes	the
T12106	8599-8608	NNS	denotes	therapies
T12107	8581-8589	NN	denotes	antibody
T12108	8590-8598	VBN	denotes	mediated
T12109	8589-8590	HYPH	denotes	-
T12110	8609-8612	VBZ	denotes	has
T12111	8623-8627	IN	denotes	that
T12112	8648-8652	VBP	denotes	play
T12113	8628-8637	VBN	denotes	activated
T12114	8638-8647	NNS	denotes	microglia
T12115	8653-8655	DT	denotes	an
T12116	8666-8670	NN	denotes	role
T12117	8656-8665	JJ	denotes	important
T12118	8671-8673	IN	denotes	in
T12119	8674-8677	DT	denotes	the
T12120	8678-8685	NN	denotes	removal
T12121	8686-8688	IN	denotes	of
T12122	8689-8698	JJ	denotes	fibrillar
T12123	8699-8706	NNS	denotes	plaques
T12124	8707-8712	IN	denotes	after
T12125	8713-8725	NN	denotes	immunization
T12126	8726-8727	-LRB-	denotes	[
T12127	8733-8735	CD	denotes	55
T12128	8727-8729	CD	denotes	50
T12129	8729-8730	,	denotes	,
T12130	8730-8732	CD	denotes	52
T12131	8732-8733	,	denotes	,
T12132	8735-8736	-RRB-	denotes	]
T12133	8736-8737	.	denotes	.
T12134	8737-8982	sentence	denotes	However, it has been noted that deletion of the Fc receptor (the primary receptor for microglial opsinization of antibody–antigen complexes) in APP transgenic mouse models has no impact on the effectiveness of antibody-mediated therapy [56,57].
T12135	8738-8745	RB	denotes	However
T12136	8759-8764	VBN	denotes	noted
T12137	8745-8747	,	denotes	,
T12138	8747-8749	PRP	denotes	it
T12139	8750-8753	VBZ	denotes	has
T12140	8754-8758	VBN	denotes	been
T12141	8765-8769	IN	denotes	that
T12142	8910-8913	VBZ	denotes	has
T12143	8770-8778	NN	denotes	deletion
T12144	8779-8781	IN	denotes	of
T12145	8782-8785	DT	denotes	the
T12146	8789-8797	NN	denotes	receptor
T12147	8786-8788	NN	denotes	Fc
T12148	8798-8799	-LRB-	denotes	(
T12149	8799-8802	DT	denotes	the
T12150	8811-8819	NN	denotes	receptor
T12151	8803-8810	JJ	denotes	primary
T12152	8820-8823	IN	denotes	for
T12153	8824-8834	JJ	denotes	microglial
T12154	8835-8847	NN	denotes	opsinization
T12155	8848-8850	IN	denotes	of
T12156	8851-8859	NN	denotes	antibody
T12157	8860-8867	NN	denotes	antigen
T12158	8859-8860	HYPH	denotes	–
T12159	8868-8877	NNS	denotes	complexes
T12160	8877-8878	-RRB-	denotes	)
T12161	8879-8881	IN	denotes	in
T12162	8882-8885	NN	denotes	APP
T12163	8886-8896	JJ	denotes	transgenic
T12164	8903-8909	NNS	denotes	models
T12165	8897-8902	NN	denotes	mouse
T12166	8914-8916	DT	denotes	no
T12167	8917-8923	NN	denotes	impact
T12168	8924-8926	IN	denotes	on
T12169	8927-8930	DT	denotes	the
T12170	8931-8944	NN	denotes	effectiveness
T12171	8945-8947	IN	denotes	of
T12172	8948-8956	NN	denotes	antibody
T12173	8957-8965	VBN	denotes	mediated
T12174	8956-8957	HYPH	denotes	-
T12175	8966-8973	NN	denotes	therapy
T12176	8974-8975	-LRB-	denotes	[
T12177	8978-8980	CD	denotes	57
T12178	8975-8977	CD	denotes	56
T12179	8977-8978	,	denotes	,
T12180	8980-8981	-RRB-	denotes	]
T12181	8981-8982	.	denotes	.
T12182	8982-9253	sentence	denotes	It is, nevertheless, possible that lack of microglia activation is the major difference between the slow clearance described here, where no perturbation of the immune system is expected, and the rapid clearance described in studies involving antibody or viral injection.
T12183	8983-8985	PRP	denotes	It
T12184	8986-8988	VBZ	denotes	is
T12185	8988-8990	,	denotes	,
T12186	8990-9002	RB	denotes	nevertheless
T12187	9002-9004	,	denotes	,
T12188	9004-9012	JJ	denotes	possible
T12189	9013-9017	IN	denotes	that
T12190	9047-9049	VBZ	denotes	is
T12191	9018-9022	NN	denotes	lack
T12192	9023-9025	IN	denotes	of
T12193	9026-9035	NNS	denotes	microglia
T12194	9036-9046	NN	denotes	activation
T12195	9050-9053	DT	denotes	the
T12196	9060-9070	NN	denotes	difference
T12197	9054-9059	JJ	denotes	major
T12198	9071-9078	IN	denotes	between
T12199	9079-9082	DT	denotes	the
T12200	9088-9097	NN	denotes	clearance
T12201	9083-9087	JJ	denotes	slow
T12202	9098-9107	VBN	denotes	described
T12203	9108-9112	RB	denotes	here
T12204	9112-9114	,	denotes	,
T12205	9114-9119	WRB	denotes	where
T12206	9160-9168	VBN	denotes	expected
T12207	9120-9122	DT	denotes	no
T12208	9123-9135	NN	denotes	perturbation
T12209	9136-9138	IN	denotes	of
T12210	9139-9142	DT	denotes	the
T12211	9150-9156	NN	denotes	system
T12212	9143-9149	JJ	denotes	immune
T12213	9157-9159	VBZ	denotes	is
T12214	9168-9170	,	denotes	,
T12215	9170-9173	CC	denotes	and
T12216	9174-9177	DT	denotes	the
T12217	9184-9193	NN	denotes	clearance
T12218	9178-9183	JJ	denotes	rapid
T12219	9194-9203	VBN	denotes	described
T12220	9204-9206	IN	denotes	in
T12221	9207-9214	NNS	denotes	studies
T12222	9215-9224	VBG	denotes	involving
T12223	9225-9233	NN	denotes	antibody
T12224	9243-9252	NN	denotes	injection
T12225	9234-9236	CC	denotes	or
T12226	9237-9242	JJ	denotes	viral
T12227	9252-9253	.	denotes	.
T12228	9253-9534	sentence	denotes	In isolation, mild activation of microglia by injection damage or opsinization may not be adequate to induce substantial phagocytosis, but when combined with an Aβ-lowering agent, such as neprilysin or Aβ-targeted antibodies, the two may work in concert to clear peptide deposits.
T12229	9254-9256	IN	denotes	In
T12230	9341-9343	VB	denotes	be
T12231	9257-9266	NN	denotes	isolation
T12232	9266-9268	,	denotes	,
T12233	9268-9272	JJ	denotes	mild
T12234	9273-9283	NN	denotes	activation
T12235	9284-9286	IN	denotes	of
T12236	9287-9296	NNS	denotes	microglia
T12237	9297-9299	IN	denotes	by
T12238	9300-9309	NN	denotes	injection
T12239	9310-9316	NN	denotes	damage
T12240	9317-9319	CC	denotes	or
T12241	9320-9332	NN	denotes	opsinization
T12242	9333-9336	MD	denotes	may
T12243	9337-9340	RB	denotes	not
T12244	9344-9352	JJ	denotes	adequate
T12245	9353-9355	TO	denotes	to
T12246	9356-9362	VB	denotes	induce
T12247	9363-9374	JJ	denotes	substantial
T12248	9375-9387	NN	denotes	phagocytosis
T12249	9387-9389	,	denotes	,
T12250	9389-9392	CC	denotes	but
T12251	9393-9397	WRB	denotes	when
T12252	9398-9406	VBN	denotes	combined
T12253	9492-9496	VB	denotes	work
T12254	9407-9411	IN	denotes	with
T12255	9412-9414	DT	denotes	an
T12256	9427-9432	NN	denotes	agent
T12257	9415-9417	NN	denotes	Aβ
T12258	9418-9426	VBG	denotes	lowering
T12259	9417-9418	HYPH	denotes	-
T12260	9432-9434	,	denotes	,
T12261	9434-9438	JJ	denotes	such
T12262	9439-9441	IN	denotes	as
T12263	9442-9452	NN	denotes	neprilysin
T12264	9459-9467	VBN	denotes	targeted
T12265	9453-9455	CC	denotes	or
T12266	9456-9458	NN	denotes	Aβ
T12267	9458-9459	HYPH	denotes	-
T12268	9468-9478	NNS	denotes	antibodies
T12269	9478-9480	,	denotes	,
T12270	9480-9483	DT	denotes	the
T12271	9484-9487	CD	denotes	two
T12272	9488-9491	MD	denotes	may
T12273	9497-9499	IN	denotes	in
T12274	9500-9507	NN	denotes	concert
T12275	9508-9510	TO	denotes	to
T12276	9511-9516	VB	denotes	clear
T12277	9517-9524	NN	denotes	peptide
T12278	9525-9533	NNS	denotes	deposits
T12279	9533-9534	.	denotes	.
T12280	9534-9765	sentence	denotes	Consistent with this hypothesis, strong activation of microglia through transgenic expression of TGFβ [58] or central injection of lipopolysaccharide [59,60] can by itself substantially reduce plaque burden in APP transgenic mice.
T12281	9535-9545	JJ	denotes	Consistent
T12282	9721-9727	VB	denotes	reduce
T12283	9546-9550	IN	denotes	with
T12284	9551-9555	DT	denotes	this
T12285	9556-9566	NN	denotes	hypothesis
T12286	9566-9568	,	denotes	,
T12287	9568-9574	JJ	denotes	strong
T12288	9575-9585	NN	denotes	activation
T12289	9586-9588	IN	denotes	of
T12290	9589-9598	NNS	denotes	microglia
T12291	9599-9606	IN	denotes	through
T12292	9607-9617	JJ	denotes	transgenic
T12293	9618-9628	NN	denotes	expression
T12294	9629-9631	IN	denotes	of
T12295	9632-9636	NN	denotes	TGFβ
T12296	9637-9638	-LRB-	denotes	[
T12297	9638-9640	CD	denotes	58
T12298	9640-9641	-RRB-	denotes	]
T12299	9642-9644	CC	denotes	or
T12300	9645-9652	JJ	denotes	central
T12301	9653-9662	NN	denotes	injection
T12302	9663-9665	IN	denotes	of
T12303	9666-9684	NN	denotes	lipopolysaccharide
T12304	9685-9686	-LRB-	denotes	[
T12305	9689-9691	CD	denotes	60
T12306	9686-9688	CD	denotes	59
T12307	9688-9689	,	denotes	,
T12308	9691-9692	-RRB-	denotes	]
T12309	9693-9696	MD	denotes	can
T12310	9697-9699	IN	denotes	by
T12311	9700-9706	PRP	denotes	itself
T12312	9707-9720	RB	denotes	substantially
T12313	9728-9734	NN	denotes	plaque
T12314	9735-9741	NN	denotes	burden
T12315	9742-9744	IN	denotes	in
T12316	9745-9748	NN	denotes	APP
T12317	9749-9759	JJ	denotes	transgenic
T12318	9760-9764	NNS	denotes	mice
T12319	9764-9765	.	denotes	.
T12320	9765-10019	sentence	denotes	But in the case of acute antibody- and/or injury-mediated activation, once the inflammation has passed, and the antibody and bound peptide have been cleared and degraded, the remaining Aβ quickly reaggregates and amyloid pathology is reestablished [49].
T12321	9766-9769	CC	denotes	But
T12322	9962-9974	VBZ	denotes	reaggregates
T12323	9770-9772	IN	denotes	in
T12324	9773-9776	DT	denotes	the
T12325	9777-9781	NN	denotes	case
T12326	9782-9784	IN	denotes	of
T12327	9785-9790	JJ	denotes	acute
T12328	9824-9834	NN	denotes	activation
T12329	9791-9799	NN	denotes	antibody
T12330	9815-9823	VBN	denotes	mediated
T12331	9799-9800	HYPH	denotes	-
T12332	9801-9804	CC	denotes	and
T12333	9804-9805	HYPH	denotes	/
T12334	9805-9807	CC	denotes	or
T12335	9808-9814	NN	denotes	injury
T12336	9814-9815	HYPH	denotes	-
T12337	9834-9836	,	denotes	,
T12338	9836-9840	IN	denotes	once
T12339	9862-9868	VBN	denotes	passed
T12340	9841-9844	DT	denotes	the
T12341	9845-9857	NN	denotes	inflammation
T12342	9858-9861	VBZ	denotes	has
T12343	9868-9870	,	denotes	,
T12344	9870-9873	CC	denotes	and
T12345	9874-9877	DT	denotes	the
T12346	9878-9886	NN	denotes	antibody
T12347	9915-9922	VBN	denotes	cleared
T12348	9887-9890	CC	denotes	and
T12349	9891-9896	VBN	denotes	bound
T12350	9897-9904	NN	denotes	peptide
T12351	9905-9909	VBP	denotes	have
T12352	9910-9914	VBN	denotes	been
T12353	9923-9926	CC	denotes	and
T12354	9927-9935	VBN	denotes	degraded
T12355	9935-9937	,	denotes	,
T12356	9937-9940	DT	denotes	the
T12357	9951-9953	NN	denotes	Aβ
T12358	9941-9950	VBG	denotes	remaining
T12359	9954-9961	RB	denotes	quickly
T12360	9975-9978	CC	denotes	and
T12361	9979-9986	NN	denotes	amyloid
T12362	9987-9996	NN	denotes	pathology
T12363	10000-10013	VBN	denotes	reestablished
T12364	9997-9999	VBZ	denotes	is
T12365	10014-10015	-LRB-	denotes	[
T12366	10015-10017	CD	denotes	49
T12367	10017-10018	-RRB-	denotes	]
T12368	10018-10019	.	denotes	.
T12369	10019-10197	sentence	denotes	This finding reinforces the notion that without continued stimulation, microglia in mouse models do not maintain the same level of sustained activation that may occur in humans.
T12370	10020-10024	DT	denotes	This
T12371	10025-10032	NN	denotes	finding
T12372	10033-10043	VBZ	denotes	reinforces
T12373	10044-10047	DT	denotes	the
T12374	10048-10054	NN	denotes	notion
T12375	10055-10059	IN	denotes	that
T12376	10124-10132	VB	denotes	maintain
T12377	10060-10067	IN	denotes	without
T12378	10068-10077	VBN	denotes	continued
T12379	10078-10089	NN	denotes	stimulation
T12380	10089-10091	,	denotes	,
T12381	10091-10100	NNS	denotes	microglia
T12382	10101-10103	IN	denotes	in
T12383	10104-10109	NN	denotes	mouse
T12384	10110-10116	NNS	denotes	models
T12385	10117-10119	VBP	denotes	do
T12386	10120-10123	RB	denotes	not
T12387	10133-10136	DT	denotes	the
T12388	10142-10147	NN	denotes	level
T12389	10137-10141	JJ	denotes	same
T12390	10148-10150	IN	denotes	of
T12391	10151-10160	VBN	denotes	sustained
T12392	10161-10171	NN	denotes	activation
T12393	10172-10176	WDT	denotes	that
T12394	10181-10186	VB	denotes	occur
T12395	10177-10180	MD	denotes	may
T12396	10187-10189	IN	denotes	in
T12397	10190-10196	NNS	denotes	humans
T12398	10196-10197	.	denotes	.
T12399	10197-10312	sentence	denotes	SantaCruz et al. recently published a study of mice that express P301L human tau via a similar vector system [61].
T12400	10198-10207	NNP	denotes	SantaCruz
T12401	10224-10233	VBD	denotes	published
T12402	10208-10210	FW	denotes	et
T12403	10211-10214	FW	denotes	al.
T12404	10215-10223	RB	denotes	recently
T12405	10234-10235	DT	denotes	a
T12406	10236-10241	NN	denotes	study
T12407	10242-10244	IN	denotes	of
T12408	10245-10249	NNS	denotes	mice
T12409	10250-10254	WDT	denotes	that
T12410	10255-10262	VBP	denotes	express
T12411	10263-10268	NN	denotes	P301L
T12412	10275-10278	NN	denotes	tau
T12413	10269-10274	JJ	denotes	human
T12414	10279-10282	IN	denotes	via
T12415	10283-10284	DT	denotes	a
T12416	10300-10306	NN	denotes	system
T12417	10285-10292	JJ	denotes	similar
T12418	10293-10299	NN	denotes	vector
T12419	10307-10308	-LRB-	denotes	[
T12420	10308-10310	CD	denotes	61
T12421	10310-10311	-RRB-	denotes	]
T12422	10311-10312	.	denotes	.
T12423	10312-10480	sentence	denotes	As in our tet-off APP mice, SantaCruz et al. found that tau neurofibrillary tangles, like amyloid plaques, are not cleared efficiently following transgene suppression.
T12424	10313-10315	IN	denotes	As
T12425	10358-10363	VBD	denotes	found
T12426	10316-10318	IN	denotes	in
T12427	10319-10322	PRP$	denotes	our
T12428	10335-10339	NNS	denotes	mice
T12429	10323-10326	NN	denotes	tet
T12430	10327-10330	NN	denotes	off
T12431	10326-10327	HYPH	denotes	-
T12432	10331-10334	NN	denotes	APP
T12433	10339-10341	,	denotes	,
T12434	10341-10350	NNP	denotes	SantaCruz
T12435	10351-10353	FW	denotes	et
T12436	10354-10357	FW	denotes	al.
T12437	10364-10368	IN	denotes	that
T12438	10428-10435	VBN	denotes	cleared
T12439	10369-10372	NN	denotes	tau
T12440	10389-10396	NNS	denotes	tangles
T12441	10373-10388	JJ	denotes	neurofibrillary
T12442	10396-10398	,	denotes	,
T12443	10398-10402	IN	denotes	like
T12444	10403-10410	NN	denotes	amyloid
T12445	10411-10418	NNS	denotes	plaques
T12446	10418-10420	,	denotes	,
T12447	10420-10423	VBP	denotes	are
T12448	10424-10427	RB	denotes	not
T12449	10436-10447	RB	denotes	efficiently
T12450	10448-10457	VBG	denotes	following
T12451	10458-10467	NN	denotes	transgene
T12452	10468-10479	NN	denotes	suppression
T12453	10479-10480	.	denotes	.
T12454	10480-10683	sentence	denotes	The lack of clearance in both models of AD pathology comes as a stark contrast to the rapid removal of protein aggregates found in similar tet-off mouse models of Huntington [32] and prion disease [62].
T12455	10481-10484	DT	denotes	The
T12456	10485-10489	NN	denotes	lack
T12457	10534-10539	VBZ	denotes	comes
T12458	10490-10492	IN	denotes	of
T12459	10493-10502	NN	denotes	clearance
T12460	10503-10505	IN	denotes	in
T12461	10506-10510	DT	denotes	both
T12462	10511-10517	NNS	denotes	models
T12463	10518-10520	IN	denotes	of
T12464	10521-10523	NN	denotes	AD
T12465	10524-10533	NN	denotes	pathology
T12466	10540-10542	IN	denotes	as
T12467	10543-10544	DT	denotes	a
T12468	10551-10559	NN	denotes	contrast
T12469	10545-10550	JJ	denotes	stark
T12470	10560-10562	IN	denotes	to
T12471	10563-10566	DT	denotes	the
T12472	10573-10580	NN	denotes	removal
T12473	10567-10572	JJ	denotes	rapid
T12474	10581-10583	IN	denotes	of
T12475	10584-10591	NN	denotes	protein
T12476	10592-10602	NNS	denotes	aggregates
T12477	10603-10608	VBN	denotes	found
T12478	10609-10611	IN	denotes	in
T12479	10612-10619	JJ	denotes	similar
T12480	10634-10640	NNS	denotes	models
T12481	10620-10623	NN	denotes	tet
T12482	10624-10627	NN	denotes	off
T12483	10623-10624	HYPH	denotes	-
T12484	10628-10633	NN	denotes	mouse
T12485	10641-10643	IN	denotes	of
T12486	10644-10654	NNP	denotes	Huntington
T12487	10670-10677	NN	denotes	disease
T12488	10655-10656	-LRB-	denotes	[
T12489	10656-10658	CD	denotes	32
T12490	10658-10659	-RRB-	denotes	]
T12491	10660-10663	CC	denotes	and
T12492	10664-10669	NN	denotes	prion
T12493	10678-10679	-LRB-	denotes	[
T12494	10679-10681	CD	denotes	62
T12495	10681-10682	-RRB-	denotes	]
T12496	10682-10683	.	denotes	.
T12497	10683-10845	sentence	denotes	In these cases, disrupting the input of new monomer to the system via dox-mediated transgene suppression led to relatively rapid clearance of protein aggregates.
T12498	10684-10686	IN	denotes	In
T12499	10789-10792	VBD	denotes	led
T12500	10687-10692	DT	denotes	these
T12501	10693-10698	NNS	denotes	cases
T12502	10698-10700	,	denotes	,
T12503	10700-10710	VBG	denotes	disrupting
T12504	10711-10714	DT	denotes	the
T12505	10715-10720	NN	denotes	input
T12506	10721-10723	IN	denotes	of
T12507	10724-10727	JJ	denotes	new
T12508	10728-10735	NN	denotes	monomer
T12509	10736-10738	IN	denotes	to
T12510	10739-10742	DT	denotes	the
T12511	10743-10749	NN	denotes	system
T12512	10750-10753	IN	denotes	via
T12513	10754-10757	NN	denotes	dox
T12514	10758-10766	VBN	denotes	mediated
T12515	10757-10758	HYPH	denotes	-
T12516	10777-10788	NN	denotes	suppression
T12517	10767-10776	NN	denotes	transgene
T12518	10793-10795	IN	denotes	to
T12519	10796-10806	RB	denotes	relatively
T12520	10807-10812	JJ	denotes	rapid
T12521	10813-10822	NN	denotes	clearance
T12522	10823-10825	IN	denotes	of
T12523	10826-10833	NN	denotes	protein
T12524	10834-10844	NNS	denotes	aggregates
T12525	10844-10845	.	denotes	.
T12526	10845-11000	sentence	denotes	By contrast, our study and that of SantaCruz et al. suggest that protein aggregates in AD may be more tenacious than in other neurodegenerative disorders.
T12527	10846-10848	IN	denotes	By
T12528	10898-10905	VBP	denotes	suggest
T12529	10849-10857	NN	denotes	contrast
T12530	10857-10859	,	denotes	,
T12531	10859-10862	PRP$	denotes	our
T12532	10863-10868	NN	denotes	study
T12533	10869-10872	CC	denotes	and
T12534	10873-10877	DT	denotes	that
T12535	10878-10880	IN	denotes	of
T12536	10881-10890	NNP	denotes	SantaCruz
T12537	10891-10893	FW	denotes	et
T12538	10894-10897	FW	denotes	al.
T12539	10906-10910	IN	denotes	that
T12540	10940-10942	VB	denotes	be
T12541	10911-10918	NN	denotes	protein
T12542	10919-10929	NNS	denotes	aggregates
T12543	10930-10932	IN	denotes	in
T12544	10933-10935	NN	denotes	AD
T12545	10936-10939	MD	denotes	may
T12546	10943-10947	RBR	denotes	more
T12547	10948-10957	JJ	denotes	tenacious
T12548	10958-10962	IN	denotes	than
T12549	10963-10965	IN	denotes	in
T12550	10966-10971	JJ	denotes	other
T12551	10990-10999	NNS	denotes	disorders
T12552	10972-10989	JJ	denotes	neurodegenerative
T12553	10999-11000	.	denotes	.
T12554	11000-11168	sentence	denotes	Perhaps once aggregated, Aβ and tau are either inherently more stable than other protein aggregates or more resistant to intra- and extracellular clearance mechanisms.
T12555	11001-11008	RB	denotes	Perhaps
T12556	11037-11040	VBP	denotes	are
T12557	11009-11013	IN	denotes	once
T12558	11014-11024	VBN	denotes	aggregated
T12559	11024-11026	,	denotes	,
T12560	11026-11028	NN	denotes	Aβ
T12561	11029-11032	CC	denotes	and
T12562	11033-11036	NN	denotes	tau
T12563	11041-11047	RB	denotes	either
T12564	11064-11070	JJ	denotes	stable
T12565	11048-11058	RB	denotes	inherently
T12566	11059-11063	RBR	denotes	more
T12567	11071-11075	IN	denotes	than
T12568	11076-11081	JJ	denotes	other
T12569	11090-11100	NNS	denotes	aggregates
T12570	11082-11089	NN	denotes	protein
T12571	11101-11103	CC	denotes	or
T12572	11104-11108	RBR	denotes	more
T12573	11109-11118	JJ	denotes	resistant
T12574	11119-11121	IN	denotes	to
T12575	11122-11127	AFX	denotes	intra
T12576	11133-11146	JJ	denotes	extracellular
T12577	11127-11128	HYPH	denotes	-
T12578	11129-11132	CC	denotes	and
T12579	11157-11167	NNS	denotes	mechanisms
T12580	11147-11156	NN	denotes	clearance
T12581	11167-11168	.	denotes	.
T12582	11168-11309	sentence	denotes	One question we were not able to address in this study is whether abrogating synthesis of new Aβ halts the progression of cognitive decline.
T12583	11169-11172	CD	denotes	One
T12584	11173-11181	NN	denotes	question
T12585	11224-11226	VBZ	denotes	is
T12586	11182-11184	PRP	denotes	we
T12587	11185-11189	VBD	denotes	were
T12588	11190-11193	RB	denotes	not
T12589	11194-11198	JJ	denotes	able
T12590	11199-11201	TO	denotes	to
T12591	11202-11209	VB	denotes	address
T12592	11210-11212	IN	denotes	in
T12593	11213-11217	DT	denotes	this
T12594	11218-11223	NN	denotes	study
T12595	11227-11234	IN	denotes	whether
T12596	11266-11271	VBZ	denotes	halts
T12597	11235-11245	VBG	denotes	abrogating
T12598	11246-11255	NN	denotes	synthesis
T12599	11256-11258	IN	denotes	of
T12600	11259-11262	JJ	denotes	new
T12601	11263-11265	NN	denotes	Aβ
T12602	11272-11275	DT	denotes	the
T12603	11276-11287	NN	denotes	progression
T12604	11288-11290	IN	denotes	of
T12605	11291-11300	JJ	denotes	cognitive
T12606	11301-11308	NN	denotes	decline
T12607	11308-11309	.	denotes	.
T12608	11309-11466	sentence	denotes	Studies from the tet-off tau mice suggest that protein clearance may in fact not be required for cognitive improvement following transgene suppression [61].
T12609	11310-11317	NNS	denotes	Studies
T12610	11344-11351	VBP	denotes	suggest
T12611	11318-11322	IN	denotes	from
T12612	11323-11326	DT	denotes	the
T12613	11339-11343	NNS	denotes	mice
T12614	11327-11330	NN	denotes	tet
T12615	11331-11334	NN	denotes	off
T12616	11330-11331	HYPH	denotes	-
T12617	11335-11338	NN	denotes	tau
T12618	11352-11356	IN	denotes	that
T12619	11394-11402	VBN	denotes	required
T12620	11357-11364	NN	denotes	protein
T12621	11365-11374	NN	denotes	clearance
T12622	11375-11378	MD	denotes	may
T12623	11379-11381	IN	denotes	in
T12624	11382-11386	NN	denotes	fact
T12625	11387-11390	RB	denotes	not
T12626	11391-11393	VB	denotes	be
T12627	11403-11406	IN	denotes	for
T12628	11407-11416	JJ	denotes	cognitive
T12629	11417-11428	NN	denotes	improvement
T12630	11429-11438	VBG	denotes	following
T12631	11439-11448	NN	denotes	transgene
T12632	11449-11460	NN	denotes	suppression
T12633	11461-11462	-LRB-	denotes	[
T12634	11462-11464	CD	denotes	61
T12635	11464-11465	-RRB-	denotes	]
T12636	11465-11466	.	denotes	.
T12637	11466-11662	sentence	denotes	At present, because of unexpected noncognitive behavioral abnormalities, it is not clear whether the tet-off APP mice can be used to address the same question in the context of amyloid pathology.
T12638	11467-11469	IN	denotes	At
T12639	11543-11545	VBZ	denotes	is
T12640	11470-11477	JJ	denotes	present
T12641	11477-11479	,	denotes	,
T12642	11479-11486	IN	denotes	because
T12643	11487-11489	IN	denotes	of
T12644	11490-11500	JJ	denotes	unexpected
T12645	11525-11538	NNS	denotes	abnormalities
T12646	11501-11513	JJ	denotes	noncognitive
T12647	11514-11524	JJ	denotes	behavioral
T12648	11538-11540	,	denotes	,
T12649	11540-11542	PRP	denotes	it
T12650	11546-11549	RB	denotes	not
T12651	11550-11555	JJ	denotes	clear
T12652	11556-11563	IN	denotes	whether
T12653	11592-11596	VBN	denotes	used
T12654	11564-11567	DT	denotes	the
T12655	11580-11584	NNS	denotes	mice
T12656	11568-11571	NN	denotes	tet
T12657	11572-11575	NN	denotes	off
T12658	11571-11572	HYPH	denotes	-
T12659	11576-11579	NN	denotes	APP
T12660	11585-11588	MD	denotes	can
T12661	11589-11591	VB	denotes	be
T12662	11597-11599	TO	denotes	to
T12663	11600-11607	VB	denotes	address
T12664	11608-11611	DT	denotes	the
T12665	11617-11625	NN	denotes	question
T12666	11612-11616	JJ	denotes	same
T12667	11626-11628	IN	denotes	in
T12668	11629-11632	DT	denotes	the
T12669	11633-11640	NN	denotes	context
T12670	11641-11643	IN	denotes	of
T12671	11644-11651	NN	denotes	amyloid
T12672	11652-11661	NN	denotes	pathology
T12673	11661-11662	.	denotes	.
T12674	11662-11814	sentence	denotes	Both lines of tTA/APP mice we studied here display extreme hyperactivity visible as cage circling and quantified by activity monitoring (see Figure 7).
T12675	11663-11667	DT	denotes	Both
T12676	11668-11673	NNS	denotes	lines
T12677	11706-11713	VBP	denotes	display
T12678	11674-11676	IN	denotes	of
T12679	11677-11680	NN	denotes	tTA
T12680	11681-11684	NN	denotes	APP
T12681	11680-11681	HYPH	denotes	/
T12682	11685-11689	NNS	denotes	mice
T12683	11690-11692	PRP	denotes	we
T12684	11693-11700	VBN	denotes	studied
T12685	11701-11705	RB	denotes	here
T12686	11714-11721	JJ	denotes	extreme
T12687	11722-11735	NN	denotes	hyperactivity
T12688	11736-11743	JJ	denotes	visible
T12689	11744-11746	IN	denotes	as
T12690	11747-11751	NN	denotes	cage
T12691	11752-11760	NN	denotes	circling
T12692	11761-11764	CC	denotes	and
T12693	11765-11775	VBN	denotes	quantified
T12694	11776-11778	IN	denotes	by
T12695	11779-11787	NN	denotes	activity
T12696	11788-11798	NN	denotes	monitoring
T12697	11799-11800	-LRB-	denotes	(
T12698	11800-11803	VB	denotes	see
T12699	11804-11810	NN	denotes	Figure
T12700	11811-11812	CD	denotes	7
T12701	11812-11813	-RRB-	denotes	)
T12702	11813-11814	.	denotes	.
T12703	11814-11958	sentence	denotes	Many of the double transgenic mice showed similar circular patterns of swimming near the edge of the tank when tested in the Morris water maze.
T12704	11815-11819	JJ	denotes	Many
T12705	11850-11856	VBD	denotes	showed
T12706	11820-11822	IN	denotes	of
T12707	11823-11826	DT	denotes	the
T12708	11845-11849	NNS	denotes	mice
T12709	11827-11833	JJ	denotes	double
T12710	11834-11844	JJ	denotes	transgenic
T12711	11857-11864	JJ	denotes	similar
T12712	11874-11882	NNS	denotes	patterns
T12713	11865-11873	JJ	denotes	circular
T12714	11883-11885	IN	denotes	of
T12715	11886-11894	NN	denotes	swimming
T12716	11895-11899	IN	denotes	near
T12717	11900-11903	DT	denotes	the
T12718	11904-11908	NN	denotes	edge
T12719	11909-11911	IN	denotes	of
T12720	11912-11915	DT	denotes	the
T12721	11916-11920	NN	denotes	tank
T12722	11921-11925	WRB	denotes	when
T12723	11926-11932	VBN	denotes	tested
T12724	11933-11935	IN	denotes	in
T12725	11936-11939	DT	denotes	the
T12726	11953-11957	NN	denotes	maze
T12727	11940-11946	NNP	denotes	Morris
T12728	11947-11952	NN	denotes	water
T12729	11957-11958	.	denotes	.
T12730	11958-12048	sentence	denotes	Expression of this phenotype makes standard tests of learning and memory uninterpretable.
T12731	11959-11969	NN	denotes	Expression
T12732	11988-11993	VBZ	denotes	makes
T12733	11970-11972	IN	denotes	of
T12734	11973-11977	DT	denotes	this
T12735	11978-11987	NN	denotes	phenotype
T12736	11994-12002	JJ	denotes	standard
T12737	12003-12008	NNS	denotes	tests
T12738	12032-12047	JJ	denotes	uninterpretable
T12739	12009-12011	IN	denotes	of
T12740	12012-12020	NN	denotes	learning
T12741	12021-12024	CC	denotes	and
T12742	12025-12031	NN	denotes	memory
T12743	12047-12048	.	denotes	.
T12744	12048-12181	sentence	denotes	Hyperactivity nonspecifically inhibits choice-driven changes in movement, the key element behind all cognitive behavioral paradigms.
T12745	12049-12062	NN	denotes	Hyperactivity
T12746	12079-12087	VBZ	denotes	inhibits
T12747	12063-12078	RB	denotes	nonspecifically
T12748	12088-12094	NN	denotes	choice
T12749	12095-12101	VBN	denotes	driven
T12750	12094-12095	HYPH	denotes	-
T12751	12102-12109	NNS	denotes	changes
T12752	12110-12112	IN	denotes	in
T12753	12113-12121	NN	denotes	movement
T12754	12121-12123	,	denotes	,
T12755	12123-12126	DT	denotes	the
T12756	12131-12138	NN	denotes	element
T12757	12127-12130	JJ	denotes	key
T12758	12139-12145	IN	denotes	behind
T12759	12146-12149	DT	denotes	all
T12760	12171-12180	NNS	denotes	paradigms
T12761	12150-12159	JJ	denotes	cognitive
T12762	12160-12170	JJ	denotes	behavioral
T12763	12180-12181	.	denotes	.
T12764	12181-12330	sentence	denotes	We are currently working to determine whether hyperactivity correlates with expression of the APPswe/ind holoprotein or its proteolytic derivatives.
T12765	12182-12184	PRP	denotes	We
T12766	12199-12206	VBG	denotes	working
T12767	12185-12188	VBP	denotes	are
T12768	12189-12198	RB	denotes	currently
T12769	12207-12209	TO	denotes	to
T12770	12210-12219	VB	denotes	determine
T12771	12220-12227	IN	denotes	whether
T12772	12242-12252	VBZ	denotes	correlates
T12773	12228-12241	NN	denotes	hyperactivity
T12774	12253-12257	IN	denotes	with
T12775	12258-12268	NN	denotes	expression
T12776	12269-12271	IN	denotes	of
T12777	12272-12275	DT	denotes	the
T12778	12287-12298	NN	denotes	holoprotein
T12779	12276-12282	NN	denotes	APPswe
T12780	12283-12286	NN	denotes	ind
T12781	12282-12283	HYPH	denotes	/
T12782	12299-12301	CC	denotes	or
T12783	12302-12305	PRP$	denotes	its
T12784	12318-12329	NNS	denotes	derivatives
T12785	12306-12317	JJ	denotes	proteolytic
T12786	12329-12330	.	denotes	.
T12787	12330-12486	sentence	denotes	Preliminary studies suggest that hyperactivity does not appear quickly when dox-reared mice are shifted to nonmedicated diets (J. L. J., unpublished data).
T12788	12331-12342	JJ	denotes	Preliminary
T12789	12343-12350	NNS	denotes	studies
T12790	12351-12358	VBP	denotes	suggest
T12791	12359-12363	IN	denotes	that
T12792	12387-12393	VB	denotes	appear
T12793	12364-12377	NN	denotes	hyperactivity
T12794	12378-12382	VBZ	denotes	does
T12795	12383-12386	RB	denotes	not
T12796	12394-12401	RB	denotes	quickly
T12797	12402-12406	WRB	denotes	when
T12798	12427-12434	VBN	denotes	shifted
T12799	12407-12410	NN	denotes	dox
T12800	12411-12417	VBN	denotes	reared
T12801	12410-12411	HYPH	denotes	-
T12802	12418-12422	NNS	denotes	mice
T12803	12423-12426	VBP	denotes	are
T12804	12435-12437	IN	denotes	to
T12805	12438-12450	JJ	denotes	nonmedicated
T12806	12451-12456	NNS	denotes	diets
T12807	12457-12458	-LRB-	denotes	(
T12808	12480-12484	NNS	denotes	data
T12809	12458-12460	NNP	denotes	J.
T12810	12464-12466	NNP	denotes	J.
T12811	12461-12463	NNP	denotes	L.
T12812	12466-12468	,	denotes	,
T12813	12468-12479	JJ	denotes	unpublished
T12814	12484-12485	-RRB-	denotes	)
T12815	12485-12486	.	denotes	.
T12816	12486-12652	sentence	denotes	These data may indicate that the neuroactive culprit is not immediately present after transgenic APP synthesis is initiated, but requires additional time to develop.
T12817	12487-12492	DT	denotes	These
T12818	12493-12497	NNS	denotes	data
T12819	12502-12510	VB	denotes	indicate
T12820	12498-12501	MD	denotes	may
T12821	12511-12515	IN	denotes	that
T12822	12540-12542	VBZ	denotes	is
T12823	12516-12519	DT	denotes	the
T12824	12532-12539	NN	denotes	culprit
T12825	12520-12531	JJ	denotes	neuroactive
T12826	12543-12546	RB	denotes	not
T12827	12547-12558	RB	denotes	immediately
T12828	12559-12566	JJ	denotes	present
T12829	12567-12572	IN	denotes	after
T12830	12601-12610	VBN	denotes	initiated
T12831	12573-12583	JJ	denotes	transgenic
T12832	12588-12597	NN	denotes	synthesis
T12833	12584-12587	NN	denotes	APP
T12834	12598-12600	VBZ	denotes	is
T12835	12610-12612	,	denotes	,
T12836	12612-12615	CC	denotes	but
T12837	12616-12624	VBZ	denotes	requires
T12838	12625-12635	JJ	denotes	additional
T12839	12636-12640	NN	denotes	time
T12840	12641-12643	TO	denotes	to
T12841	12644-12651	VB	denotes	develop
T12842	12651-12652	.	denotes	.
T12843	12652-12783	sentence	denotes	Alternatively, hyperactivity may be caused by neuronal alterations due to transgene expression during early postnatal development.
T12844	12653-12666	RB	denotes	Alternatively
T12845	12689-12695	VBN	denotes	caused
T12846	12666-12668	,	denotes	,
T12847	12668-12681	NN	denotes	hyperactivity
T12848	12682-12685	MD	denotes	may
T12849	12686-12688	VB	denotes	be
T12850	12696-12698	IN	denotes	by
T12851	12699-12707	JJ	denotes	neuronal
T12852	12708-12719	NNS	denotes	alterations
T12853	12720-12723	IN	denotes	due
T12854	12724-12726	IN	denotes	to
T12855	12727-12736	NN	denotes	transgene
T12856	12737-12747	NN	denotes	expression
T12857	12748-12754	IN	denotes	during
T12858	12755-12760	JJ	denotes	early
T12859	12761-12770	JJ	denotes	postnatal
T12860	12771-12782	NN	denotes	development
T12861	12782-12783	.	denotes	.
T12862	12783-12858	sentence	denotes	Further experiments are needed to distinguish between these possibilities.
T12863	12784-12791	JJ	denotes	Further
T12864	12792-12803	NNS	denotes	experiments
T12865	12808-12814	VBN	denotes	needed
T12866	12804-12807	VBP	denotes	are
T12867	12815-12817	TO	denotes	to
T12868	12818-12829	VB	denotes	distinguish
T12869	12830-12837	IN	denotes	between
T12870	12838-12843	DT	denotes	these
T12871	12844-12857	NNS	denotes	possibilities
T12872	12857-12858	.	denotes	.
T12873	12858-13018	sentence	denotes	In summary, we demonstrate that abrogating Aβ production halts the progression of pathologic changes in a transgenic mouse model of Alzheimer-type amyloidosis.
T12874	12859-12861	IN	denotes	In
T12875	12874-12885	VBP	denotes	demonstrate
T12876	12862-12869	NN	denotes	summary
T12877	12869-12871	,	denotes	,
T12878	12871-12873	PRP	denotes	we
T12879	12886-12890	IN	denotes	that
T12880	12916-12921	VBZ	denotes	halts
T12881	12891-12901	VBG	denotes	abrogating
T12882	12902-12904	NN	denotes	Aβ
T12883	12905-12915	NN	denotes	production
T12884	12922-12925	DT	denotes	the
T12885	12926-12937	NN	denotes	progression
T12886	12938-12940	IN	denotes	of
T12887	12941-12951	JJ	denotes	pathologic
T12888	12952-12959	NNS	denotes	changes
T12889	12960-12962	IN	denotes	in
T12890	12963-12964	DT	denotes	a
T12891	12982-12987	NN	denotes	model
T12892	12965-12975	JJ	denotes	transgenic
T12893	12976-12981	NN	denotes	mouse
T12894	12988-12990	IN	denotes	of
T12895	12991-13000	NNP	denotes	Alzheimer
T12896	13001-13005	NN	denotes	type
T12897	13000-13001	HYPH	denotes	-
T12898	13006-13017	NN	denotes	amyloidosis
T12899	13017-13018	.	denotes	.
T12900	13018-13153	sentence	denotes	However, despite dramatic reductions in Aβ synthesis, neuritic plaques are stable structures in vivo that do not quickly disaggregate.
T12901	13019-13026	RB	denotes	However
T12902	13090-13093	VBP	denotes	are
T12903	13026-13028	,	denotes	,
T12904	13028-13035	IN	denotes	despite
T12905	13036-13044	JJ	denotes	dramatic
T12906	13045-13055	NNS	denotes	reductions
T12907	13056-13058	IN	denotes	in
T12908	13059-13061	NN	denotes	Aβ
T12909	13062-13071	NN	denotes	synthesis
T12910	13071-13073	,	denotes	,
T12911	13073-13081	JJ	denotes	neuritic
T12912	13082-13089	NNS	denotes	plaques
T12913	13094-13100	JJ	denotes	stable
T12914	13101-13111	NNS	denotes	structures
T12915	13112-13114	FW	denotes	in
T12916	13115-13119	FW	denotes	vivo
T12917	13120-13124	WDT	denotes	that
T12918	13140-13152	VB	denotes	disaggregate
T12919	13125-13127	VBP	denotes	do
T12920	13128-13131	RB	denotes	not
T12921	13132-13139	RB	denotes	quickly
T12922	13152-13153	.	denotes	.
T12923	13153-13349	sentence	denotes	It is possible that a combination of therapies to limit Aβ production, increase Aβ degradation, and enhance phagocytosis of deposited amyloid may be required to reverse damage associated with AD.
T12924	13154-13156	PRP	denotes	It
T12925	13157-13159	VBZ	denotes	is
T12926	13160-13168	JJ	denotes	possible
T12927	13169-13173	IN	denotes	that
T12928	13303-13311	VBN	denotes	required
T12929	13174-13175	DT	denotes	a
T12930	13176-13187	NN	denotes	combination
T12931	13188-13190	IN	denotes	of
T12932	13191-13200	NNS	denotes	therapies
T12933	13201-13203	TO	denotes	to
T12934	13204-13209	VB	denotes	limit
T12935	13210-13212	NN	denotes	Aβ
T12936	13213-13223	NN	denotes	production
T12937	13223-13225	,	denotes	,
T12938	13225-13233	VB	denotes	increase
T12939	13234-13236	NN	denotes	Aβ
T12940	13237-13248	NN	denotes	degradation
T12941	13248-13250	,	denotes	,
T12942	13250-13253	CC	denotes	and
T12943	13254-13261	VBP	denotes	enhance
T12944	13262-13274	NN	denotes	phagocytosis
T12945	13275-13277	IN	denotes	of
T12946	13278-13287	VBN	denotes	deposited
T12947	13288-13295	NN	denotes	amyloid
T12948	13296-13299	MD	denotes	may
T12949	13300-13302	VB	denotes	be
T12950	13312-13314	TO	denotes	to
T12951	13315-13322	VB	denotes	reverse
T12952	13323-13329	NN	denotes	damage
T12953	13330-13340	VBN	denotes	associated
T12954	13341-13345	IN	denotes	with
T12955	13346-13348	NN	denotes	AD
T12956	13348-13349	.	denotes	.
T12957	13349-13531	sentence	denotes	However, if started early enough in the course of disease, secretase inhibitors alone could provide substantial benefit in slowing pathogenic processes linked to amyloid deposition.
T12958	13350-13357	RB	denotes	However
T12959	13442-13449	VB	denotes	provide
T12960	13357-13359	,	denotes	,
T12961	13359-13361	IN	denotes	if
T12962	13362-13369	VBN	denotes	started
T12963	13370-13375	RB	denotes	early
T12964	13376-13382	RB	denotes	enough
T12965	13383-13385	IN	denotes	in
T12966	13386-13389	DT	denotes	the
T12967	13390-13396	NN	denotes	course
T12968	13397-13399	IN	denotes	of
T12969	13400-13407	NN	denotes	disease
T12970	13407-13409	,	denotes	,
T12971	13409-13418	NN	denotes	secretase
T12972	13419-13429	NNS	denotes	inhibitors
T12973	13430-13435	RB	denotes	alone
T12974	13436-13441	MD	denotes	could
T12975	13450-13461	JJ	denotes	substantial
T12976	13462-13469	NN	denotes	benefit
T12977	13470-13472	IN	denotes	in
T12978	13473-13480	VBG	denotes	slowing
T12979	13481-13491	JJ	denotes	pathogenic
T12980	13492-13501	NNS	denotes	processes
T12981	13502-13508	VBN	denotes	linked
T12982	13509-13511	IN	denotes	to
T12983	13512-13519	NN	denotes	amyloid
T12984	13520-13530	NN	denotes	deposition
T12985	13530-13531	.	denotes	.
T12986	13531-13766	sentence	denotes	Even at later stages in the disease, the presence of substantial microglial activation in human AD [40] suggests that simply slowing the formation of new amyloid deposits may allow ongoing phagocytosis to diminish preexisting lesions.
T12987	13532-13536	RB	denotes	Even
T12988	13537-13539	IN	denotes	at
T12989	13636-13644	VBZ	denotes	suggests
T12990	13540-13545	JJR	denotes	later
T12991	13546-13552	NNS	denotes	stages
T12992	13553-13555	IN	denotes	in
T12993	13556-13559	DT	denotes	the
T12994	13560-13567	NN	denotes	disease
T12995	13567-13569	,	denotes	,
T12996	13569-13572	DT	denotes	the
T12997	13573-13581	NN	denotes	presence
T12998	13582-13584	IN	denotes	of
T12999	13585-13596	JJ	denotes	substantial
T13000	13608-13618	NN	denotes	activation
T13001	13597-13607	JJ	denotes	microglial
T13002	13619-13621	IN	denotes	in
T13003	13622-13627	JJ	denotes	human
T13004	13628-13630	NN	denotes	AD
T13005	13631-13632	-LRB-	denotes	[
T13006	13632-13634	CD	denotes	40
T13007	13634-13635	-RRB-	denotes	]
T13008	13645-13649	IN	denotes	that
T13009	13707-13712	VB	denotes	allow
T13010	13650-13656	RB	denotes	simply
T13011	13657-13664	VBG	denotes	slowing
T13012	13665-13668	DT	denotes	the
T13013	13669-13678	NN	denotes	formation
T13014	13679-13681	IN	denotes	of
T13015	13682-13685	JJ	denotes	new
T13016	13694-13702	NNS	denotes	deposits
T13017	13686-13693	NN	denotes	amyloid
T13018	13703-13706	MD	denotes	may
T13019	13713-13720	JJ	denotes	ongoing
T13020	13721-13733	NN	denotes	phagocytosis
T13021	13737-13745	VB	denotes	diminish
T13022	13734-13736	TO	denotes	to
T13023	13746-13757	JJ	denotes	preexisting
T13024	13758-13765	NNS	denotes	lesions
T13025	13765-13766	.	denotes	.
T13026	13766-14005	sentence	denotes	However, the development of safe and effective secretase inhibitors will ultimately be required to determine whether the human brain has the capacity to repair amyloid-associated damage of AD once the progression of pathology is arrested.
T13027	13767-13774	RB	denotes	However
T13028	13854-13862	VBN	denotes	required
T13029	13774-13776	,	denotes	,
T13030	13776-13779	DT	denotes	the
T13031	13780-13791	NN	denotes	development
T13032	13792-13794	IN	denotes	of
T13033	13795-13799	JJ	denotes	safe
T13034	13824-13834	NNS	denotes	inhibitors
T13035	13800-13803	CC	denotes	and
T13036	13804-13813	JJ	denotes	effective
T13037	13814-13823	NN	denotes	secretase
T13038	13835-13839	MD	denotes	will
T13039	13840-13850	RB	denotes	ultimately
T13040	13851-13853	VB	denotes	be
T13041	13863-13865	TO	denotes	to
T13042	13866-13875	VB	denotes	determine
T13043	13876-13883	IN	denotes	whether
T13044	13900-13903	VBZ	denotes	has
T13045	13884-13887	DT	denotes	the
T13046	13894-13899	NN	denotes	brain
T13047	13888-13893	JJ	denotes	human
T13048	13904-13907	DT	denotes	the
T13049	13908-13916	NN	denotes	capacity
T13050	13917-13919	TO	denotes	to
T13051	13920-13926	VB	denotes	repair
T13052	13927-13934	NN	denotes	amyloid
T13053	13935-13945	VBN	denotes	associated
T13054	13934-13935	HYPH	denotes	-
T13055	13946-13952	NN	denotes	damage
T13056	13953-13955	IN	denotes	of
T13057	13956-13958	NN	denotes	AD
T13058	13959-13963	IN	denotes	once
T13059	13996-14004	VBN	denotes	arrested
T13060	13964-13967	DT	denotes	the
T13061	13968-13979	NN	denotes	progression
T13062	13980-13982	IN	denotes	of
T13063	13983-13992	NN	denotes	pathology
T13064	13993-13995	VBZ	denotes	is
T13065	14004-14005	.	denotes	.
R6986	T10541	T10542	nsubj	We,present
R6987	T10543	T10544	det	a,model
R6988	T10544	T10542	dobj	model,present
R6989	T10545	T10544	amod	new,model
R6990	T10546	T10544	compound	mouse,model
R6991	T10547	T10544	prep	for,model
R6992	T10548	T10547	pobj	AD,for
R6993	T10549	T10550	dep	that,designed
R6994	T10550	T10544	relcl	designed,model
R6995	T10551	T10550	auxpass	was,designed
R6996	T10552	T10553	aux	to,test
R6997	T10553	T10550	advcl	test,designed
R6998	T10554	T10555	det	the,consequences
R6999	T10555	T10553	dobj	consequences,test
R7000	T10556	T10555	prep	of,consequences
R7001	T10557	T10556	pcomp	inhibiting,of
R7002	T10558	T10559	compound	Aβ,production
R7003	T10559	T10557	dobj	production,inhibiting
R7004	T10560	T10557	prep	after,inhibiting
R7005	T10561	T10562	det	the,onset
R7006	T10562	T10560	pobj	onset,after
R7007	T10563	T10562	prep	of,onset
R7008	T10564	T10565	compound	amyloid,pathology
R7009	T10565	T10563	pobj	pathology,of
R7010	T10566	T10542	punct	.,present
R7011	T10568	T10569	amod	New,lines
R7012	T10569	T10570	nsubjpass	lines,developed
R7013	T10571	T10569	prep	of,lines
R7014	T10572	T10573	amod	transgenic,mice
R7015	T10573	T10571	pobj	mice,of
R7016	T10574	T10570	auxpass	were,developed
R7017	T10575	T10570	prep	for,developed
R7018	T10576	T10577	det	this,study
R7019	T10577	T10575	pobj	study,for
R7020	T10578	T10579	dep	that,express
R7021	T10579	T10570	ccomp	express,developed
R7022	T10580	T10581	amod	high,levels
R7023	T10581	T10579	dobj	levels,express
R7024	T10582	T10581	prep	of,levels
R7025	T10583	T10584	compound	APPswe,ind
R7026	T10584	T10582	pobj	ind,of
R7027	T10585	T10584	punct	/,ind
R7028	T10586	T10579	prep	under,express
R7029	T10587	T10588	det	the,control
R7030	T10588	T10586	pobj	control,under
R7031	T10589	T10588	prep	of,control
R7032	T10590	T10591	det	a,promoter
R7033	T10591	T10589	pobj	promoter,of
R7034	T10592	T10593	npadvmod	tetracycline,responsive
R7035	T10593	T10591	amod	responsive,promoter
R7036	T10594	T10593	punct	-,responsive
R7037	T10595	T10570	punct	.,developed
R7038	T10597	T10598	nsubj	We,demonstrate
R7039	T10599	T10600	mark	that,suppresses
R7040	T10600	T10598	ccomp	suppresses,demonstrate
R7041	T10601	T10600	nsubj	treatment,suppresses
R7042	T10602	T10601	prep	with,treatment
R7043	T10603	T10602	pobj	dox,with
R7044	T10604	T10605	amod	steady,state
R7045	T10605	T10607	compound	state,levels
R7046	T10606	T10605	punct	-,state
R7047	T10607	T10600	dobj	levels,suppresses
R7048	T10608	T10607	prep	of,levels
R7049	T10609	T10610	preconj	both,ind
R7050	T10610	T10608	pobj	ind,of
R7051	T10611	T10610	compound	APPswe,ind
R7052	T10612	T10610	punct	/,ind
R7053	T10613	T10610	cc	and,ind
R7054	T10614	T10615	poss	its,fragments
R7055	T10615	T10610	conj	fragments,ind
R7056	T10616	T10615	nmod	C,fragments
R7057	T10617	T10615	punct	-,fragments
R7058	T10618	T10615	amod	terminal,fragments
R7059	T10619	T10600	punct	", ",suppresses
R7060	T10620	T10600	advcl	indicating,suppresses
R7061	T10621	T10622	mark	that,have
R7062	T10622	T10620	ccomp	have,indicating
R7063	T10623	T10624	det	the,proteins
R7064	T10624	T10622	nsubj	proteins,have
R7065	T10625	T10624	compound	mutant,proteins
R7066	T10626	T10627	det	a,life
R7067	T10627	T10622	dobj	life,have
R7068	T10628	T10629	advmod	relatively,short
R7069	T10629	T10627	amod	short,life
R7070	T10630	T10627	compound	half,life
R7071	T10631	T10627	punct	-,life
R7072	T10632	T10633	advmod	in,vivo
R7073	T10633	T10622	advmod	vivo,have
R7074	T10634	T10598	punct	.,demonstrate
R7075	T10636	T10637	amod	Transgenic,expression
R7076	T10637	T10638	nsubj	expression,cause
R7077	T10639	T10637	prep	of,expression
R7078	T10640	T10641	compound	APPswe,ind
R7079	T10641	T10639	pobj	ind,of
R7080	T10642	T10641	punct	/,ind
R7081	T10643	T10637	cc	and,expression
R7082	T10644	T10645	amod	consequent,overproduction
R7083	T10645	T10637	conj	overproduction,expression
R7084	T10646	T10645	prep	of,overproduction
R7085	T10647	T10646	pobj	Aβ42,of
R7086	T10648	T10649	amod	early,onset
R7087	T10649	T10651	compound	onset,deposition
R7088	T10650	T10649	punct	-,onset
R7089	T10651	T10638	dobj	deposition,cause
R7090	T10652	T10651	compound	amyloid,deposition
R7091	T10653	T10638	prep	in,cause
R7092	T10654	T10655	amod	untreated,mice
R7093	T10655	T10653	pobj	mice,in
R7094	T10656	T10655	punct	", ",mice
R7095	T10657	T10658	prep	in,appear
R7096	T10658	T10655	relcl	appear,mice
R7097	T10659	T10657	pobj	which,in
R7098	T10660	T10658	nsubj	deposits,appear
R7099	T10661	T10662	advmod	as,early
R7100	T10662	T10658	advmod	early,appear
R7101	T10663	T10662	prep	as,early
R7102	T10664	T10665	nummod	2,mo
R7103	T10665	T10663	pobj	mo,as
R7104	T10666	T10665	prep	of,mo
R7105	T10667	T10666	pobj	age,of
R7106	T10668	T10638	punct	.,cause
R7107	T10670	T10671	compound	Amyloid,burden
R7108	T10671	T10672	nsubj	burden,worsens
R7109	T10673	T10672	advmod	significantly,worsens
R7110	T10674	T10672	prep	with,worsens
R7111	T10675	T10674	pobj	age,with
R7112	T10676	T10672	punct	", ",worsens
R7113	T10677	T10672	cc	and,worsens
R7114	T10678	T10679	prep	by,filled
R7115	T10679	T10672	conj	filled,worsens
R7116	T10680	T10681	nummod	9,mo
R7117	T10681	T10678	pobj	mo,by
R7118	T10682	T10679	punct	", ",filled
R7119	T10683	T10684	det	the,hippocampus
R7120	T10684	T10679	nsubjpass	hippocampus,filled
R7121	T10685	T10684	cc	and,hippocampus
R7122	T10686	T10684	conj	cortex,hippocampus
R7123	T10687	T10684	prep	of,hippocampus
R7124	T10688	T10689	amod	untreated,mice
R7125	T10689	T10687	pobj	mice,of
R7126	T10690	T10679	auxpass	are,filled
R7127	T10691	T10679	advmod	largely,filled
R7128	T10692	T10679	prep	with,filled
R7129	T10693	T10694	amod	aggregated,peptide
R7130	T10694	T10692	pobj	peptide,with
R7131	T10695	T10679	punct	.,filled
R7132	T10697	T10698	nsubj	We,find
R7133	T10699	T10700	mark	that,halts
R7134	T10700	T10698	ccomp	halts,find
R7135	T10701	T10700	nsubj	suppression,halts
R7136	T10702	T10701	prep	of,suppression
R7137	T10703	T10704	amod	transgenic,APP
R7138	T10704	T10702	pobj	APP,of
R7139	T10705	T10701	prep	by,suppression
R7140	T10706	T10707	amod	more,95
R7141	T10707	T10709	nummod	95,%
R7142	T10708	T10707	quantmod	than,95
R7143	T10709	T10705	pobj	%,by
R7144	T10710	T10700	advmod	abruptly,halts
R7145	T10711	T10712	det	the,progression
R7146	T10712	T10700	dobj	progression,halts
R7147	T10713	T10712	prep	of,progression
R7148	T10714	T10715	compound	amyloid,pathology
R7149	T10715	T10713	pobj	pathology,of
R7150	T10716	T10698	punct	.,find
R7151	T10718	T10719	advmod	Importantly,occurs
R7152	T10720	T10719	punct	", ",occurs
R7153	T10721	T10722	det	this,outcome
R7154	T10722	T10719	nsubj	outcome,occurs
R7155	T10723	T10719	prep	in,occurs
R7156	T10724	T10723	pobj	animals,in
R7157	T10725	T10726	advmod	already,harboring
R7158	T10726	T10724	acl	harboring,animals
R7159	T10727	T10728	amod	considerable,pathology
R7160	T10728	T10726	dobj	pathology,harboring
R7161	T10729	T10728	compound	amyloid,pathology
R7162	T10730	T10719	punct	", ",occurs
R7163	T10731	T10732	det	a,situation
R7164	T10732	T10719	npadvmod	situation,occurs
R7165	T10733	T10732	amod	similar,situation
R7166	T10734	T10733	prep	to,similar
R7167	T10735	T10736	dep	what,expected
R7168	T10736	T10734	pcomp	expected,to
R7169	T10737	T10736	aux	might,expected
R7170	T10738	T10736	auxpass	be,expected
R7171	T10739	T10736	prep	in,expected
R7172	T10740	T10739	pobj	patients,in
R7173	T10741	T10742	aux	to,treated
R7174	T10742	T10740	advcl	treated,patients
R7175	T10743	T10742	auxpass	be,treated
R7176	T10744	T10742	prep	with,treated
R7177	T10745	T10746	compound	secretase,inhibitors
R7178	T10746	T10744	pobj	inhibitors,with
R7179	T10747	T10719	punct	.,occurs
R7180	T10749	T10750	advmod	Somewhat,unexpectedly
R7181	T10750	T10751	advmod	unexpectedly,observe
R7182	T10752	T10751	punct	", ",observe
R7183	T10753	T10751	nsubj	we,observe
R7184	T10754	T10755	det	no,clearance
R7185	T10755	T10751	dobj	clearance,observe
R7186	T10756	T10755	amod	appreciable,clearance
R7187	T10757	T10755	prep	of,clearance
R7188	T10758	T10759	amod	deposited,amyloid
R7189	T10759	T10757	pobj	amyloid,of
R7190	T10760	T10761	advmod	even,following
R7191	T10761	T10751	prep	following,observe
R7192	T10762	T10761	pobj	periods,following
R7193	T10763	T10762	prep	of,periods
R7194	T10764	T10765	compound	transgene,suppression
R7195	T10765	T10763	pobj	suppression,of
R7196	T10766	T10762	amod	equal,periods
R7197	T10767	T10766	prep	to,equal
R7198	T10768	T10769	det	the,time
R7199	T10769	T10767	pobj	time,to
R7200	T10770	T10769	advcl	taken,time
R7201	T10771	T10772	mark	for,form
R7202	T10772	T10770	advcl	form,taken
R7203	T10773	T10772	nsubj	plaques,form
R7204	T10774	T10772	aux	to,form
R7205	T10775	T10751	punct	.,observe
R7206	T10777	T10778	det	This,finding
R7207	T10778	T10780	nsubj	finding,indicates
R7208	T10779	T10778	amod	latter,finding
R7209	T10781	T10782	mark	that,is
R7210	T10782	T10780	ccomp	is,indicates
R7211	T10783	T10782	prep	compared,is
R7212	T10784	T10783	prep	to,compared
R7213	T10785	T10786	amod	other,aggregates
R7214	T10786	T10784	pobj	aggregates,to
R7215	T10787	T10788	npadvmod	disease,associated
R7216	T10788	T10786	amod	associated,aggregates
R7217	T10789	T10788	punct	-,associated
R7218	T10790	T10786	compound	protein,aggregates
R7219	T10791	T10792	amod	such,as
R7220	T10792	T10786	prep	as,aggregates
R7221	T10793	T10794	compound	mutant,huntingtin
R7222	T10794	T10792	pobj	huntingtin,as
R7223	T10795	T10794	punct	", ",huntingtin
R7224	T10796	T10797	dep	which,clear
R7225	T10797	T10794	relcl	clear,huntingtin
R7226	T10798	T10797	prep	in,clear
R7227	T10799	T10800	amod	less,3
R7228	T10800	T10802	nummod	3,mo
R7229	T10801	T10800	quantmod	than,3
R7230	T10802	T10798	pobj	mo,in
R7231	T10803	T10804	punct	[,32
R7232	T10804	T10797	parataxis	32,clear
R7233	T10805	T10804	punct	],32
R7234	T10806	T10782	punct	", ",is
R7235	T10807	T10808	det	the,disaggregation
R7236	T10808	T10782	nsubj	disaggregation,is
R7237	T10809	T10808	prep	of,disaggregation
R7238	T10810	T10811	amod	extracellular,amyloid
R7239	T10811	T10809	pobj	amyloid,of
R7240	T10812	T10813	advmod	relatively,slow
R7241	T10813	T10782	acomp	slow,is
R7242	T10814	T10780	punct	.,indicates
R7243	T10816	T10817	advmod	Notably,show
R7244	T10818	T10817	punct	", ",show
R7245	T10819	T10820	amod	pharmaceutical,inhibitors
R7246	T10820	T10817	nsubj	inhibitors,show
R7247	T10821	T10822	punct	γ,secretase
R7248	T10822	T10820	compound	secretase,inhibitors
R7249	T10823	T10822	punct	-,secretase
R7250	T10824	T10820	acl	published,inhibitors
R7251	T10825	T10824	prep	to,published
R7252	T10826	T10825	pobj	date,to
R7253	T10827	T10828	advmod	less,strict
R7254	T10828	T10829	amod	strict,regulation
R7255	T10829	T10817	dobj	regulation,show
R7256	T10830	T10829	prep	of,regulation
R7257	T10831	T10832	compound	Aβ,production
R7258	T10832	T10830	pobj	production,of
R7259	T10833	T10829	prep	following,regulation
R7260	T10834	T10835	amod	chronic,administration
R7261	T10835	T10833	pobj	administration,following
R7262	T10836	T10837	mark	than,attained
R7263	T10837	T10829	advcl	attained,regulation
R7264	T10838	T10837	nsubj	we,attained
R7265	T10839	T10837	aux	have,attained
R7266	T10840	T10837	advmod	here,attained
R7267	T10841	T10817	punct	.,show
R7268	T10843	T10844	nummod	Two,compounds
R7269	T10844	T10846	nsubj	compounds,show
R7270	T10845	T10844	amod	independent,compounds
R7271	T10847	T10844	acl	tested,compounds
R7272	T10848	T10847	prep	in,tested
R7273	T10849	T10850	npadvmod	Tg2576,transgenic
R7274	T10850	T10859	amod	transgenic,mice
R7275	T10851	T10852	punct	[,33
R7276	T10852	T10849	parataxis	33,Tg2576
R7277	T10853	T10852	punct	],33
R7278	T10854	T10849	cc	and,Tg2576
R7279	T10855	T10849	conj	TgCRND8,Tg2576
R7280	T10856	T10857	punct	[,34
R7281	T10857	T10855	parataxis	34,TgCRND8
R7282	T10858	T10857	punct	],34
R7283	T10859	T10848	pobj	mice,in
R7284	T10860	T10861	neg	no,85
R7285	T10861	T10864	nummod	85,%
R7286	T10862	T10861	amod	more,85
R7287	T10863	T10861	quantmod	than,85
R7288	T10864	T10865	compound	%,suppression
R7289	T10865	T10846	dobj	suppression,show
R7290	T10866	T10865	prep	of,suppression
R7291	T10867	T10868	compound	Aβ40,levels
R7292	T10868	T10866	pobj	levels,of
R7293	T10869	T10865	punct	", ",suppression
R7294	T10870	T10865	cc	and,suppression
R7295	T10871	T10872	advmod	where,measured
R7296	T10872	T10873	advcl	measured,suppression
R7297	T10873	T10865	conj	suppression,suppression
R7298	T10874	T10873	punct	", ",suppression
R7299	T10875	T10876	advmod	even,less
R7300	T10876	T10873	amod	less,suppression
R7301	T10877	T10873	prep	of,suppression
R7302	T10878	T10877	pobj	Aβ42,of
R7303	T10879	T10880	punct	(,%
R7304	T10880	T10878	parataxis	%,Aβ42
R7305	T10881	T10882	advmod	approximately,60
R7306	T10882	T10880	nummod	60,%
R7307	T10883	T10880	punct	),%
R7308	T10884	T10885	punct	[,36
R7309	T10885	T10846	parataxis	36,show
R7310	T10886	T10885	nummod	35,36
R7311	T10887	T10885	punct	",",36
R7312	T10888	T10885	punct	],36
R7313	T10889	T10846	punct	.,show
R7314	T10891	T10892	advmod	Thus,achieved
R7315	T10893	T10892	punct	", ",achieved
R7316	T10894	T10895	advmod	even,after
R7317	T10895	T10892	prep	after,achieved
R7318	T10896	T10895	pcomp	accounting,after
R7319	T10897	T10896	prep	for,accounting
R7320	T10898	T10899	det	the,levels
R7321	T10899	T10897	pobj	levels,for
R7322	T10900	T10901	advmod	much,higher
R7323	T10901	T10899	amod	higher,levels
R7324	T10902	T10899	compound	APP,levels
R7325	T10903	T10899	compound	expression,levels
R7326	T10904	T10899	prep	in,levels
R7327	T10905	T10906	poss	our,mice
R7328	T10906	T10904	pobj	mice,in
R7329	T10907	T10899	prep	than,levels
R7330	T10908	T10907	prep	in,than
R7331	T10909	T10910	det	the,lines
R7332	T10910	T10908	pobj	lines,in
R7333	T10911	T10910	nmod	Tg2576,lines
R7334	T10912	T10911	cc	and,Tg2576
R7335	T10913	T10911	conj	TgCRND8,Tg2576
R7336	T10914	T10892	punct	", ",achieved
R7337	T10915	T10892	nsubj	we,achieved
R7338	T10916	T10892	aux	have,achieved
R7339	T10917	T10918	advmod	better,suppression
R7340	T10918	T10892	dobj	suppression,achieved
R7341	T10919	T10918	amod	absolute,suppression
R7342	T10920	T10918	prep	of,suppression
R7343	T10921	T10922	compound	Aβ,production
R7344	T10922	T10920	pobj	production,of
R7345	T10923	T10918	prep	with,suppression
R7346	T10924	T10925	det	the,system
R7347	T10925	T10923	pobj	system,with
R7348	T10926	T10927	compound	tet,off
R7349	T10927	T10925	compound	off,system
R7350	T10928	T10927	punct	-,off
R7351	T10929	T10930	mark	than,is
R7352	T10930	T10918	advcl	is,suppression
R7353	T10931	T10930	advmod	currently,is
R7354	T10932	T10930	acomp	possible,is
R7355	T10933	T10930	prep	with,is
R7356	T10934	T10935	amod	published,inhibitors
R7357	T10935	T10933	pobj	inhibitors,with
R7358	T10936	T10937	punct	γ,secretase
R7359	T10937	T10935	compound	secretase,inhibitors
R7360	T10938	T10937	punct	-,secretase
R7361	T10939	T10892	punct	.,achieved
R7362	T10941	T10942	mark	Since,are
R7363	T10942	T10950	advcl	are,provides
R7364	T10943	T10944	advmod	even,agents
R7365	T10944	T10942	nsubj	agents,are
R7366	T10945	T10944	det	the,agents
R7367	T10946	T10947	advmod	most,advanced
R7368	T10947	T10944	amod	advanced,agents
R7369	T10948	T10944	amod	future,agents
R7370	T10949	T10944	amod	pharmaceutical,agents
R7371	T10951	T10942	acomp	unlikely,are
R7372	T10952	T10953	aux	to,attain
R7373	T10953	T10951	xcomp	attain,unlikely
R7374	T10954	T10955	advmod	more,complete
R7375	T10955	T10956	amod	complete,control
R7376	T10956	T10953	dobj	control,attain
R7377	T10957	T10956	prep	of,control
R7378	T10958	T10959	compound	Aβ,production
R7379	T10959	T10957	pobj	production,of
R7380	T10960	T10961	mark	than,achieved
R7381	T10961	T10956	advcl	achieved,control
R7382	T10962	T10961	advmod	here,achieved
R7383	T10963	T10950	punct	", ",provides
R7384	T10964	T10965	det	this,system
R7385	T10965	T10950	nsubj	system,provides
R7386	T10966	T10967	det	a,test
R7387	T10967	T10950	dobj	test,provides
R7388	T10968	T10967	amod	salient,test
R7389	T10969	T10967	prep	of,test
R7390	T10970	T10971	amod	therapeutic,intervention
R7391	T10971	T10969	pobj	intervention,of
R7392	T10972	T10971	prep	with,intervention
R7393	T10973	T10974	npadvmod	Aβ,lowering
R7394	T10974	T10976	amod	lowering,compounds
R7395	T10975	T10974	punct	-,lowering
R7396	T10976	T10972	pobj	compounds,with
R7397	T10977	T10950	punct	.,provides
R7398	T10979	T10980	mark	Although,arrested
R7399	T10980	T10988	advcl	arrested,found
R7400	T10981	T10982	det	the,progression
R7401	T10982	T10980	nsubjpass	progression,arrested
R7402	T10983	T10982	prep	of,progression
R7403	T10984	T10985	compound	amyloid,deposition
R7404	T10985	T10983	pobj	deposition,of
R7405	T10986	T10980	auxpass	was,arrested
R7406	T10987	T10980	advmod	sharply,arrested
R7407	T10989	T10980	agent	by,arrested
R7408	T10990	T10991	det	this,approach
R7409	T10991	T10989	pobj	approach,by
R7410	T10992	T10988	punct	", ",found
R7411	T10993	T10988	nsubj	we,found
R7412	T10994	T10995	mark	that,remained
R7413	T10995	T10988	ccomp	remained,found
R7414	T10996	T10997	det	a,burden
R7415	T10997	T10995	nsubj	burden,remained
R7416	T10998	T10997	amod	substantial,burden
R7417	T10999	T10997	compound	amyloid,burden
R7418	T11000	T11001	advmod	even,after
R7419	T11001	T10995	prep	after,remained
R7420	T11002	T11003	amod	long,periods
R7421	T11003	T11001	pobj	periods,after
R7422	T11004	T11003	prep	of,periods
R7423	T11005	T11006	compound	transgene,suppression
R7424	T11006	T11004	pobj	suppression,of
R7425	T11007	T10988	punct	.,found
R7426	T11009	T11010	nsubj	We,examined
R7427	T11011	T11012	det	a,number
R7428	T11012	T11010	dobj	number,examined
R7429	T11013	T11012	amod	small,number
R7430	T11014	T11012	prep	of,number
R7431	T11015	T11014	pobj	animals,of
R7432	T11016	T11010	prep	after,examined
R7433	T11017	T11018	nummod	12,mo
R7434	T11018	T11016	pobj	mo,after
R7435	T11019	T11018	prep	of,mo
R7436	T11020	T11021	compound	dox,treatment
R7437	T11021	T11019	pobj	treatment,of
R7438	T11022	T11021	punct	(,treatment
R7439	T11023	T11021	acl	beginning,treatment
R7440	T11024	T11023	prep	at,beginning
R7441	T11025	T11026	nummod	6,mo
R7442	T11026	T11024	pobj	mo,at
R7443	T11027	T11026	prep	of,mo
R7444	T11028	T11027	pobj	age,of
R7445	T11029	T11021	punct	),treatment
R7446	T11030	T11010	punct	", ",examined
R7447	T11031	T11010	cc	and,examined
R7448	T11032	T11010	conj	found,examined
R7449	T11033	T11034	mark	that,were
R7450	T11034	T11032	ccomp	were,found
R7451	T11035	T11036	compound	amyloid,deposits
R7452	T11036	T11034	nsubj	deposits,were
R7453	T11037	T11034	advmod	still,were
R7454	T11038	T11039	advmod	relatively,abundant
R7455	T11039	T11034	acomp	abundant,were
R7456	T11040	T11010	punct	.,examined
R7457	T11042	T11043	amod	Longer,term
R7458	T11043	T11045	compound	term,treatments
R7459	T11044	T11043	punct	-,term
R7460	T11045	T11046	nsubj	treatments,are
R7461	T11047	T11046	advmod	now,are
R7462	T11048	T11046	prep	in,are
R7463	T11049	T11048	pobj	progress,in
R7464	T11050	T11046	punct	.,are
R7465	T11052	T11053	prep	At,showed
R7466	T11054	T11055	det	the,interval
R7467	T11055	T11052	pobj	interval,At
R7468	T11056	T11055	amod	latest,interval
R7469	T11057	T11055	compound	treatment,interval
R7470	T11058	T11055	acl	analyzed,interval
R7471	T11059	T11058	agent	by,analyzed
R7472	T11060	T11059	pobj	ELISA,by
R7473	T11061	T11053	punct	", ",showed
R7474	T11062	T11053	nsubj	animals,showed
R7475	T11063	T11062	acl	administered,animals
R7476	T11064	T11063	dobj	dox,administered
R7477	T11065	T11063	prep	for,administered
R7478	T11066	T11067	nummod	6,mo
R7479	T11067	T11065	pobj	mo,for
R7480	T11068	T11069	amod	elevated,levels
R7481	T11069	T11053	dobj	levels,showed
R7482	T11070	T11069	prep	of,levels
R7483	T11071	T11072	npadvmod	PBS,soluble
R7484	T11072	T11074	amod	soluble,Aβ
R7485	T11073	T11072	punct	-,soluble
R7486	T11074	T11070	pobj	Aβ,of
R7487	T11075	T11076	punct	(,see
R7488	T11076	T11074	parataxis	see,Aβ
R7489	T11077	T11076	dobj	Figure,see
R7490	T11078	T11077	nummod	5,Figure
R7491	T11079	T11076	punct	),see
R7492	T11080	T11081	dep	that,interpreted
R7493	T11081	T11069	relcl	interpreted,levels
R7494	T11082	T11081	aux	could,interpreted
R7495	T11083	T11081	auxpass	be,interpreted
R7496	T11084	T11081	prep	as,interpreted
R7497	T11085	T11086	det	an,indication
R7498	T11086	T11084	pobj	indication,as
R7499	T11087	T11088	mark	that,releasing
R7500	T11088	T11086	acl	releasing,indication
R7501	T11089	T11090	det	the,plaques
R7502	T11090	T11088	nsubj	plaques,releasing
R7503	T11091	T11088	aux	are,releasing
R7504	T11092	T11088	advmod	slowly,releasing
R7505	T11093	T11088	dobj	peptide,releasing
R7506	T11094	T11093	punct	(,peptide
R7507	T11095	T11093	cc	or,peptide
R7508	T11096	T11097	amod	oligomeric,Aβ
R7509	T11097	T11093	conj	Aβ,peptide
R7510	T11098	T11097	punct	),Aβ
R7511	T11099	T11088	prep	into,releasing
R7512	T11100	T11101	det	the,pool
R7513	T11101	T11099	pobj	pool,into
R7514	T11102	T11101	amod	soluble,pool
R7515	T11103	T11088	cc	and,releasing
R7516	T11104	T11105	aux	might,dissolve
R7517	T11105	T11088	conj	dissolve,releasing
R7518	T11106	T11105	advmod	eventually,dissolve
R7519	T11107	T11053	punct	.,showed
R7520	T11109	T11110	mark	Whether,result
R7521	T11110	T11124	csubj	result,is
R7522	T11111	T11110	csubj	inhibiting,result
R7523	T11112	T11113	compound	Aβ,production
R7524	T11113	T11111	dobj	production,inhibiting
R7525	T11114	T11111	advmod	longer,inhibiting
R7526	T11115	T11114	prep	than,longer
R7527	T11116	T11117	nummod	6,mo
R7528	T11117	T11115	pobj	mo,than
R7529	T11118	T11116	punct	(,6
R7530	T11119	T11116	cc	or,6
R7531	T11120	T11116	conj	12,6
R7532	T11121	T11117	punct	),mo
R7533	T11122	T11110	aux	may,result
R7534	T11123	T11110	advmod	ultimately,result
R7535	T11124	T11129	ccomp	is,limits
R7536	T11125	T11110	prep	in,result
R7537	T11126	T11125	pobj	clearance,in
R7538	T11127	T11126	prep	of,clearance
R7539	T11128	T11127	pobj	amyloid,of
R7540	T11130	T11124	prep	under,is
R7541	T11131	T11130	pobj	investigation,under
R7542	T11132	T11129	punct	;,limits
R7543	T11133	T11129	advmod	unfortunately,limits
R7544	T11134	T11129	punct	", ",limits
R7545	T11135	T11136	det	the,span
R7546	T11136	T11129	nsubj	span,limits
R7547	T11137	T11136	compound	life,span
R7548	T11138	T11136	prep	of,span
R7549	T11139	T11140	det	the,model
R7550	T11140	T11138	pobj	model,of
R7551	T11141	T11129	advmod	eventually,limits
R7552	T11142	T11143	det	this,experiment
R7553	T11143	T11129	dobj	experiment,limits
R7554	T11144	T11129	punct	.,limits
R7555	T11146	T11147	nsubj	Therapeutics,have
R7556	T11148	T11146	acl	used,Therapeutics
R7557	T11149	T11148	prep	in,used
R7558	T11150	T11149	pobj	humans,in
R7559	T11151	T11147	aux	will,have
R7560	T11152	T11153	advmod	considerably,more
R7561	T11153	T11154	amod	more,time
R7562	T11154	T11147	dobj	time,have
R7563	T11155	T11156	aux	to,act
R7564	T11156	T11154	advcl	act,time
R7565	T11157	T11158	mark	than,is
R7566	T11158	T11154	advcl	is,time
R7567	T11159	T11158	acomp	possible,is
R7568	T11160	T11158	prep	within,is
R7569	T11161	T11162	det	the,span
R7570	T11162	T11160	pobj	span,within
R7571	T11163	T11162	compound	life,span
R7572	T11164	T11162	prep	of,span
R7573	T11165	T11166	compound	rodent,models
R7574	T11166	T11164	pobj	models,of
R7575	T11167	T11147	punct	.,have
R7576	T11169	T11170	amod	Long,term
R7577	T11170	T11172	compound	term,treatments
R7578	T11171	T11170	punct	-,term
R7579	T11172	T11173	nsubj	treatments,be
R7580	T11174	T11173	aux	would,be
R7581	T11175	T11173	advmod	certainly,be
R7582	T11176	T11173	acomp	possible,be
R7583	T11177	T11173	cc	and,be
R7584	T11178	T11179	aux	could,be
R7585	T11179	T11173	conj	be,be
R7586	T11180	T11181	det	a,key
R7587	T11181	T11179	attr	key,be
R7588	T11182	T11181	prep	to,key
R7589	T11183	T11184	amod	effective,therapy
R7590	T11184	T11182	pobj	therapy,to
R7591	T11185	T11173	punct	.,be
R7592	T11187	T11188	advmod	Overall,interpret
R7593	T11189	T11188	punct	", ",interpret
R7594	T11190	T11188	advmod	however,interpret
R7595	T11191	T11188	punct	", ",interpret
R7596	T11192	T11188	nsubj	we,interpret
R7597	T11193	T11194	poss	our,findings
R7598	T11194	T11188	dobj	findings,interpret
R7599	T11195	T11188	prep	as,interpret
R7600	T11196	T11195	pobj	evidence,as
R7601	T11197	T11198	mark	that,reverse
R7602	T11198	T11196	acl	reverse,evidence
R7603	T11199	T11200	compound	AD,therapies
R7604	T11200	T11198	nsubj	therapies,reverse
R7605	T11201	T11202	dep	that,lower
R7606	T11202	T11200	relcl	lower,therapies
R7607	T11203	T11202	advmod	significantly,lower
R7608	T11204	T11205	det	the,production
R7609	T11205	T11202	dobj	production,lower
R7610	T11206	T11205	prep	of,production
R7611	T11207	T11206	pobj	Aβ,of
R7612	T11208	T11202	punct	(,lower
R7613	T11209	T11202	prep	by,lower
R7614	T11210	T11211	preconj	either,inhibiting
R7615	T11211	T11209	pcomp	inhibiting,by
R7616	T11212	T11213	compound	secretase,activity
R7617	T11213	T11211	dobj	activity,inhibiting
R7618	T11214	T11211	cc	or,inhibiting
R7619	T11215	T11211	conj	inhibiting,inhibiting
R7620	T11216	T11217	compound	APP,expression
R7621	T11217	T11215	dobj	expression,inhibiting
R7622	T11218	T11202	punct	),lower
R7623	T11219	T11198	aux	may,reverse
R7624	T11220	T11198	neg	not,reverse
R7625	T11221	T11198	advmod	quickly,reverse
R7626	T11222	T11223	amod	preexisting,pathology
R7627	T11223	T11198	dobj	pathology,reverse
R7628	T11224	T11198	punct	", ",reverse
R7629	T11225	T11198	cc	but,reverse
R7630	T11226	T11227	aux	should,halt
R7631	T11227	T11198	conj	halt,reverse
R7632	T11228	T11227	advmod	effectively,halt
R7633	T11229	T11230	amod	further,deposition
R7634	T11230	T11227	dobj	deposition,halt
R7635	T11231	T11230	prep	of,deposition
R7636	T11232	T11231	pobj	amyloid,of
R7637	T11233	T11188	punct	.,interpret
R7638	T11235	T11236	prep	In,remembered
R7639	T11237	T11235	pcomp	interpreting,In
R7640	T11238	T11239	poss	our,study
R7641	T11239	T11237	dobj	study,interpreting
R7642	T11240	T11236	punct	", ",remembered
R7643	T11241	T11236	nsubjpass	it,remembered
R7644	T11242	T11236	aux	should,remembered
R7645	T11243	T11236	auxpass	be,remembered
R7646	T11244	T11245	mark	that,are
R7647	T11245	T11236	ccomp	are,remembered
R7648	T11246	T11247	det	the,plaques
R7649	T11247	T11245	nsubj	plaques,are
R7650	T11248	T11247	amod	earliest,plaques
R7651	T11249	T11250	aux	to,appear
R7652	T11250	T11247	advcl	appear,plaques
R7653	T11251	T11250	prep	in,appear
R7654	T11252	T11253	det	these,mice
R7655	T11253	T11251	pobj	mice,in
R7656	T11254	T11247	punct	", ",plaques
R7657	T11255	T11247	prep	like,plaques
R7658	T11256	T11257	amod	other,transgenics
R7659	T11257	T11255	pobj	transgenics,like
R7660	T11258	T11257	compound	APP,transgenics
R7661	T11259	T11257	acl	harboring,transgenics
R7662	T11260	T11261	det	the,mutation
R7663	T11261	T11259	dobj	mutation,harboring
R7664	T11262	T11261	amod	Swedish,mutation
R7665	T11263	T11264	punct	[,27
R7666	T11264	T11259	parataxis	27,harboring
R7667	T11265	T11264	punct	],27
R7668	T11266	T11245	punct	", ",are
R7669	T11267	T11245	advmod	predominantly,are
R7670	T11268	T11269	amod	fibrillar,deposits
R7671	T11269	T11245	attr	deposits,are
R7672	T11270	T11269	punct	", ",deposits
R7673	T11271	T11272	dep	which,be
R7674	T11272	T11269	relcl	be,deposits
R7675	T11273	T11272	aux	may,be
R7676	T11274	T11275	advmod	less,tractable
R7677	T11275	T11272	acomp	tractable,be
R7678	T11276	T11275	prep	than,tractable
R7679	T11277	T11278	det	the,aggregates
R7680	T11278	T11276	pobj	aggregates,than
R7681	T11279	T11278	amod	diffuse,aggregates
R7682	T11280	T11278	acl	thought,aggregates
R7683	T11281	T11282	aux	to,come
R7684	T11282	T11280	xcomp	come,thought
R7685	T11283	T11282	advmod	first,come
R7686	T11284	T11282	prep	in,come
R7687	T11285	T11286	det	the,course
R7688	T11286	T11284	pobj	course,in
R7689	T11287	T11286	prep	of,course
R7690	T11288	T11289	det	the,disease
R7691	T11289	T11287	pobj	disease,of
R7692	T11290	T11289	amod	human,disease
R7693	T11291	T11236	punct	.,remembered
R7694	T11293	T11294	advmod	However,suggest
R7695	T11295	T11294	punct	", ",suggest
R7696	T11296	T11297	poss	our,data
R7697	T11297	T11294	nsubj	data,suggest
R7698	T11298	T11299	mark	that,cleared
R7699	T11299	T11294	ccomp	cleared,suggest
R7700	T11300	T11301	mark	once,formed
R7701	T11301	T11299	advcl	formed,cleared
R7702	T11302	T11303	amod	diffuse,deposits
R7703	T11303	T11301	nsubjpass	deposits,formed
R7704	T11304	T11301	auxpass	are,formed
R7705	T11305	T11301	prep	in,formed
R7706	T11306	T11307	det	these,mice
R7707	T11307	T11305	pobj	mice,in
R7708	T11308	T11299	punct	", ",cleared
R7709	T11309	T11299	nsubjpass	they,cleared
R7710	T11310	T11299	auxpass	are,cleared
R7711	T11311	T11312	neg	no,more
R7712	T11312	T11313	advmod	more,easily
R7713	T11313	T11299	advmod	easily,cleared
R7714	T11314	T11299	prep	in,cleared
R7715	T11315	T11316	poss	our,system
R7716	T11316	T11314	pobj	system,in
R7717	T11317	T11299	prep	than,cleared
R7718	T11318	T11319	amod	cored,plaques
R7719	T11319	T11317	pobj	plaques,than
R7720	T11320	T11321	punct	(,see
R7721	T11321	T11299	parataxis	see,cleared
R7722	T11322	T11323	compound	Figure,S4
R7723	T11323	T11321	dobj	S4,see
R7724	T11324	T11321	punct	),see
R7725	T11325	T11294	punct	.,suggest
R7726	T11327	T11328	det	An,consideration
R7727	T11328	T11330	nsubj	consideration,is
R7728	T11329	T11328	amod	additional,consideration
R7729	T11331	T11332	nsubj	we,recognize
R7730	T11332	T11328	advcl	recognize,consideration
R7731	T11333	T11334	mark	that,continues
R7732	T11334	T11330	advcl	continues,is
R7733	T11335	T11336	det	a,amount
R7734	T11336	T11334	nsubj	amount,continues
R7735	T11337	T11336	amod	small,amount
R7736	T11338	T11336	prep	of,amount
R7737	T11339	T11340	compound	transgene,expression
R7738	T11340	T11338	pobj	expression,of
R7739	T11341	T11334	prep	in,continues
R7740	T11342	T11343	det	the,presence
R7741	T11343	T11341	pobj	presence,in
R7742	T11344	T11343	prep	of,presence
R7743	T11345	T11344	pobj	dox,of
R7744	T11346	T11334	cc	and,continues
R7745	T11347	T11348	mark	that,continues
R7746	T11348	T11334	conj	continues,continues
R7747	T11349	T11350	amod	endogenous,Aβ
R7748	T11350	T11348	nsubj	Aβ,continues
R7749	T11351	T11350	compound	mouse,Aβ
R7750	T11352	T11353	aux	to,produced
R7751	T11353	T11348	xcomp	produced,continues
R7752	T11354	T11353	auxpass	be,produced
R7753	T11355	T11330	punct	.,is
R7754	T11357	T11358	nsubj	It,is
R7755	T11359	T11358	acomp	possible,is
R7756	T11360	T11361	mark	that,are
R7757	T11361	T11358	ccomp	are,is
R7758	T11362	T11363	det	the,levels
R7759	T11363	T11361	nsubj	levels,are
R7760	T11364	T11363	amod	combined,levels
R7761	T11365	T11363	amod	low,levels
R7762	T11366	T11363	prep	of,levels
R7763	T11367	T11368	amod	endogenous,Aβ
R7764	T11368	T11370	nmod	Aβ,peptide
R7765	T11369	T11368	nmod	mouse,Aβ
R7766	T11370	T11366	pobj	peptide,of
R7767	T11371	T11368	cc	and,Aβ
R7768	T11372	T11373	amod	nonsuppressed,human
R7769	T11373	T11368	conj	human,Aβ
R7770	T11374	T11361	acomp	sufficient,are
R7771	T11375	T11376	aux	to,maintain
R7772	T11376	T11374	xcomp	maintain,sufficient
R7773	T11377	T11378	amod	existing,deposits
R7774	T11378	T11376	dobj	deposits,maintain
R7775	T11379	T11358	punct	.,is
R7776	T11381	T11382	advmod	However,are
R7777	T11383	T11382	punct	", ",are
R7778	T11384	T11385	det	these,levels
R7779	T11385	T11382	nsubj	levels,are
R7780	T11386	T11385	amod	low,levels
R7781	T11387	T11385	prep	of,levels
R7782	T11388	T11387	pobj	peptide,of
R7783	T11389	T11382	neg	not,are
R7784	T11390	T11382	acomp	sufficient,are
R7785	T11391	T11392	aux	to,induce
R7786	T11392	T11390	xcomp	induce,sufficient
R7787	T11393	T11394	amod	new,formation
R7788	T11394	T11392	dobj	formation,induce
R7789	T11395	T11394	compound	amyloid,formation
R7790	T11396	T11382	punct	", ",are
R7791	T11397	T11398	mark	as,develop
R7792	T11398	T11382	advcl	develop,are
R7793	T11399	T11400	nmod	CaMKIIα,ind
R7794	T11400	T11406	compound	ind,mice
R7795	T11401	T11400	punct	-,ind
R7796	T11402	T11400	nmod	tTA,ind
R7797	T11403	T11400	punct	×,ind
R7798	T11404	T11400	compound	tetAPPswe,ind
R7799	T11405	T11400	punct	/,ind
R7800	T11406	T11398	nsubj	mice,develop
R7801	T11407	T11406	acl	raised,mice
R7802	T11408	T11407	prep	on,raised
R7803	T11409	T11408	pobj	dox,on
R7804	T11410	T11407	prep	for,raised
R7805	T11411	T11412	quantmod	up,a
R7806	T11412	T11414	nummod	a,year
R7807	T11413	T11412	quantmod	to,a
R7808	T11414	T11410	pobj	year,for
R7809	T11415	T11398	aux	do,develop
R7810	T11416	T11398	neg	not,develop
R7811	T11417	T11418	compound	amyloid,lesions
R7812	T11418	T11398	dobj	lesions,develop
R7813	T11419	T11420	punct	(,shown
R7814	T11420	T11398	parataxis	shown,develop
R7815	T11421	T11420	nsubj	data,shown
R7816	T11422	T11420	neg	not,shown
R7817	T11423	T11420	punct	),shown
R7818	T11424	T11382	punct	.,are
R7819	T11426	T11427	nsubj	It,is
R7820	T11428	T11427	advmod	also,is
R7821	T11429	T11427	acomp	clear,is
R7822	T11430	T11431	mark	that,raised
R7823	T11431	T11427	ccomp	raised,is
R7824	T11432	T11431	prep	in,raised
R7825	T11433	T11434	det	this,system
R7826	T11434	T11432	pobj	system,in
R7827	T11435	T11434	amod	genetic,system
R7828	T11436	T11431	punct	", ",raised
R7829	T11437	T11431	nsubj	we,raised
R7830	T11438	T11431	aux	have,raised
R7831	T11439	T11440	det	the,production
R7832	T11440	T11431	dobj	production,raised
R7833	T11441	T11440	prep	of,production
R7834	T11442	T11441	pobj	Aβ,of
R7835	T11443	T11431	prep	to,raised
R7836	T11444	T11443	pobj	levels,to
R7837	T11445	T11446	neg	not,found
R7838	T11446	T11444	acl	found,levels
R7839	T11447	T11446	prep	in,found
R7840	T11448	T11447	pobj	humans,in
R7841	T11449	T11450	aux	to,accelerate
R7842	T11450	T11431	advcl	accelerate,raised
R7843	T11451	T11450	dobj	pathology,accelerate
R7844	T11452	T11450	prep	into,accelerate
R7845	T11453	T11454	det	an,frame
R7846	T11454	T11452	pobj	frame,into
R7847	T11455	T11456	advmod	experimentally,feasible
R7848	T11456	T11454	amod	feasible,frame
R7849	T11457	T11454	compound	time,frame
R7850	T11458	T11427	punct	.,is
R7851	T11460	T11461	det	This,system
R7852	T11461	T11462	nsubj	system,allowed
R7853	T11462	T11463	ccomp	allowed,favored
R7854	T11464	T11465	nsubj	us,create
R7855	T11465	T11462	ccomp	create,allowed
R7856	T11466	T11465	aux	to,create
R7857	T11467	T11468	det	an,differential
R7858	T11468	T11465	dobj	differential,create
R7859	T11469	T11470	advmod	approximately,20-fold
R7860	T11470	T11468	amod	20-fold,differential
R7861	T11471	T11468	prep	between,differential
R7862	T11472	T11473	nmod	APP,Aβ
R7863	T11473	T11475	nmod	Aβ,rates
R7864	T11474	T11473	punct	/,Aβ
R7865	T11475	T11471	pobj	rates,between
R7866	T11476	T11475	amod	synthetic,rates
R7867	T11477	T11465	prep	before,create
R7868	T11478	T11477	cc	and,before
R7869	T11479	T11477	conj	after,before
R7870	T11480	T11479	pobj	treatment,after
R7871	T11481	T11463	punct	", ",favored
R7872	T11482	T11463	advmod	yet,favored
R7873	T11483	T11484	det	the,equilibrium
R7874	T11484	T11463	nsubj	equilibrium,favored
R7875	T11485	T11486	advmod	in,vivo
R7876	T11486	T11484	amod	vivo,equilibrium
R7877	T11487	T11484	prep	between,equilibrium
R7878	T11488	T11489	amod	aggregated,states
R7879	T11489	T11487	pobj	states,between
R7880	T11490	T11488	cc	and,aggregated
R7881	T11491	T11488	conj	disaggregated,aggregated
R7882	T11492	T11489	prep	of,states
R7883	T11493	T11492	pobj	Aβ,of
R7884	T11494	T11463	advmod	still,favored
R7885	T11495	T11496	det	the,maintenance
R7886	T11496	T11463	dobj	maintenance,favored
R7887	T11497	T11496	prep	of,maintenance
R7888	T11498	T11499	compound	amyloid,deposits
R7889	T11499	T11497	pobj	deposits,of
R7890	T11500	T11463	punct	.,favored
R7891	T11502	T11503	prep	In,seems
R7892	T11504	T11505	poss	our,opinion
R7893	T11505	T11502	pobj	opinion,In
R7894	T11506	T11503	punct	", ",seems
R7895	T11507	T11503	nsubj	it,seems
R7896	T11508	T11503	oprd	unlikely,seems
R7897	T11509	T11510	mark	that,be
R7898	T11510	T11503	ccomp	be,seems
R7899	T11511	T11512	compound	amyloid,deposits
R7900	T11512	T11510	nsubj	deposits,be
R7901	T11513	T11512	prep	in,deposits
R7902	T11514	T11515	amod	human,brain
R7903	T11515	T11513	pobj	brain,in
R7904	T11516	T11510	aux	would,be
R7905	T11517	T11510	advmod	inherently,be
R7906	T11518	T11519	advmod	any,stable
R7907	T11519	T11510	acomp	stable,be
R7908	T11520	T11519	advmod	less,stable
R7909	T11521	T11519	prep	than,stable
R7910	T11522	T11521	pobj	those,than
R7911	T11523	T11522	acl	formed,those
R7912	T11524	T11523	prep	in,formed
R7913	T11525	T11526	compound	mouse,brain
R7914	T11526	T11524	pobj	brain,in
R7915	T11527	T11503	punct	.,seems
R7916	T11529	T11530	advmod	However,harbor
R7917	T11531	T11530	punct	", ",harbor
R7918	T11532	T11533	det	the,brain
R7919	T11533	T11530	nsubj	brain,harbor
R7920	T11534	T11533	amod	human,brain
R7921	T11535	T11530	aux	may,harbor
R7922	T11536	T11537	compound	clearance,mechanisms
R7923	T11537	T11530	dobj	mechanisms,harbor
R7924	T11538	T11539	neg	not,shared
R7925	T11539	T11537	acl	shared,mechanisms
R7926	T11540	T11539	agent	by,shared
R7927	T11541	T11540	pobj	mice,by
R7928	T11542	T11543	dep	that,allow
R7929	T11543	T11537	relcl	allow,mechanisms
R7930	T11544	T11543	aux	would,allow
R7931	T11545	T11546	advmod	more,efficient
R7932	T11546	T11547	amod	efficient,removal
R7933	T11547	T11543	dobj	removal,allow
R7934	T11548	T11547	prep	of,removal
R7935	T11549	T11550	amod	preexisting,amyloid
R7936	T11550	T11548	pobj	amyloid,of
R7937	T11551	T11530	punct	.,harbor
R7938	T11553	T11554	nummod	One,mechanism
R7939	T11554	T11556	nsubj	mechanism,is
R7940	T11555	T11554	amod	potential,mechanism
R7941	T11557	T11558	prep	by,removed
R7942	T11558	T11554	relcl	removed,mechanism
R7943	T11559	T11557	pobj	which,by
R7944	T11560	T11558	nsubjpass	amyloid,removed
R7945	T11561	T11558	aux	may,removed
R7946	T11562	T11558	auxpass	be,removed
R7947	T11563	T11564	advmod	more,efficiently
R7948	T11564	T11558	advmod	efficiently,removed
R7949	T11565	T11558	prep	in,removed
R7950	T11566	T11567	det	the,disease
R7951	T11567	T11565	pobj	disease,in
R7952	T11568	T11567	amod	human,disease
R7953	T11569	T11558	prep	than,removed
R7954	T11570	T11569	prep	in,than
R7955	T11571	T11572	det	the,models
R7956	T11572	T11570	pobj	models,in
R7957	T11573	T11572	compound	mouse,models
R7958	T11574	T11556	prep	through,is
R7959	T11575	T11576	amod	microglial,phagocytosis
R7960	T11576	T11574	pobj	phagocytosis,through
R7961	T11577	T11556	punct	.,is
R7962	T11579	T11580	amod	Resident,microglia
R7963	T11580	T11581	nsubj	microglia,localize
R7964	T11582	T11580	prep	in,microglia
R7965	T11583	T11584	amod	transgenic,models
R7966	T11584	T11582	pobj	models,in
R7967	T11585	T11584	compound	mouse,models
R7968	T11586	T11581	prep	to,localize
R7969	T11587	T11586	pobj	tissue,to
R7970	T11588	T11587	acl	surrounding,tissue
R7971	T11589	T11588	dobj	plaques,surrounding
R7972	T11590	T11581	cc	but,localize
R7973	T11591	T11581	conj	show,localize
R7974	T11592	T11593	amod	little,evidence
R7975	T11593	T11591	dobj	evidence,show
R7976	T11594	T11593	prep	of,evidence
R7977	T11595	T11596	compound	amyloid,engulfment
R7978	T11596	T11594	pobj	engulfment,of
R7979	T11597	T11598	punct	[,37
R7980	T11598	T11591	parataxis	37,show
R7981	T11599	T11600	punct	–,40
R7982	T11600	T11598	prep	40,37
R7983	T11601	T11598	punct	],37
R7984	T11602	T11581	punct	.,localize
R7985	T11604	T11605	prep	In,show
R7986	T11606	T11604	pobj	contrast,In
R7987	T11607	T11605	punct	", ",show
R7988	T11608	T11605	nsubj	microglia,show
R7989	T11609	T11608	acl	surrounding,microglia
R7990	T11610	T11611	compound	amyloid,plaques
R7991	T11611	T11609	dobj	plaques,surrounding
R7992	T11612	T11609	prep	in,surrounding
R7993	T11613	T11614	amod	human,brain
R7994	T11614	T11612	pobj	brain,in
R7995	T11615	T11616	det	a,state
R7996	T11616	T11605	dobj	state,show
R7997	T11617	T11618	advmod	much,higher
R7998	T11618	T11616	amod	higher,state
R7999	T11619	T11616	prep	of,state
R8000	T11620	T11619	pobj	activation,of
R8001	T11621	T11605	prep	with,show
R8002	T11622	T11623	amod	greater,expression
R8003	T11623	T11621	pobj	expression,with
R8004	T11624	T11623	prep	of,expression
R8005	T11625	T11626	compound	complement,receptor
R8006	T11626	T11624	pobj	receptor,of
R8007	T11627	T11628	punct	[,40
R8008	T11628	T11605	parataxis	40,show
R8009	T11629	T11628	punct	],40
R8010	T11630	T11605	punct	.,show
R8011	T11632	T11633	advmod	Thus,is
R8012	T11634	T11633	punct	", ",is
R8013	T11635	T11636	det	the,role
R8014	T11636	T11633	nsubj	role,is
R8015	T11637	T11636	prep	of,role
R8016	T11638	T11637	pobj	microglia,of
R8017	T11639	T11636	prep	in,role
R8018	T11640	T11641	compound	amyloid,metabolism
R8019	T11641	T11639	pobj	metabolism,in
R8020	T11642	T11633	acomp	minor,is
R8021	T11643	T11633	prep	in,is
R8022	T11644	T11645	amod	transgenic,models
R8023	T11645	T11643	pobj	models,in
R8024	T11646	T11633	prep	compared,is
R8025	T11647	T11646	prep	to,compared
R8026	T11648	T11649	det	the,condition
R8027	T11649	T11647	pobj	condition,to
R8028	T11650	T11649	amod	human,condition
R8029	T11651	T11633	punct	.,is
R8030	T11653	T11654	advmod	Somewhat,paradoxically
R8031	T11654	T11655	advmod	paradoxically,demonstrate
R8032	T11656	T11655	punct	", ",demonstrate
R8033	T11657	T11658	amod	several,studies
R8034	T11658	T11655	nsubj	studies,demonstrate
R8035	T11659	T11655	advmod	further,demonstrate
R8036	T11660	T11661	mark	that,lowers
R8037	T11661	T11655	ccomp	lowers,demonstrate
R8038	T11662	T11661	nsubj	treatment,lowers
R8039	T11663	T11662	prep	with,treatment
R8040	T11664	T11665	amod	anti-inflammatory,drugs
R8041	T11665	T11663	pobj	drugs,with
R8042	T11666	T11667	aux	to,reduce
R8043	T11667	T11662	advcl	reduce,treatment
R8044	T11668	T11669	amod	microglial,activation
R8045	T11669	T11667	dobj	activation,reduce
R8046	T11670	T11661	advmod	actually,lowers
R8047	T11671	T11672	compound	amyloid,load
R8048	T11672	T11661	dobj	load,lowers
R8049	T11673	T11661	prep	in,lowers
R8050	T11674	T11675	npadvmod	APP,transgenic
R8051	T11675	T11676	amod	transgenic,mice
R8052	T11676	T11673	pobj	mice,in
R8053	T11677	T11661	punct	", ",lowers
R8054	T11678	T11661	advcl	suggesting,lowers
R8055	T11679	T11680	det	a,role
R8056	T11680	T11678	dobj	role,suggesting
R8057	T11681	T11680	prep	for,role
R8058	T11682	T11683	compound	mouse,microglia
R8059	T11683	T11681	pobj	microglia,for
R8060	T11684	T11680	prep	in,role
R8061	T11685	T11686	det	the,formation
R8062	T11686	T11684	pobj	formation,in
R8063	T11687	T11686	cc	and,formation
R8064	T11688	T11686	conj	maintenance,formation
R8065	T11689	T11686	prep	of,formation
R8066	T11690	T11691	compound	amyloid,aggregates
R8067	T11691	T11689	pobj	aggregates,of
R8068	T11692	T11693	punct	[,41
R8069	T11693	T11661	parataxis	41,lowers
R8070	T11694	T11695	punct	–,43
R8071	T11695	T11693	prep	43,41
R8072	T11696	T11693	punct	],41
R8073	T11697	T11655	punct	.,demonstrate
R8074	T11699	T11700	advmod	However,explained
R8075	T11701	T11700	punct	", ",explained
R8076	T11702	T11703	det	this,outcome
R8077	T11703	T11700	nsubjpass	outcome,explained
R8078	T11704	T11700	aux	may,explained
R8079	T11705	T11700	auxpass	be,explained
R8080	T11706	T11700	advmod	alternatively,explained
R8081	T11707	T11700	agent	by,explained
R8082	T11708	T11709	amod	direct,effects
R8083	T11709	T11707	pobj	effects,by
R8084	T11710	T11709	prep	of,effects
R8085	T11711	T11712	amod	many,drugs
R8086	T11712	T11710	pobj	drugs,of
R8087	T11713	T11712	amod	anti-inflammatory,drugs
R8088	T11714	T11709	prep	on,effects
R8089	T11715	T11716	punct	γ,secretase
R8090	T11716	T11718	compound	secretase,cleavage
R8091	T11717	T11716	punct	-,secretase
R8092	T11718	T11714	pobj	cleavage,on
R8093	T11719	T11720	punct	[,44
R8094	T11720	T11700	parataxis	44,explained
R8095	T11721	T11722	punct	–,47
R8096	T11722	T11720	prep	47,44
R8097	T11723	T11720	punct	],44
R8098	T11724	T11700	punct	.,explained
R8099	T11726	T11727	advmod	Nonetheless,is
R8100	T11728	T11727	punct	", ",is
R8101	T11729	T11730	det	the,role
R8102	T11730	T11727	nsubj	role,is
R8103	T11731	T11730	prep	of,role
R8104	T11732	T11731	pobj	microglia,of
R8105	T11733	T11730	prep	in,role
R8106	T11734	T11735	preconj	both,condition
R8107	T11735	T11733	pobj	condition,in
R8108	T11736	T11735	det	the,condition
R8109	T11737	T11735	amod	human,condition
R8110	T11738	T11735	cc	and,condition
R8111	T11739	T11740	det	the,models
R8112	T11740	T11735	conj	models,condition
R8113	T11741	T11740	compound	mouse,models
R8114	T11742	T11743	advmod	poorly,understood
R8115	T11743	T11727	acomp	understood,is
R8116	T11744	T11727	punct	", ",is
R8117	T11745	T11727	cc	and,is
R8118	T11746	T11747	nsubj	differences,lead
R8119	T11747	T11727	conj	lead,is
R8120	T11748	T11746	prep	in,differences
R8121	T11749	T11750	amod	microglial,reactivity
R8122	T11750	T11748	pobj	reactivity,in
R8123	T11751	T11746	prep	between,differences
R8124	T11752	T11753	det	the,two
R8125	T11753	T11751	pobj	two,between
R8126	T11754	T11747	aux	could,lead
R8127	T11755	T11747	prep	to,lead
R8128	T11756	T11757	advmod	significantly,faster
R8129	T11757	T11758	amod	faster,clearance
R8130	T11758	T11755	pobj	clearance,to
R8131	T11759	T11758	compound	amyloid,clearance
R8132	T11760	T11758	prep	in,clearance
R8133	T11761	T11762	det	the,brains
R8134	T11762	T11760	pobj	brains,in
R8135	T11763	T11762	prep	of,brains
R8136	T11764	T11763	pobj	patients,of
R8137	T11765	T11764	prep	with,patients
R8138	T11766	T11765	pobj	AD,with
R8139	T11767	T11768	mark	than,observe
R8140	T11768	T11758	advcl	observe,clearance
R8141	T11769	T11768	nsubj	we,observe
R8142	T11770	T11768	prep	in,observe
R8143	T11771	T11772	det	the,mice
R8144	T11772	T11770	pobj	mice,in
R8145	T11773	T11774	compound	tet,off
R8146	T11774	T11772	compound	off,mice
R8147	T11775	T11774	punct	-,off
R8148	T11776	T11772	compound	APP,mice
R8149	T11777	T11747	punct	.,lead
R8150	T11779	T11780	prep	Given,think
R8151	T11781	T11782	det	the,role
R8152	T11782	T11779	pobj	role,Given
R8153	T11783	T11784	advmod	relatively,minor
R8154	T11784	T11782	amod	minor,role
R8155	T11785	T11782	acl	played,role
R8156	T11786	T11785	agent	by,played
R8157	T11787	T11786	pobj	microglia,by
R8158	T11788	T11785	prep	in,played
R8159	T11789	T11790	amod	other,models
R8160	T11790	T11788	pobj	models,in
R8161	T11791	T11790	compound	mouse,models
R8162	T11792	T11790	prep	of,models
R8163	T11793	T11792	pobj	amyloidosis,of
R8164	T11794	T11780	punct	", ",think
R8165	T11795	T11780	nsubj	we,think
R8166	T11796	T11797	nsubj	it,unlikely
R8167	T11797	T11780	advcl	unlikely,think
R8168	T11798	T11799	mark	that,influenced
R8169	T11799	T11797	advcl	influenced,unlikely
R8170	T11800	T11801	det	these,cells
R8171	T11801	T11799	nsubj	cells,influenced
R8172	T11802	T11799	aux	have,influenced
R8173	T11803	T11804	det	the,rate
R8174	T11804	T11799	dobj	rate,influenced
R8175	T11805	T11804	prep	of,rate
R8176	T11806	T11807	compound	amyloid,clearance
R8177	T11807	T11805	pobj	clearance,of
R8178	T11808	T11799	prep	in,influenced
R8179	T11809	T11810	det	the,mice
R8180	T11810	T11808	pobj	mice,in
R8181	T11811	T11812	compound	tet,off
R8182	T11812	T11810	compound	off,mice
R8183	T11813	T11812	punct	-,off
R8184	T11814	T11810	compound	APP,mice
R8185	T11815	T11780	punct	.,think
R8186	T11817	T11818	advmod	Even,so
R8187	T11818	T11819	advmod	so,considered
R8188	T11820	T11819	punct	", ",considered
R8189	T11821	T11819	nsubj	we,considered
R8190	T11822	T11823	det	the,possibility
R8191	T11823	T11819	dobj	possibility,considered
R8192	T11824	T11825	mark	that,altered
R8193	T11825	T11823	acl	altered,possibility
R8194	T11826	T11827	amod	chronic,treatment
R8195	T11827	T11825	nsubj	treatment,altered
R8196	T11828	T11827	compound	dox,treatment
R8197	T11829	T11825	aux	may,altered
R8198	T11830	T11825	aux	have,altered
R8199	T11831	T11832	det	the,state
R8200	T11832	T11825	dobj	state,altered
R8201	T11833	T11832	compound	activation,state
R8202	T11834	T11832	prep	of,state
R8203	T11835	T11834	pobj	microglia,of
R8204	T11836	T11825	prep	in,altered
R8205	T11837	T11838	poss	our,mice
R8206	T11838	T11836	pobj	mice,in
R8207	T11839	T11838	amod	treated,mice
R8208	T11840	T11819	punct	.,considered
R8209	T11842	T11843	nsubj	Dox,is
R8210	T11844	T11845	advmod	structurally,similar
R8211	T11845	T11843	acomp	similar,is
R8212	T11846	T11845	prep	to,similar
R8213	T11847	T11846	pobj	minocycline,to
R8214	T11848	T11847	punct	", ",minocycline
R8215	T11849	T11850	det	a,drug
R8216	T11850	T11847	appos	drug,minocycline
R8217	T11851	T11850	amod	reported,drug
R8218	T11852	T11850	amod	anti-inflammatory,drug
R8219	T11853	T11850	cc	and,drug
R8220	T11854	T11850	conj	inhibitor,drug
R8221	T11855	T11854	prep	of,inhibitor
R8222	T11856	T11857	amod	microglial,activation
R8223	T11857	T11855	pobj	activation,of
R8224	T11858	T11859	punct	[,48
R8225	T11859	T11843	parataxis	48,is
R8226	T11860	T11859	punct	],48
R8227	T11861	T11843	punct	.,is
R8228	T11863	T11864	advmod	However,expected
R8229	T11865	T11864	punct	", ",expected
R8230	T11866	T11867	mark	if,have
R8231	T11867	T11864	advcl	have,expected
R8232	T11868	T11867	nsubj	dox,have
R8233	T11869	T11867	aux	does,have
R8234	T11870	T11871	amod	anti-inflammatory,activity
R8235	T11871	T11867	dobj	activity,have
R8236	T11872	T11864	punct	", ",expected
R8237	T11873	T11864	advmod	then,expected
R8238	T11874	T11864	punct	", ",expected
R8239	T11875	T11864	prep	based,expected
R8240	T11876	T11875	prep	on,based
R8241	T11877	T11878	amod	previous,studies
R8242	T11878	T11876	pobj	studies,on
R8243	T11879	T11878	prep	with,studies
R8244	T11880	T11881	amod	other,anti-inflammatories
R8245	T11881	T11879	pobj	anti-inflammatories,with
R8246	T11882	T11864	punct	", ",expected
R8247	T11883	T11864	nsubj	we,expected
R8248	T11884	T11864	aux	would,expected
R8249	T11885	T11864	aux	have,expected
R8250	T11886	T11887	aux	to,find
R8251	T11887	T11864	xcomp	find,expected
R8252	T11888	T11889	advmod	less,amyloid
R8253	T11889	T11887	dobj	amyloid,find
R8254	T11890	T11887	prep	in,find
R8255	T11891	T11892	det	the,animals
R8256	T11892	T11890	pobj	animals,in
R8257	T11893	T11894	npadvmod	dox,treated
R8258	T11894	T11892	amod	treated,animals
R8259	T11895	T11894	punct	-,treated
R8260	T11896	T11864	punct	.,expected
R8261	T11898	T11899	advmod	Clearly,was
R8262	T11900	T11899	punct	", ",was
R8263	T11901	T11899	nsubj	that,was
R8264	T11902	T11899	neg	not,was
R8265	T11903	T11904	det	the,case
R8266	T11904	T11899	attr	case,was
R8267	T11905	T11899	punct	.,was
R8268	T11907	T11908	mark	While,is
R8269	T11908	T11910	advcl	is,demonstrate
R8270	T11909	T11908	nsubj	it,is
R8271	T11911	T11908	acomp	possible,is
R8272	T11912	T11913	mark	that,acts
R8273	T11913	T11908	ccomp	acts,is
R8274	T11914	T11913	nsubj	dox,acts
R8275	T11915	T11913	prep	in,acts
R8276	T11916	T11917	det	some,way
R8277	T11917	T11915	pobj	way,in
R8278	T11918	T11917	amod	other,way
R8279	T11919	T11920	aux	to,slow
R8280	T11920	T11913	advcl	slow,acts
R8281	T11921	T11922	compound	amyloid,clearance
R8282	T11922	T11920	dobj	clearance,slow
R8283	T11923	T11910	punct	", ",demonstrate
R8284	T11924	T11910	nsubj	data,demonstrate
R8285	T11925	T11924	prep	from,data
R8286	T11926	T11927	amod	multiple,studies
R8287	T11927	T11925	pobj	studies,from
R8288	T11928	T11929	mark	that,are
R8289	T11929	T11910	ccomp	are,demonstrate
R8290	T11930	T11931	amod	microglial,responses
R8291	T11931	T11929	nsubj	responses,are
R8292	T11932	T11929	advmod	normally,are
R8293	T11933	T11929	acomp	weak,are
R8294	T11934	T11929	prep	in,are
R8295	T11935	T11936	det	the,models
R8296	T11936	T11934	pobj	models,in
R8297	T11937	T11936	compound	mouse,models
R8298	T11938	T11936	compound	AD,models
R8299	T11939	T11940	punct	[,37
R8300	T11940	T11929	parataxis	37,are
R8301	T11941	T11942	punct	–,40
R8302	T11942	T11940	prep	40,37
R8303	T11943	T11940	punct	],37
R8304	T11944	T11929	punct	", ",are
R8305	T11945	T11929	cc	and,are
R8306	T11946	T11947	advmod	thus,is
R8307	T11947	T11929	conj	is,are
R8308	T11948	T11947	nsubj	it,is
R8309	T11949	T11947	acomp	doubtful,is
R8310	T11950	T11951	mark	that,affected
R8311	T11951	T11947	ccomp	affected,is
R8312	T11952	T11953	npadvmod	dox,mediated
R8313	T11953	T11955	amod	mediated,inhibition
R8314	T11954	T11953	punct	-,mediated
R8315	T11955	T11951	nsubj	inhibition,affected
R8316	T11956	T11955	amod	microglial,inhibition
R8317	T11957	T11958	det	the,outcome
R8318	T11958	T11951	dobj	outcome,affected
R8319	T11959	T11958	prep	of,outcome
R8320	T11960	T11961	poss	our,study
R8321	T11961	T11959	pobj	study,of
R8322	T11962	T11910	punct	.,demonstrate
R8323	T11964	T11965	det	The,persistence
R8324	T11965	T11966	nsubj	persistence,is
R8325	T11967	T11965	cc	and,persistence
R8326	T11968	T11965	conj	stability,persistence
R8327	T11969	T11965	prep	of,persistence
R8328	T11970	T11971	compound	amyloid,deposits
R8329	T11971	T11969	pobj	deposits,of
R8330	T11972	T11965	prep	in,persistence
R8331	T11973	T11974	poss	our,system
R8332	T11974	T11972	pobj	system,in
R8333	T11975	T11966	acomp	unexpected,is
R8334	T11976	T11966	prep	given,is
R8335	T11977	T11978	det	the,speed
R8336	T11978	T11976	pobj	speed,given
R8337	T11979	T11980	prep	with,cleared
R8338	T11980	T11978	relcl	cleared,speed
R8339	T11981	T11979	pobj	which,with
R8340	T11982	T11983	compound	Aβ,aggregates
R8341	T11983	T11980	nsubjpass	aggregates,cleared
R8342	T11984	T11980	auxpass	are,cleared
R8343	T11985	T11980	prep	in,cleared
R8344	T11986	T11987	amod	other,models
R8345	T11987	T11985	pobj	models,in
R8346	T11988	T11987	compound	mouse,models
R8347	T11989	T11987	prep	of,models
R8348	T11990	T11991	amod	therapeutic,intervention
R8349	T11991	T11989	pobj	intervention,of
R8350	T11992	T11966	punct	.,is
R8351	T11994	T11995	amod	Anti-Aβ,antibodies
R8352	T11995	T11996	nsubjpass	antibodies,shown
R8353	T11997	T11995	acl	injected,antibodies
R8354	T11998	T11997	advmod	directly,injected
R8355	T11999	T11997	prep	into,injected
R8356	T12000	T12001	det	the,brain
R8357	T12001	T11999	pobj	brain,into
R8358	T12002	T11996	aux	have,shown
R8359	T12003	T11996	auxpass	been,shown
R8360	T12004	T12005	aux	to,eliminate
R8361	T12005	T11996	xcomp	eliminate,shown
R8362	T12006	T12007	compound	amyloid,deposits
R8363	T12007	T12005	dobj	deposits,eliminate
R8364	T12008	T12005	prep	in,eliminate
R8365	T12009	T12010	advmod	as,1
R8366	T12010	T12013	nummod	1,wk
R8367	T12011	T12010	amod	little,1
R8368	T12012	T12010	quantmod	as,1
R8369	T12013	T12008	pobj	wk,in
R8370	T12014	T12013	prep	after,wk
R8371	T12015	T12014	pobj	treatment,after
R8372	T12016	T12017	punct	[,49
R8373	T12017	T12005	parataxis	49,eliminate
R8374	T12018	T12019	punct	–,51
R8375	T12019	T12017	prep	51,49
R8376	T12020	T12017	punct	],49
R8377	T12021	T11996	punct	.,shown
R8378	T12023	T12024	amod	Peripheral,injection
R8379	T12024	T12026	nsubj	injection,decreases
R8380	T12025	T12024	compound	antibody,injection
R8381	T12027	T12028	compound	amyloid,load
R8382	T12028	T12026	dobj	load,decreases
R8383	T12029	T12030	advmod	more,broadly
R8384	T12030	T12026	advmod	broadly,decreases
R8385	T12031	T12026	punct	", ",decreases
R8386	T12032	T12026	cc	and,decreases
R8387	T12033	T12034	mark	although,appear
R8388	T12034	T12038	advcl	appear,reduce
R8389	T12035	T12034	nsubj	it,appear
R8390	T12036	T12034	aux	does,appear
R8391	T12037	T12034	neg	not,appear
R8392	T12038	T12026	conj	reduce,decreases
R8393	T12039	T12040	aux	to,act
R8394	T12040	T12034	xcomp	act,appear
R8395	T12041	T12042	advmod	as,quickly
R8396	T12042	T12040	advmod	quickly,act
R8397	T12043	T12042	prep	as,quickly
R8398	T12044	T12045	amod	local,injection
R8399	T12045	T12043	pobj	injection,as
R8400	T12046	T12038	punct	", ",reduce
R8401	T12047	T12038	aux	can,reduce
R8402	T12048	T12038	advmod	significantly,reduce
R8403	T12086	T12084	pobj	area,in
R8404	T12049	T12050	compound	amyloid,load
R8405	T12087	T12086	prep	of,area
R8406	T12050	T12038	dobj	load,reduce
R8407	T12088	T12089	det	the,site
R8408	T12051	T12038	prep	within,reduce
R8409	T12052	T12053	nummod	2,mo
R8410	T12089	T12087	pobj	site,of
R8411	T12090	T12089	compound	injection,site
R8412	T12053	T12051	pobj	mo,within
R8413	T12091	T12092	punct	[,54
R8414	T12092	T12073	parataxis	54,reduce
R8415	T12054	T12053	prep	of,mo
R8416	T12093	T12092	punct	],54
R8417	T12094	T12066	punct	.,shown
R8418	T12055	T12056	amod	initial,treatment
R8419	T12096	T12097	amod	Careful,study
R8420	T12097	T12098	nsubj	study,suggested
R8421	T12056	T12054	pobj	treatment,of
R8422	T12099	T12097	prep	of,study
R8423	T12057	T12058	punct	[,53
R8424	T12100	T12101	det	the,mechanism
R8425	T12101	T12099	pobj	mechanism,of
R8426	T12058	T12038	parataxis	53,reduce
R8427	T12102	T12101	prep	behind,mechanism
R8428	T12103	T12102	pobj	several,behind
R8429	T12104	T12103	prep	of,several
R8430	T12059	T12058	nummod	52,53
R8431	T12105	T12106	det	the,therapies
R8432	T12106	T12104	pobj	therapies,of
R8433	T12107	T12108	npadvmod	antibody,mediated
R8434	T12108	T12106	amod	mediated,therapies
R8435	T12109	T12108	punct	-,mediated
R8436	T12060	T12058	punct	",",53
R8437	T12110	T12098	aux	has,suggested
R8438	T12111	T12112	mark	that,play
R8439	T12112	T12098	ccomp	play,suggested
R8440	T12061	T12058	punct	],53
R8441	T12113	T12114	amod	activated,microglia
R8442	T12114	T12112	nsubj	microglia,play
R8443	T12115	T12116	det	an,role
R8444	T12062	T12026	punct	.,decreases
R8445	T12116	T12112	dobj	role,play
R8446	T12117	T12116	amod	important,role
R8447	T12064	T12065	advmod	More,recently
R8448	T12118	T12112	prep	in,play
R8449	T12119	T12120	det	the,removal
R8450	T12120	T12118	pobj	removal,in
R8451	T12121	T12120	prep	of,removal
R8452	T12065	T12066	advmod	recently,shown
R8453	T12122	T12123	amod	fibrillar,plaques
R8454	T12123	T12121	pobj	plaques,of
R8455	T12124	T12112	prep	after,play
R8456	T12067	T12066	punct	", ",shown
R8457	T12125	T12124	pobj	immunization,after
R8458	T12126	T12127	punct	[,55
R8459	T12127	T12098	parataxis	55,suggested
R8461	T12068	T12069	det	an,approach
R8462	T12129	T12127	punct	",",55
R8463	T12130	T12127	nummod	52,55
R8464	T12131	T12127	punct	",",55
R8465	T12069	T12066	nsubj	approach,shown
R8466	T12132	T12127	punct	],55
R8467	T12133	T12098	punct	.,suggested
R8468	T12070	T12069	amod	alternative,approach
R8469	T12135	T12136	advmod	However,noted
R8470	T12071	T12066	aux	has,shown
R8471	T12137	T12136	punct	", ",noted
R8472	T12138	T12136	nsubjpass	it,noted
R8473	T12139	T12136	aux	has,noted
R8474	T12072	T12073	mark	that,reduce
R8475	T12140	T12136	auxpass	been,noted
R8476	T12141	T12142	mark	that,has
R8477	T12073	T12066	ccomp	reduce,shown
R8478	T12142	T12136	ccomp	has,noted
R8479	T12143	T12142	nsubj	deletion,has
R8480	T12144	T12143	prep	of,deletion
R8481	T12074	T12075	amod	lentiviral,transfer
R8482	T12145	T12146	det	the,receptor
R8483	T12146	T12144	pobj	receptor,of
R8484	T12147	T12146	compound	Fc,receptor
R8485	T12148	T12146	punct	(,receptor
R8486	T12149	T12150	det	the,receptor
R8487	T12075	T12073	nsubj	transfer,reduce
R8488	T12150	T12146	appos	receptor,receptor
R8489	T12151	T12150	amod	primary,receptor
R8490	T12152	T12150	prep	for,receptor
R8491	T12076	T12075	prep	of,transfer
R8492	T12153	T12154	amod	microglial,opsinization
R8493	T12154	T12152	pobj	opsinization,for
R8494	T12155	T12154	prep	of,opsinization
R8495	T12077	T12076	pobj	neprilysin,of
R8496	T12156	T12157	compound	antibody,antigen
R8497	T12157	T12159	compound	antigen,complexes
R8498	T12158	T12157	punct	–,antigen
R8499	T12078	T12073	aux	can,reduce
R8500	T12159	T12155	pobj	complexes,of
R8501	T12160	T12143	punct	),deletion
R8502	T12079	T12073	advmod	also,reduce
R8503	T12161	T12143	prep	in,deletion
R8504	T12162	T12163	npadvmod	APP,transgenic
R8505	T12163	T12164	amod	transgenic,models
R8506	T12080	T12081	det	the,number
R8507	T12164	T12161	pobj	models,in
R8508	T12165	T12164	compound	mouse,models
R8509	T12166	T12167	det	no,impact
R8510	T12081	T12073	dobj	number,reduce
R8511	T12167	T12142	dobj	impact,has
R8512	T12168	T12167	prep	on,impact
R8513	T12082	T12081	prep	of,number
R8514	T12169	T12170	det	the,effectiveness
R8515	T12170	T12168	pobj	effectiveness,on
R8516	T12171	T12170	prep	of,effectiveness
R8517	T12083	T12082	pobj	aggregates,of
R8518	T12172	T12173	npadvmod	antibody,mediated
R8519	T12084	T12073	prep	in,reduce
R8520	T12085	T12086	det	the,area
R8521	T12173	T12175	amod	mediated,therapy
R8522	T12192	T12191	prep	of,lack
R8523	T12174	T12173	punct	-,mediated
R8524	T12175	T12171	pobj	therapy,of
R8525	T12176	T12177	punct	[,57
R8526	T12177	T12142	parataxis	57,has
R8527	T12193	T12194	compound	microglia,activation
R8528	T12178	T12177	nummod	56,57
R8529	T12179	T12177	punct	",",57
R8530	T12180	T12177	punct	],57
R8531	T12194	T12192	pobj	activation,of
R8532	T12181	T12136	punct	.,noted
R8533	T12195	T12196	det	the,difference
R8534	T12183	T12184	nsubj	It,is
R8535	T12196	T12190	attr	difference,is
R8536	T12185	T12184	punct	", ",is
R8537	T12186	T12184	advmod	nevertheless,is
R8538	T12187	T12184	punct	", ",is
R8539	T12188	T12184	acomp	possible,is
R8540	T12189	T12190	mark	that,is
R8541	T12190	T12184	ccomp	is,is
R8542	T12197	T12196	amod	major,difference
R8543	T12191	T12190	nsubj	lack,is
R8544	T12198	T12196	prep	between,difference
R8545	T12199	T12200	det	the,clearance
R8546	T12200	T12198	pobj	clearance,between
R8547	T12201	T12200	amod	slow,clearance
R8548	T12202	T12200	acl	described,clearance
R8549	T12203	T12202	advmod	here,described
R8550	T12298	T12297	punct	],58
R8551	T12299	T12293	cc	or,expression
R8552	T12204	T12200	punct	", ",clearance
R8553	T12300	T12301	amod	central,injection
R8554	T12301	T12293	conj	injection,expression
R8555	T12302	T12301	prep	of,injection
R8556	T12205	T12206	advmod	where,expected
R8557	T12303	T12302	pobj	lipopolysaccharide,of
R8558	T12304	T12305	punct	[,60
R8559	T12305	T12303	parataxis	60,lipopolysaccharide
R8560	T12206	T12200	relcl	expected,clearance
R8561	T12306	T12305	nummod	59,60
R8562	T12307	T12305	punct	",",60
R8563	T12207	T12208	det	no,perturbation
R8564	T12308	T12305	punct	],60
R8565	T12309	T12282	aux	can,reduce
R8566	T12310	T12282	prep	by,reduce
R8567	T12208	T12206	nsubjpass	perturbation,expected
R8568	T12311	T12310	pobj	itself,by
R8569	T12312	T12282	advmod	substantially,reduce
R8570	T12209	T12208	prep	of,perturbation
R8571	T12313	T12314	compound	plaque,burden
R8572	T12314	T12282	dobj	burden,reduce
R8573	T12315	T12282	prep	in,reduce
R8574	T12210	T12211	det	the,system
R8575	T12316	T12317	npadvmod	APP,transgenic
R8576	T12317	T12318	amod	transgenic,mice
R8577	T12211	T12209	pobj	system,of
R8578	T12318	T12315	pobj	mice,in
R8579	T12319	T12282	punct	.,reduce
R8580	T12212	T12211	amod	immune,system
R8581	T12321	T12322	cc	But,reaggregates
R8582	T12213	T12206	auxpass	is,expected
R8583	T12323	T12322	prep	in,reaggregates
R8584	T12324	T12325	det	the,case
R8585	T12325	T12323	pobj	case,in
R8586	T12214	T12200	punct	", ",clearance
R8587	T12326	T12325	prep	of,case
R8588	T12327	T12328	amod	acute,activation
R8589	T12328	T12326	pobj	activation,of
R8590	T12329	T12330	npadvmod	antibody,mediated
R8591	T12330	T12328	amod	mediated,activation
R8592	T12215	T12200	cc	and,clearance
R8593	T12331	T12329	punct	-,antibody
R8594	T12332	T12329	cc	and,antibody
R8595	T12333	T12332	punct	/,and
R8596	T12216	T12217	det	the,clearance
R8597	T12334	T12332	cc	or,and
R8598	T12335	T12329	conj	injury,antibody
R8599	T12336	T12330	punct	-,mediated
R8600	T12217	T12200	conj	clearance,clearance
R8601	T12337	T12322	punct	", ",reaggregates
R8602	T12338	T12339	mark	once,passed
R8603	T12339	T12322	advcl	passed,reaggregates
R8604	T12218	T12217	amod	rapid,clearance
R8605	T12340	T12341	det	the,inflammation
R8606	T12341	T12339	nsubj	inflammation,passed
R8607	T12219	T12217	acl	described,clearance
R8608	T12342	T12339	aux	has,passed
R8609	T12220	T12219	prep	in,described
R8610	T12343	T12339	punct	", ",passed
R8611	T12221	T12220	pobj	studies,in
R8612	T12344	T12339	cc	and,passed
R8613	T12345	T12346	det	the,antibody
R8614	T12346	T12347	nsubjpass	antibody,cleared
R8615	T12222	T12221	acl	involving,studies
R8616	T12347	T12339	conj	cleared,passed
R8617	T12223	T12224	nmod	antibody,injection
R8618	T12348	T12346	cc	and,antibody
R8619	T12349	T12350	amod	bound,peptide
R8620	T12350	T12346	conj	peptide,antibody
R8621	T12224	T12222	dobj	injection,involving
R8622	T12351	T12347	aux	have,cleared
R8623	T12352	T12347	auxpass	been,cleared
R8624	T12353	T12347	cc	and,cleared
R8625	T12225	T12223	cc	or,antibody
R8626	T12354	T12347	conj	degraded,cleared
R8627	T12355	T12322	punct	", ",reaggregates
R8628	T12356	T12357	det	the,Aβ
R8629	T12226	T12223	conj	viral,antibody
R8630	T12357	T12322	nsubj	Aβ,reaggregates
R8631	T12358	T12357	amod	remaining,Aβ
R8632	T12227	T12184	punct	.,is
R8633	T12359	T12322	advmod	quickly,reaggregates
R8634	T12360	T12322	cc	and,reaggregates
R8635	T12361	T12362	compound	amyloid,pathology
R8636	T12229	T12230	prep	In,be
R8637	T12362	T12363	nsubjpass	pathology,reestablished
R8638	T12363	T12322	conj	reestablished,reaggregates
R8639	T12364	T12363	auxpass	is,reestablished
R8640	T12365	T12366	punct	[,49
R8641	T12366	T12363	parataxis	49,reestablished
R8642	T12367	T12366	punct	],49
R8643	T12368	T12322	punct	.,reaggregates
R8644	T12231	T12229	pobj	isolation,In
R8645	T12370	T12371	det	This,finding
R8646	T12371	T12372	nsubj	finding,reinforces
R8647	T12232	T12230	punct	", ",be
R8648	T12373	T12374	det	the,notion
R8649	T12374	T12372	dobj	notion,reinforces
R8650	T12375	T12376	mark	that,maintain
R8651	T12233	T12234	amod	mild,activation
R8652	T12376	T12374	acl	maintain,notion
R8653	T12377	T12376	prep	without,maintain
R8654	T12234	T12230	nsubj	activation,be
R8655	T12378	T12379	amod	continued,stimulation
R8656	T12379	T12377	pobj	stimulation,without
R8657	T12380	T12376	punct	", ",maintain
R8658	T12235	T12234	prep	of,activation
R8659	T12381	T12376	nsubj	microglia,maintain
R8660	T12382	T12381	prep	in,microglia
R8661	T12236	T12235	pobj	microglia,of
R8662	T12383	T12384	compound	mouse,models
R8663	T12384	T12382	pobj	models,in
R8664	T12385	T12376	aux	do,maintain
R8665	T12237	T12234	prep	by,activation
R8666	T12386	T12376	neg	not,maintain
R8667	T12387	T12388	det	the,level
R8668	T12388	T12376	dobj	level,maintain
R8669	T12238	T12239	compound	injection,damage
R8670	T12389	T12388	amod	same,level
R8671	T12390	T12388	prep	of,level
R8672	T12239	T12237	pobj	damage,by
R8673	T12391	T12392	amod	sustained,activation
R8674	T12392	T12390	pobj	activation,of
R8675	T12393	T12394	dep	that,occur
R8676	T12240	T12239	cc	or,damage
R8677	T12394	T12388	relcl	occur,level
R8678	T12395	T12394	aux	may,occur
R8679	T12241	T12239	conj	opsinization,damage
R8680	T12396	T12394	prep	in,occur
R8681	T12397	T12396	pobj	humans,in
R8682	T12398	T12372	punct	.,reinforces
R8683	T12242	T12230	aux	may,be
R8684	T12400	T12401	nsubj	SantaCruz,published
R8685	T12243	T12230	neg	not,be
R8686	T12402	T12403	advmod	et,al.
R8687	T12403	T12400	advmod	al.,SantaCruz
R8688	T12244	T12230	acomp	adequate,be
R8689	T12245	T12246	aux	to,induce
R8690	T12246	T12230	advcl	induce,be
R8691	T12404	T12401	advmod	recently,published
R8692	T12247	T12248	amod	substantial,phagocytosis
R8693	T12405	T12406	det	a,study
R8694	T12406	T12401	dobj	study,published
R8695	T12407	T12406	prep	of,study
R8696	T12408	T12407	pobj	mice,of
R8697	T12409	T12410	dep	that,express
R8698	T12410	T12408	relcl	express,mice
R8699	T12248	T12246	dobj	phagocytosis,induce
R8700	T12411	T12412	nmod	P301L,tau
R8701	T12412	T12410	dobj	tau,express
R8702	T12249	T12230	punct	", ",be
R8703	T12413	T12412	amod	human,tau
R8704	T12414	T12410	prep	via,express
R8705	T12415	T12416	det	a,system
R8706	T12250	T12230	cc	but,be
R8707	T12416	T12414	pobj	system,via
R8708	T12417	T12416	amod	similar,system
R8709	T12251	T12252	advmod	when,combined
R8710	T12418	T12416	compound	vector,system
R8711	T12419	T12420	punct	[,61
R8712	T12420	T12401	parataxis	61,published
R8713	T12252	T12253	advcl	combined,work
R8714	T12421	T12420	punct	],61
R8715	T12422	T12401	punct	.,published
R8716	T12253	T12230	conj	work,be
R8717	T12424	T12425	prep	As,found
R8718	T12254	T12252	prep	with,combined
R8719	T12426	T12424	prep	in,As
R8720	T12427	T12428	poss	our,mice
R8721	T12255	T12256	det	an,agent
R8722	T12256	T12254	pobj	agent,with
R8723	T12428	T12426	pobj	mice,in
R8724	T12429	T12430	compound	tet,off
R8725	T12257	T12258	npadvmod	Aβ,lowering
R8726	T12430	T12428	compound	off,mice
R8727	T12431	T12430	punct	-,off
R8728	T12258	T12256	amod	lowering,agent
R8729	T12432	T12428	compound	APP,mice
R8730	T12433	T12425	punct	", ",found
R8731	T12434	T12425	nsubj	SantaCruz,found
R8732	T12259	T12258	punct	-,lowering
R8733	T12435	T12436	advmod	et,al.
R8734	T12436	T12434	advmod	al.,SantaCruz
R8735	T12437	T12438	mark	that,cleared
R8736	T12260	T12256	punct	", ",agent
R8737	T12438	T12425	ccomp	cleared,found
R8738	T12439	T12440	nmod	tau,tangles
R8739	T12261	T12262	amod	such,as
R8740	T12440	T12438	nsubjpass	tangles,cleared
R8741	T12441	T12440	amod	neurofibrillary,tangles
R8742	T12262	T12256	prep	as,agent
R8743	T12442	T12440	punct	", ",tangles
R8744	T12443	T12440	prep	like,tangles
R8745	T12444	T12445	compound	amyloid,plaques
R8746	T12445	T12443	pobj	plaques,like
R8747	T12446	T12438	punct	", ",cleared
R8748	T12263	T12264	npadvmod	neprilysin,targeted
R8749	T12447	T12438	auxpass	are,cleared
R8750	T12448	T12438	neg	not,cleared
R8751	T12449	T12438	advmod	efficiently,cleared
R8752	T12450	T12438	prep	following,cleared
R8753	T12264	T12268	amod	targeted,antibodies
R8754	T12451	T12452	compound	transgene,suppression
R8755	T12452	T12450	pobj	suppression,following
R8756	T12453	T12425	punct	.,found
R8757	T12265	T12263	cc	or,neprilysin
R8758	T12455	T12456	det	The,lack
R8759	T12456	T12457	nsubj	lack,comes
R8760	T12266	T12263	conj	Aβ,neprilysin
R8761	T12458	T12456	prep	of,lack
R8762	T12267	T12264	punct	-,targeted
R8763	T12459	T12458	pobj	clearance,of
R8764	T12460	T12456	prep	in,lack
R8765	T12461	T12462	det	both,models
R8766	T12268	T12262	pobj	antibodies,as
R8767	T12462	T12460	pobj	models,in
R8768	T12463	T12462	prep	of,models
R8769	T12269	T12253	punct	", ",work
R8770	T12464	T12465	compound	AD,pathology
R8771	T12465	T12463	pobj	pathology,of
R8772	T12466	T12457	prep	as,comes
R8773	T12270	T12271	det	the,two
R8774	T12467	T12468	det	a,contrast
R8775	T12468	T12466	pobj	contrast,as
R8776	T12271	T12253	nsubj	two,work
R8777	T12469	T12468	amod	stark,contrast
R8778	T12470	T12468	prep	to,contrast
R8779	T12471	T12472	det	the,removal
R8780	T12272	T12253	aux	may,work
R8781	T12472	T12470	pobj	removal,to
R8782	T12473	T12472	amod	rapid,removal
R8783	T12273	T12253	prep	in,work
R8784	T12474	T12472	prep	of,removal
R8785	T12475	T12476	compound	protein,aggregates
R8786	T12476	T12474	pobj	aggregates,of
R8787	T12274	T12273	pobj	concert,in
R8788	T12477	T12472	acl	found,removal
R8789	T12478	T12477	prep	in,found
R8790	T12479	T12480	amod	similar,models
R8791	T12275	T12276	aux	to,clear
R8792	T12480	T12478	pobj	models,in
R8793	T12481	T12482	compound	tet,off
R8794	T12276	T12253	advcl	clear,work
R8795	T12482	T12480	compound	off,models
R8797	T12484	T12480	compound	mouse,models
R8798	T12485	T12480	prep	of,models
R8799	T12486	T12487	nmod	Huntington,disease
R8800	T12487	T12485	pobj	disease,of
R8801	T12277	T12278	compound	peptide,deposits
R8805	T12278	T12276	dobj	deposits,clear
R8806	T12491	T12486	cc	and,Huntington
R8807	T12492	T12486	conj	prion,Huntington
R8809	T12279	T12253	punct	.,work
R8810	T12494	T12487	parataxis	62,disease
R8811	T12495	T12494	punct	],62
R8812	T12281	T12282	advcl	Consistent,reduce
R8813	T12496	T12457	punct	.,comes
R8814	T12498	T12499	prep	In,led
R8815	T12283	T12281	prep	with,Consistent
R8816	T12500	T12501	det	these,cases
R8817	T12501	T12498	pobj	cases,In
R8818	T12502	T12499	punct	", ",led
R8819	T12503	T12499	csubj	disrupting,led
R8820	T12284	T12285	det	this,hypothesis
R8821	T12504	T12505	det	the,input
R8822	T12505	T12503	dobj	input,disrupting
R8823	T12506	T12505	prep	of,input
R8824	T12285	T12283	pobj	hypothesis,with
R8825	T12507	T12508	amod	new,monomer
R8826	T12508	T12506	pobj	monomer,of
R8827	T12509	T12505	prep	to,input
R8828	T12286	T12282	punct	", ",reduce
R8829	T12287	T12288	amod	strong,activation
R8830	T12288	T12282	nsubj	activation,reduce
R8831	T12289	T12288	prep	of,activation
R8832	T12510	T12511	det	the,system
R8833	T12290	T12289	pobj	microglia,of
R8834	T12511	T12509	pobj	system,to
R8835	T12512	T12503	prep	via,disrupting
R8836	T12513	T12514	npadvmod	dox,mediated
R8837	T12291	T12288	prep	through,activation
R8838	T12292	T12293	amod	transgenic,expression
R8839	T12514	T12516	amod	mediated,suppression
R8840	T12293	T12291	pobj	expression,through
R8841	T12515	T12514	punct	-,mediated
R8842	T12516	T12512	pobj	suppression,via
R8843	T12517	T12516	compound	transgene,suppression
R8844	T12294	T12293	prep	of,expression
R8845	T12518	T12499	prep	to,led
R8846	T12519	T12520	advmod	relatively,rapid
R8847	T12295	T12294	pobj	TGFβ,of
R8848	T12520	T12521	amod	rapid,clearance
R8849	T12521	T12518	pobj	clearance,to
R8850	T12522	T12521	prep	of,clearance
R8851	T12523	T12524	compound	protein,aggregates
R8852	T12296	T12297	punct	[,58
R8853	T12524	T12522	pobj	aggregates,of
R8854	T12525	T12499	punct	.,led
R8855	T12297	T12295	parataxis	58,TGFβ
R8856	T12527	T12528	prep	By,suggest
R8857	T12529	T12527	pobj	contrast,By
R8858	T12616	T12615	punct	-,off
R8859	T12530	T12528	punct	", ",suggest
R8860	T12531	T12532	poss	our,study
R8861	T12532	T12528	nsubj	study,suggest
R8862	T12617	T12613	compound	tau,mice
R8863	T12533	T12532	cc	and,study
R8864	T12534	T12532	conj	that,study
R8865	T12535	T12534	prep	of,that
R8866	T12618	T12619	mark	that,required
R8867	T12536	T12535	pobj	SantaCruz,of
R8868	T12537	T12538	advmod	et,al.
R8869	T12538	T12536	advmod	al.,SantaCruz
R8870	T12619	T12610	ccomp	required,suggest
R8871	T12539	T12540	mark	that,be
R8872	T12540	T12528	ccomp	be,suggest
R8873	T12541	T12542	compound	protein,aggregates
R8874	T12620	T12621	compound	protein,clearance
R8875	T12542	T12540	nsubj	aggregates,be
R8876	T12543	T12542	prep	in,aggregates
R8877	T12621	T12619	nsubjpass	clearance,required
R8878	T12544	T12543	pobj	AD,in
R8879	T12545	T12540	aux	may,be
R8880	T12546	T12547	advmod	more,tenacious
R8881	T12622	T12619	aux	may,required
R8882	T12547	T12540	acomp	tenacious,be
R8883	T12548	T12547	prep	than,tenacious
R8884	T12549	T12548	prep	in,than
R8885	T12623	T12619	prep	in,required
R8886	T12550	T12551	amod	other,disorders
R8887	T12551	T12549	pobj	disorders,in
R8888	T12624	T12623	pobj	fact,in
R8889	T12552	T12551	amod	neurodegenerative,disorders
R8890	T12553	T12528	punct	.,suggest
R8891	T12625	T12619	neg	not,required
R8892	T12555	T12556	advmod	Perhaps,are
R8893	T12626	T12619	auxpass	be,required
R8894	T12557	T12558	mark	once,aggregated
R8895	T12558	T12556	advcl	aggregated,are
R8896	T12627	T12619	prep	for,required
R8897	T12559	T12556	punct	", ",are
R8898	T12560	T12556	nsubj	Aβ,are
R8899	T12561	T12560	cc	and,Aβ
R8900	T12628	T12629	amod	cognitive,improvement
R8901	T12562	T12560	conj	tau,Aβ
R8902	T12563	T12564	advmod	either,stable
R8903	T12564	T12556	acomp	stable,are
R8904	T12565	T12564	advmod	inherently,stable
R8905	T12566	T12564	advmod	more,stable
R8906	T12629	T12627	pobj	improvement,for
R8907	T12567	T12564	prep	than,stable
R8908	T12568	T12569	amod	other,aggregates
R8909	T12569	T12567	pobj	aggregates,than
R8910	T12630	T12619	prep	following,required
R8911	T12570	T12569	compound	protein,aggregates
R8912	T12571	T12564	cc	or,stable
R8913	T12572	T12573	advmod	more,resistant
R8914	T12631	T12632	compound	transgene,suppression
R8915	T12573	T12564	conj	resistant,stable
R8916	T12574	T12573	prep	to,resistant
R8917	T12575	T12576	advmod	intra,extracellular
R8918	T12632	T12630	pobj	suppression,following
R8919	T12576	T12579	amod	extracellular,mechanisms
R8920	T12577	T12576	punct	-,extracellular
R8921	T12633	T12634	punct	[,61
R8922	T12578	T12576	cc	and,extracellular
R8923	T12579	T12574	pobj	mechanisms,to
R8924	T12580	T12579	compound	clearance,mechanisms
R8925	T12634	T12619	parataxis	61,required
R8926	T12581	T12556	punct	.,are
R8927	T12635	T12634	punct	],61
R8928	T12583	T12584	nummod	One,question
R8929	T12584	T12585	nsubj	question,is
R8930	T12636	T12610	punct	.,suggest
R8931	T12586	T12587	nsubj	we,were
R8932	T12587	T12584	advcl	were,question
R8933	T12638	T12639	prep	At,is
R8934	T12588	T12587	neg	not,were
R8935	T12589	T12587	acomp	able,were
R8936	T12590	T12591	aux	to,address
R8937	T12591	T12589	xcomp	address,able
R8938	T12640	T12638	amod	present,At
R8939	T12592	T12591	prep	in,address
R8940	T12593	T12594	det	this,study
R8941	T12594	T12592	pobj	study,in
R8942	T12595	T12596	mark	whether,halts
R8943	T12641	T12639	punct	", ",is
R8944	T12596	T12585	ccomp	halts,is
R8945	T12597	T12596	csubj	abrogating,halts
R8946	T12642	T12639	prep	because,is
R8947	T12598	T12597	dobj	synthesis,abrogating
R8948	T12599	T12598	prep	of,synthesis
R8949	T12643	T12642	pcomp	of,because
R8950	T12600	T12601	amod	new,Aβ
R8951	T12601	T12599	pobj	Aβ,of
R8952	T12644	T12645	amod	unexpected,abnormalities
R8953	T12602	T12603	det	the,progression
R8954	T12603	T12596	dobj	progression,halts
R8955	T12604	T12603	prep	of,progression
R8956	T12645	T12642	pobj	abnormalities,because
R8957	T12605	T12606	amod	cognitive,decline
R8958	T12606	T12604	pobj	decline,of
R8959	T12607	T12585	punct	.,is
R8960	T12646	T12645	amod	noncognitive,abnormalities
R8961	T12609	T12610	nsubj	Studies,suggest
R8962	T12647	T12645	amod	behavioral,abnormalities
R8963	T12611	T12609	prep	from,Studies
R8964	T12612	T12613	det	the,mice
R8965	T12648	T12639	punct	", ",is
R8966	T12613	T12611	pobj	mice,from
R8967	T12614	T12615	compound	tet,off
R8968	T12649	T12639	nsubj	it,is
R8969	T12615	T12613	compound	off,mice
R8970	T12650	T12639	neg	not,is
R8971	T12651	T12639	acomp	clear,is
R8972	T12652	T12653	mark	whether,used
R8973	T12653	T12639	ccomp	used,is
R8974	T12722	T12723	advmod	when,tested
R8975	T12654	T12655	det	the,mice
R8976	T12723	T12705	advcl	tested,showed
R8977	T12724	T12723	prep	in,tested
R8978	T12655	T12653	nsubjpass	mice,used
R8979	T12725	T12726	det	the,maze
R8980	T12726	T12724	pobj	maze,in
R8981	T12656	T12657	compound	tet,off
R8982	T12727	T12726	compound	Morris,maze
R8983	T12728	T12726	compound	water,maze
R8984	T12729	T12705	punct	.,showed
R8985	T12657	T12655	compound	off,mice
R8986	T12731	T12732	nsubj	Expression,makes
R8987	T12658	T12657	punct	-,off
R8988	T12733	T12731	prep	of,Expression
R8989	T12734	T12735	det	this,phenotype
R8990	T12659	T12655	compound	APP,mice
R8991	T12735	T12733	pobj	phenotype,of
R8992	T12736	T12737	amod	standard,tests
R8993	T12737	T12738	nsubj	tests,uninterpretable
R8994	T12660	T12653	aux	can,used
R8995	T12738	T12732	ccomp	uninterpretable,makes
R8996	T12739	T12737	prep	of,tests
R8997	T12740	T12739	pobj	learning,of
R8998	T12661	T12653	auxpass	be,used
R8999	T12741	T12740	cc	and,learning
R9000	T12742	T12740	conj	memory,learning
R9001	T12662	T12663	aux	to,address
R9002	T12743	T12732	punct	.,makes
R9003	T12745	T12746	nsubj	Hyperactivity,inhibits
R9004	T12663	T12653	advcl	address,used
R9005	T12747	T12746	advmod	nonspecifically,inhibits
R9006	T12748	T12749	npadvmod	choice,driven
R9007	T12749	T12751	amod	driven,changes
R9008	T12664	T12665	det	the,question
R9009	T12750	T12749	punct	-,driven
R9010	T12751	T12746	dobj	changes,inhibits
R9011	T12665	T12663	dobj	question,address
R9012	T12752	T12751	prep	in,changes
R9013	T12753	T12752	pobj	movement,in
R9014	T12666	T12665	amod	same,question
R9015	T12754	T12751	punct	", ",changes
R9016	T12755	T12756	det	the,element
R9017	T12756	T12751	appos	element,changes
R9018	T12667	T12663	prep	in,address
R9019	T12757	T12756	amod	key,element
R9020	T12758	T12756	prep	behind,element
R9021	T12759	T12760	det	all,paradigms
R9022	T12668	T12669	det	the,context
R9023	T12760	T12758	pobj	paradigms,behind
R9024	T12761	T12760	amod	cognitive,paradigms
R9025	T12669	T12667	pobj	context,in
R9026	T12762	T12760	amod	behavioral,paradigms
R9027	T12763	T12746	punct	.,inhibits
R9028	T12670	T12669	prep	of,context
R9029	T12765	T12766	nsubj	We,working
R9030	T12671	T12672	compound	amyloid,pathology
R9031	T12767	T12766	aux	are,working
R9032	T12768	T12766	advmod	currently,working
R9033	T12769	T12770	aux	to,determine
R9034	T12672	T12670	pobj	pathology,of
R9035	T12770	T12766	xcomp	determine,working
R9036	T12771	T12772	mark	whether,correlates
R9037	T12772	T12770	ccomp	correlates,determine
R9038	T12673	T12639	punct	.,is
R9039	T12773	T12772	nsubj	hyperactivity,correlates
R9040	T12774	T12772	prep	with,correlates
R9041	T12675	T12676	det	Both,lines
R9042	T12775	T12774	pobj	expression,with
R9043	T12776	T12775	prep	of,expression
R9044	T12777	T12778	det	the,holoprotein
R9045	T12676	T12677	nsubj	lines,display
R9046	T12678	T12676	prep	of,lines
R9047	T12778	T12776	pobj	holoprotein,of
R9048	T12779	T12780	compound	APPswe,ind
R9049	T12780	T12778	compound	ind,holoprotein
R9050	T12781	T12780	punct	/,ind
R9051	T12679	T12680	compound	tTA,APP
R9052	T12782	T12775	cc	or,expression
R9053	T12783	T12784	poss	its,derivatives
R9054	T12784	T12775	conj	derivatives,expression
R9055	T12680	T12682	compound	APP,mice
R9056	T12785	T12784	amod	proteolytic,derivatives
R9057	T12786	T12766	punct	.,working
R9058	T12788	T12789	amod	Preliminary,studies
R9059	T12681	T12680	punct	/,APP
R9060	T12789	T12790	nsubj	studies,suggest
R9061	T12791	T12792	mark	that,appear
R9062	T12682	T12678	pobj	mice,of
R9063	T12792	T12790	ccomp	appear,suggest
R9064	T12793	T12792	nsubj	hyperactivity,appear
R9065	T12683	T12684	nsubj	we,studied
R9066	T12794	T12792	aux	does,appear
R9067	T12795	T12792	neg	not,appear
R9068	T12684	T12676	advcl	studied,lines
R9069	T12796	T12792	advmod	quickly,appear
R9070	T12797	T12798	advmod	when,shifted
R9071	T12798	T12792	advcl	shifted,appear
R9072	T12685	T12684	advmod	here,studied
R9073	T12799	T12800	npadvmod	dox,reared
R9074	T12800	T12802	amod	reared,mice
R9075	T12801	T12800	punct	-,reared
R9076	T12686	T12687	amod	extreme,hyperactivity
R9077	T12802	T12798	nsubjpass	mice,shifted
R9078	T12803	T12798	auxpass	are,shifted
R9079	T12687	T12677	dobj	hyperactivity,display
R9080	T12804	T12798	prep	to,shifted
R9081	T12805	T12806	amod	nonmedicated,diets
R9082	T12806	T12804	pobj	diets,to
R9083	T12688	T12687	amod	visible,hyperactivity
R9084	T12807	T12808	punct	(,data
R9085	T12808	T12798	parataxis	data,shifted
R9086	T12809	T12810	compound	J.,J.
R9087	T12689	T12688	prep	as,visible
R9088	T12810	T12808	dep	J.,data
R9089	T12811	T12810	compound	L.,J.
R9090	T12812	T12808	punct	", ",data
R9091	T12690	T12691	compound	cage,circling
R9092	T12813	T12808	amod	unpublished,data
R9093	T12814	T12808	punct	),data
R9094	T12815	T12790	punct	.,suggest
R9095	T12691	T12689	pobj	circling,as
R9096	T12817	T12818	det	These,data
R9097	T12692	T12688	cc	and,visible
R9098	T12818	T12819	nsubj	data,indicate
R9099	T12820	T12819	aux	may,indicate
R9100	T12693	T12688	conj	quantified,visible
R9101	T12821	T12822	mark	that,is
R9102	T12822	T12819	ccomp	is,indicate
R9103	T12694	T12693	agent	by,quantified
R9104	T12823	T12824	det	the,culprit
R9105	T12824	T12822	nsubj	culprit,is
R9106	T12825	T12824	amod	neuroactive,culprit
R9107	T12695	T12696	compound	activity,monitoring
R9108	T12826	T12827	neg	not,immediately
R9109	T12827	T12822	advmod	immediately,is
R9110	T12696	T12694	pobj	monitoring,by
R9111	T12697	T12698	punct	(,see
R9112	T12828	T12822	acomp	present,is
R9113	T12698	T12677	parataxis	see,display
R9114	T12829	T12830	mark	after,initiated
R9115	T12830	T12822	advcl	initiated,is
R9116	T12831	T12832	amod	transgenic,synthesis
R9117	T12699	T12698	dobj	Figure,see
R9118	T12832	T12830	nsubjpass	synthesis,initiated
R9119	T12700	T12699	nummod	7,Figure
R9121	T12834	T12830	auxpass	is,initiated
R9122	T12835	T12822	punct	", ",is
R9123	T12701	T12698	punct	),see
R9124	T12836	T12822	cc	but,is
R9125	T12837	T12822	conj	requires,is
R9126	T12702	T12677	punct	.,display
R9129	T12704	T12705	nsubj	Many,showed
R9130	T12840	T12841	aux	to,develop
R9131	T12841	T12839	advcl	develop,time
R9132	T12842	T12819	punct	.,indicate
R9133	T12706	T12704	prep	of,Many
R9134	T12844	T12845	advmod	Alternatively,caused
R9135	T12707	T12708	det	the,mice
R9136	T12846	T12845	punct	", ",caused
R9137	T12847	T12845	nsubjpass	hyperactivity,caused
R9138	T12708	T12706	pobj	mice,of
R9139	T12848	T12845	aux	may,caused
R9140	T12849	T12845	auxpass	be,caused
R9141	T12850	T12845	agent	by,caused
R9142	T12709	T12710	amod	double,transgenic
R9143	T12851	T12852	amod	neuronal,alterations
R9144	T12852	T12850	pobj	alterations,by
R9145	T12853	T12845	prep	due,caused
R9146	T12710	T12708	amod	transgenic,mice
R9147	T12854	T12853	pcomp	to,due
R9148	T12855	T12856	compound	transgene,expression
R9149	T12711	T12712	amod	similar,patterns
R9150	T12856	T12853	pobj	expression,due
R9151	T12857	T12856	prep	during,expression
R9152	T12858	T12859	amod	early,postnatal
R9153	T12712	T12705	dobj	patterns,showed
R9154	T12859	T12860	amod	postnatal,development
R9155	T12860	T12857	pobj	development,during
R9156	T12861	T12845	punct	.,caused
R9157	T12713	T12712	amod	circular,patterns
R9158	T12863	T12864	amod	Further,experiments
R9159	T12714	T12712	prep	of,patterns
R9160	T12864	T12865	nsubjpass	experiments,needed
R9161	T12866	T12865	auxpass	are,needed
R9162	T12715	T12714	pobj	swimming,of
R9163	T12867	T12868	aux	to,distinguish
R9164	T12868	T12865	advcl	distinguish,needed
R9165	T12869	T12868	prep	between,distinguish
R9166	T12716	T12712	prep	near,patterns
R9167	T12870	T12871	det	these,possibilities
R9168	T12871	T12869	pobj	possibilities,between
R9169	T12717	T12718	det	the,edge
R9170	T12872	T12865	punct	.,needed
R9171	T12874	T12875	prep	In,demonstrate
R9172	T12718	T12716	pobj	edge,near
R9173	T12876	T12874	pobj	summary,In
R9174	T12719	T12718	prep	of,edge
R9175	T12877	T12875	punct	", ",demonstrate
R9176	T12878	T12875	nsubj	we,demonstrate
R9177	T12720	T12721	det	the,tank
R9178	T12879	T12880	mark	that,halts
R9179	T12880	T12875	ccomp	halts,demonstrate
R9180	T12721	T12719	pobj	tank,of
R9181	T12881	T12880	csubj	abrogating,halts
R9182	T12882	T12883	compound	Aβ,production
R9183	T12883	T12881	dobj	production,abrogating
R9184	T12934	T12932	advcl	limit,therapies
R9185	T12884	T12885	det	the,progression
R9186	T12885	T12880	dobj	progression,halts
R9187	T12886	T12885	prep	of,progression
R9188	T12887	T12888	amod	pathologic,changes
R9189	T12935	T12936	compound	Aβ,production
R9190	T12888	T12886	pobj	changes,of
R9191	T12889	T12885	prep	in,progression
R9192	T12890	T12891	det	a,model
R9193	T12936	T12934	dobj	production,limit
R9194	T12891	T12889	pobj	model,in
R9195	T12892	T12891	amod	transgenic,model
R9196	T12937	T12934	punct	", ",limit
R9197	T12893	T12891	compound	mouse,model
R9198	T12894	T12891	prep	of,model
R9199	T12895	T12896	compound	Alzheimer,type
R9200	T12938	T12934	conj	increase,limit
R9201	T12896	T12898	compound	type,amyloidosis
R9202	T12897	T12896	punct	-,type
R9203	T12898	T12894	pobj	amyloidosis,of
R9204	T12939	T12940	compound	Aβ,degradation
R9205	T12899	T12875	punct	.,demonstrate
R9206	T12901	T12902	advmod	However,are
R9207	T12940	T12938	dobj	degradation,increase
R9208	T12903	T12902	punct	", ",are
R9209	T12941	T12938	punct	", ",increase
R9210	T12904	T12902	prep	despite,are
R9211	T12905	T12906	amod	dramatic,reductions
R9212	T12906	T12904	pobj	reductions,despite
R9213	T12907	T12906	prep	in,reductions
R9214	T12908	T12909	compound	Aβ,synthesis
R9215	T12909	T12907	pobj	synthesis,in
R9216	T12942	T12938	cc	and,increase
R9217	T12910	T12902	punct	", ",are
R9218	T12911	T12912	amod	neuritic,plaques
R9219	T12943	T12938	conj	enhance,increase
R9220	T12912	T12902	nsubj	plaques,are
R9221	T12913	T12914	amod	stable,structures
R9222	T12914	T12902	attr	structures,are
R9223	T12944	T12943	dobj	phagocytosis,enhance
R9224	T12915	T12916	advmod	in,vivo
R9225	T12916	T12914	advmod	vivo,structures
R9226	T12945	T12944	prep	of,phagocytosis
R9227	T12917	T12918	dep	that,disaggregate
R9228	T12918	T12914	relcl	disaggregate,structures
R9229	T12919	T12918	aux	do,disaggregate
R9230	T12946	T12947	amod	deposited,amyloid
R9231	T12920	T12918	neg	not,disaggregate
R9232	T12921	T12918	advmod	quickly,disaggregate
R9233	T12947	T12945	pobj	amyloid,of
R9234	T12922	T12902	punct	.,are
R9235	T12948	T12928	aux	may,required
R9236	T12924	T12925	nsubj	It,is
R9237	T12926	T12925	acomp	possible,is
R9238	T12949	T12928	auxpass	be,required
R9239	T12927	T12928	mark	that,required
R9240	T12928	T12925	ccomp	required,is
R9241	T12929	T12930	det	a,combination
R9242	T12950	T12951	aux	to,reverse
R9243	T12930	T12928	nsubjpass	combination,required
R9244	T12931	T12930	prep	of,combination
R9245	T12951	T12928	advcl	reverse,required
R9246	T12932	T12931	pobj	therapies,of
R9247	T12933	T12934	aux	to,limit
R9248	T12952	T12951	dobj	damage,reverse
R9249	T12953	T12952	acl	associated,damage
R9250	T12954	T12953	prep	with,associated
R9251	T13040	T13028	auxpass	be,required
R9252	T12955	T12954	pobj	AD,with
R9253	T12956	T12925	punct	.,is
R9254	T13041	T13042	aux	to,determine
R9255	T13042	T13028	advcl	determine,required
R9256	T12958	T12959	advmod	However,provide
R9257	T13043	T13044	mark	whether,has
R9258	T13044	T13042	ccomp	has,determine
R9259	T13045	T13046	det	the,brain
R9260	T12960	T12959	punct	", ",provide
R9261	T13046	T13044	nsubj	brain,has
R9262	T13047	T13046	amod	human,brain
R9263	T13048	T13049	det	the,capacity
R9264	T12961	T12962	mark	if,started
R9265	T13049	T13044	dobj	capacity,has
R9266	T12962	T12959	advcl	started,provide
R9267	T13050	T13051	aux	to,repair
R9268	T13051	T13049	acl	repair,capacity
R9269	T12963	T12964	advmod	early,enough
R9270	T13052	T13053	npadvmod	amyloid,associated
R9271	T13053	T13055	amod	associated,damage
R9272	T13054	T13053	punct	-,associated
R9273	T12964	T12962	advmod	enough,started
R9274	T13055	T13051	dobj	damage,repair
R9275	T13056	T13055	prep	of,damage
R9276	T13057	T13056	pobj	AD,of
R9277	T12965	T12962	prep	in,started
R9278	T13058	T13059	mark	once,arrested
R9279	T13059	T13051	advcl	arrested,repair
R9280	T12966	T12967	det	the,course
R9281	T13060	T13061	det	the,progression
R9282	T13061	T13059	nsubjpass	progression,arrested
R9283	T13062	T13061	prep	of,progression
R9284	T12967	T12965	pobj	course,in
R9285	T13063	T13062	pobj	pathology,of
R9286	T13064	T13059	auxpass	is,arrested
R9287	T13065	T13028	punct	.,required
R9288	T12968	T12967	prep	of,course
R9289	T12969	T12968	pobj	disease,of
R9290	T12970	T12959	punct	", ",provide
R9291	T12971	T12972	compound	secretase,inhibitors
R9292	T12972	T12959	nsubj	inhibitors,provide
R9293	T12973	T12972	advmod	alone,inhibitors
R9294	T12974	T12959	aux	could,provide
R9295	T12975	T12976	amod	substantial,benefit
R9296	T12976	T12959	dobj	benefit,provide
R9297	T12977	T12976	prep	in,benefit
R9298	T12978	T12977	pcomp	slowing,in
R9299	T12979	T12980	amod	pathogenic,processes
R9300	T12980	T12978	dobj	processes,slowing
R9301	T12981	T12980	acl	linked,processes
R9302	T12982	T12981	prep	to,linked
R9303	T12983	T12984	compound	amyloid,deposition
R9304	T12984	T12982	pobj	deposition,to
R9305	T12985	T12959	punct	.,provide
R9306	T12987	T12988	advmod	Even,at
R9307	T12988	T12989	prep	at,suggests
R9308	T12990	T12991	amod	later,stages
R9309	T12991	T12988	pobj	stages,at
R9310	T12992	T12991	prep	in,stages
R9311	T12993	T12994	det	the,disease
R9312	T12994	T12992	pobj	disease,in
R9313	T12995	T12989	punct	", ",suggests
R9314	T12996	T12997	det	the,presence
R9315	T12997	T12989	nsubj	presence,suggests
R9316	T12998	T12997	prep	of,presence
R9317	T12999	T13000	amod	substantial,activation
R9318	T13000	T12998	pobj	activation,of
R9319	T13001	T13000	amod	microglial,activation
R9320	T13002	T12997	prep	in,presence
R9321	T13003	T13004	amod	human,AD
R9322	T13004	T13002	pobj	AD,in
R9323	T13005	T13006	punct	[,40
R9324	T13006	T13004	parataxis	40,AD
R9325	T13007	T13006	punct	],40
R9326	T13008	T13009	mark	that,allow
R9327	T13009	T12989	ccomp	allow,suggests
R9328	T13010	T13011	advmod	simply,slowing
R9329	T13011	T13009	csubj	slowing,allow
R9330	T13012	T13013	det	the,formation
R9331	T13013	T13011	dobj	formation,slowing
R9332	T13014	T13013	prep	of,formation
R9333	T13015	T13016	amod	new,deposits
R9334	T13016	T13014	pobj	deposits,of
R9335	T13017	T13016	compound	amyloid,deposits
R9336	T13018	T13009	aux	may,allow
R9337	T13019	T13020	amod	ongoing,phagocytosis
R9338	T13020	T13021	nsubj	phagocytosis,diminish
R9339	T13021	T13009	ccomp	diminish,allow
R9340	T13022	T13021	aux	to,diminish
R9341	T13023	T13024	amod	preexisting,lesions
R9342	T13024	T13021	dobj	lesions,diminish
R9343	T13025	T12989	punct	.,suggests
R9344	T13027	T13028	advmod	However,required
R9345	T13029	T13028	punct	", ",required
R9346	T13030	T13031	det	the,development
R9347	T13031	T13028	nsubjpass	development,required
R9348	T13032	T13031	prep	of,development
R9349	T13033	T13034	amod	safe,inhibitors
R9350	T13034	T13032	pobj	inhibitors,of
R9351	T13035	T13033	cc	and,safe
R9352	T13036	T13033	conj	effective,safe
R9353	T13037	T13034	compound	secretase,inhibitors
R9354	T13038	T13028	aux	will,required
R9355	T13039	T13028	advmod	ultimately,required
R8460	T12128	T12127	nummod	50,55
R8796	T12483	T12482	punct	-,off
R8802	T12488	T12489	punct	[,32
R8803	T12489	T12486	parataxis	32,Huntington
R8804	T12490	T12489	punct	],32
R8808	T12493	T12494	punct	[,62
R9120	T12833	T12832	compound	APP,synthesis
R9127	T12838	T12839	amod	additional,time
R9128	T12839	T12837	dobj	time,requires

2_test

Id	Subject	Object	Predicate	Lexical cue
16279840-10778856-86242777	1466-1468	10778856	denotes	32
16279840-8810256-86242778	1750-1752	8810256	denotes	33
16279840-11279122-86242779	1767-1769	11279122	denotes	34
16279840-14709552-86242780	1908-1910	14709552	denotes	35
16279840-15452193-86242781	1911-1913	15452193	denotes	36
16279840-9354339-86242782	3991-3993	9354339	denotes	27
16279840-12404061-86242783	5843-5845	12404061	denotes	37
16279840-15353209-86242783	5843-5845	15353209	denotes	37
16279840-11164276-86242783	5843-5845	11164276	denotes	37
16279840-15191802-86242783	5843-5845	15191802	denotes	37
16279840-15191802-86242784	6004-6006	15191802	denotes	40
16279840-11896164-86242785	6405-6407	11896164	denotes	41
16279840-10908610-86242785	6405-6407	10908610	denotes	41
16279840-12930788-86242785	6405-6407	12930788	denotes	41
16279840-12897211-86242786	6541-6543	12897211	denotes	44
16279840-11700559-86242786	6541-6543	11700559	denotes	44
16279840-12805356-86242786	6541-6543	12805356	denotes	44
16279840-15448688-86242786	6541-6543	15448688	denotes	44
16279840-9861045-86242787	7295-7297	9861045	denotes	48
16279840-12404061-86242788	7709-7711	12404061	denotes	37
16279840-15353209-86242788	7709-7711	15353209	denotes	37
16279840-11164276-86242788	7709-7711	11164276	denotes	37
16279840-15191802-86242788	7709-7711	15191802	denotes	37
16279840-15294141-86242789	8134-8136	15294141	denotes	49
16279840-12736345-86242789	8134-8136	12736345	denotes	49
16279840-11231639-86242789	8134-8136	11231639	denotes	49
16279840-10932230-86242790	8351-8353	10932230	denotes	52
16279840-15240806-86242791	8354-8356	15240806	denotes	53
16279840-12657655-86242792	8523-8525	12657655	denotes	54
16279840-12736345-86242793	8727-8729	12736345	denotes	50
16279840-10932230-86242794	8730-8732	10932230	denotes	52
16279840-14751766-86242795	8733-8735	14751766	denotes	55
16279840-13679422-86242796	8975-8977	13679422	denotes	56
16279840-12223540-86242797	8978-8980	12223540	denotes	57
16279840-11329064-86242798	9638-9640	11329064	denotes	58
16279840-11755009-86242799	9686-9688	11755009	denotes	59
16279840-15473997-86242800	9689-9691	15473997	denotes	60
16279840-15294141-86242801	10015-10017	15294141	denotes	49
16279840-16020737-86242802	10308-10310	16020737	denotes	61
16279840-10778856-86242803	10656-10658	10778856	denotes	32
16279840-16020737-86242804	11462-11464	16020737	denotes	61
16279840-15191802-86242805	13632-13634	15191802	denotes	40
T17182	1466-1468	10778856	denotes	32
T35842	1750-1752	8810256	denotes	33
T45931	1767-1769	11279122	denotes	34
T75343	1908-1910	14709552	denotes	35
T70534	1911-1913	15452193	denotes	36
T85491	3991-3993	9354339	denotes	27
T39948	5843-5845	12404061	denotes	37
T66452	5843-5845	15353209	denotes	37
T47811	5843-5845	11164276	denotes	37
T18572	5843-5845	15191802	denotes	37
T58634	6004-6006	15191802	denotes	40
T83416	6405-6407	11896164	denotes	41
T54064	6405-6407	10908610	denotes	41
T75448	6405-6407	12930788	denotes	41
T36841	6541-6543	12897211	denotes	44
T24141	6541-6543	11700559	denotes	44
T67406	6541-6543	12805356	denotes	44
T45503	6541-6543	15448688	denotes	44
T6243	7295-7297	9861045	denotes	48
T28273	7709-7711	12404061	denotes	37
T59342	7709-7711	15353209	denotes	37
T92299	7709-7711	11164276	denotes	37
T40804	7709-7711	15191802	denotes	37
T6534	8134-8136	15294141	denotes	49
T25436	8134-8136	12736345	denotes	49
T73130	8134-8136	11231639	denotes	49
T95188	8351-8353	10932230	denotes	52
T32095	8354-8356	15240806	denotes	53
T53094	8523-8525	12657655	denotes	54
T47250	8727-8729	12736345	denotes	50
T49423	8730-8732	10932230	denotes	52
T67630	8733-8735	14751766	denotes	55
T24008	8975-8977	13679422	denotes	56
T10578	8978-8980	12223540	denotes	57
T22755	9638-9640	11329064	denotes	58
T78765	9686-9688	11755009	denotes	59
T2807	9689-9691	15473997	denotes	60
T86071	10015-10017	15294141	denotes	49
T97521	10308-10310	16020737	denotes	61
T40745	10656-10658	10778856	denotes	32
T43043	11462-11464	16020737	denotes	61
T8156	13632-13634	15191802	denotes	40

craft-ca-core-ex-dev

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id	Subject	Object	Predicate	Lexical cue
T10200	28-33	NCBITaxon:10088	denotes	mouse
T10201	104-106	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10202	104-117	GO:0034205	denotes	Aβ production
T10203	137-144	CHEBI:60425	denotes	amyloid
T10204	169-179	SO_EXT:transgenic_entity	denotes	transgenic
T10205	180-184	NCBITaxon:10088	denotes	mice
T10206	220-227	GO:0010467	denotes	express
T10207	264-271	GO:0065007	denotes	control
T10208	277-289	CHEBI:27902	denotes	tetracycline
T10209	301-309	SO_EXT:0000167	denotes	promoter
T10210	346-349	CHEBI:50845	denotes	dox
T10211	408-418	CHEBI_SO_EXT:C_terminus_or_C_terminal_region	denotes	C-terminal
T10212	450-456	SO_EXT:sequence_altered_entity_or_alteration_process	denotes	mutant
T10213	457-465	CHEBI_PR_EXT:protein	denotes	proteins
T10214	509-519	SO_EXT:transgenic_entity	denotes	Transgenic
T10215	520-530	GO:0010467	denotes	expression
T10216	578-582	CHEBI_PR_EXT:amyloid_beta_42	denotes	Aβ42
T10217	601-608	CHEBI:60425	denotes	amyloid
T10218	633-637	NCBITaxon:10088	denotes	mice
T10219	689-696	CHEBI:60425	denotes	Amyloid
T10220	753-764	UBERON_EXT:hippocampus_proper_or_hippocampal_formation	denotes	hippocampus
T10221	769-775	UBERON:0001851	denotes	cortex
T10222	789-793	NCBITaxon:10088	denotes	mice
T10223	829-836	CHEBI_SO_EXT:peptide_or_peptide_region	denotes	peptide
T10224	866-876	SO_EXT:transgenic_entity	denotes	transgenic
T10225	877-880	PR_EXT:000004168	denotes	APP
T10226	932-939	CHEBI:60425	denotes	amyloid
T10227	987-994	NCBITaxon:33208	denotes	animals
T10228	1026-1033	CHEBI:60425	denotes	amyloid
T10229	1132-1142	CHEBI_EXT:35222	denotes	inhibitors
T10230	1216-1223	CHEBI:60425	denotes	amyloid
T10231	1250-1259	SO_EXT:0000902	denotes	transgene
T10232	1389-1396	CHEBI_PR_EXT:protein	denotes	protein
T10233	1416-1422	SO_EXT:sequence_altered_entity_or_alteration_process	denotes	mutant
T10234	1423-1433	PR_EXT:000008840	denotes	huntingtin
T10235	1493-1506	GO:0005576	denotes	extracellular
T10236	1498-1506	CL_GO_EXT:cell	denotes	cellular
T10237	1507-1514	CHEBI:60425	denotes	amyloid
T10238	1544-1558	CHEBI_EXT:52217	denotes	pharmaceutical
T10239	1559-1570	GO:0070765	denotes	γ-secretase
T10240	1571-1581	CHEBI_EXT:35222	denotes	inhibitors
T10241	1617-1644	GO:1902003	denotes	regulation of Aβ production
T10242	1631-1633	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10243	1722-1731	CHEBI:36357	denotes	compounds
T10244	1771-1781	SO_EXT:transgenic_entity	denotes	transgenic
T10245	1782-1786	NCBITaxon:10088	denotes	mice
T10246	1824-1828	CHEBI_PR_EXT:amyloid_beta_40	denotes	Aβ40
T10247	1882-1886	CHEBI_PR_EXT:amyloid_beta_42	denotes	Aβ42
T10248	1964-1967	PR_EXT:000004168	denotes	APP
T10249	1968-1978	GO:0010467	denotes	expression
T10250	1993-1997	NCBITaxon:10088	denotes	mice
T10251	2084-2086	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10252	2084-2097	GO:0034205	denotes	Aβ production
T10253	2164-2175	GO:0070765	denotes	γ-secretase
T10254	2176-2186	CHEBI_EXT:35222	denotes	inhibitors
T10255	2224-2245	CHEBI_EXT:52217	denotes	pharmaceutical agents
T10256	2283-2307	GO:1902003	denotes	control of Aβ production
T10257	2294-2296	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10258	2397-2399	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10259	2409-2418	CHEBI:36357	denotes	compounds
T10260	2448-2455	CHEBI:60425	denotes	amyloid
T10261	2534-2541	CHEBI:60425	denotes	amyloid
T10262	2585-2594	SO_EXT:0000902	denotes	transgene
T10263	2638-2645	NCBITaxon:33208	denotes	animals
T10264	2661-2664	CHEBI:50845	denotes	dox
T10265	2718-2725	CHEBI:60425	denotes	amyloid
T10266	2863-2870	NCBITaxon:33208	denotes	animals
T10267	2884-2887	CHEBI:50845	denotes	dox
T10268	2935-2937	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10269	3024-3033	GO_EXT:biological_release	denotes	releasing
T10270	3034-3041	CHEBI_SO_EXT:peptide_or_peptide_region	denotes	peptide
T10271	3046-3056	GO_EXT:oligomeric_macromolecular_complex	denotes	oligomeric
T10272	3057-3059	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10273	3133-3135	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10274	3133-3146	GO:0034205	denotes	Aβ production
T10275	3210-3217	CHEBI:60425	denotes	amyloid
T10276	3261-3270	UBERON:0000104	denotes	life span
T10277	3340-3346	NCBITaxon:9606	denotes	humans
T10278	3415-3424	UBERON:0000104	denotes	life span
T10279	3428-3434	NCBITaxon:9989	denotes	rodent
T10280	3636-3652	GO:0034205	denotes	production of Aβ
T10281	3650-3652	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10282	3708-3711	PR_EXT:000004168	denotes	APP
T10283	3712-3722	GO:0010467	denotes	expression
T10284	3821-3828	CHEBI:60425	denotes	amyloid
T10285	3926-3930	NCBITaxon:10088	denotes	mice
T10286	3943-3946	PR_EXT:000004168	denotes	APP
T10287	3947-3958	SO_EXT:transgenic_entity	denotes	transgenics
T10288	3981-3989	SO_EXT:sequence_alteration_entity_or_process	denotes	mutation
T10289	4133-4138	NCBITaxon:9606	denotes	human
T10290	4221-4225	NCBITaxon:10088	denotes	mice
T10291	4376-4385	SO_EXT:0000902	denotes	transgene
T10292	4386-4396	GO:0010467	denotes	expression
T10293	4426-4429	CHEBI:50845	denotes	dox
T10294	4450-4455	NCBITaxon:10088	denotes	mouse
T10295	4456-4458	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10296	4543-4548	NCBITaxon:10088	denotes	mouse
T10297	4549-4551	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10298	4570-4575	NCBITaxon:9606	denotes	human
T10299	11033-11036	PR_EXT:000010173	denotes	tau
T10300	4576-4583	CHEBI_SO_EXT:peptide_or_peptide_region	denotes	peptide
T10301	4659-4666	CHEBI_SO_EXT:peptide_or_peptide_region	denotes	peptide
T10303	4722-4729	PR_EXT:000003199	denotes	CaMKIIα
T10304	4750-4754	NCBITaxon:10088	denotes	mice
T10305	4765-4768	CHEBI:50845	denotes	dox
T10306	4801-4808	CHEBI:60425	denotes	amyloid
T10307	4865-4872	SO_EXT:0000704	denotes	genetic
T10308	4900-4916	GO:0034205	denotes	production of Aβ
T10309	4914-4916	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10310	4940-4946	NCBITaxon:9606	denotes	humans
T10311	5094-5097	PR_EXT:000004168	denotes	APP
T10312	5094-5097	_FRAGMENT	denotes	APP
T10313	5101-5110	GO:0042983	denotes	synthetic
T10314	5098-5100	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10315	5098-5110	GO:0034205	denotes	Aβ synthetic
T10316	5220-5222	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10317	5256-5263	CHEBI:60425	denotes	amyloid
T10318	5313-5320	CHEBI:60425	denotes	amyloid
T10319	5333-5338	NCBITaxon:9606	denotes	human
T10320	5339-5344	UBERON:0000955	denotes	brain
T10321	5402-5407	NCBITaxon:10088	denotes	mouse
T10322	5408-5413	UBERON:0000955	denotes	brain
T10323	5428-5433	NCBITaxon:9606	denotes	human
T10324	5434-5439	UBERON:0000955	denotes	brain
T10325	5486-5490	NCBITaxon:10088	denotes	mice
T10326	5546-5553	CHEBI:60425	denotes	amyloid
T10327	5588-5595	CHEBI:60425	denotes	amyloid
T10328	5635-5640	NCBITaxon:9606	denotes	human
T10329	5661-5666	NCBITaxon:10088	denotes	mouse
T10330	5685-5695	CL:0000129	denotes	microglial
T10331	5696-5708	GO:0006909	denotes	phagocytosis
T10332	5719-5728	CL:0000129	denotes	microglia
T10333	5732-5742	SO_EXT:transgenic_entity	denotes	transgenic
T10334	5743-5748	NCBITaxon:10088	denotes	mouse
T10335	5756-5764	GO_PATO_EXT:biological_localization_process_or_quality	denotes	localize
T10336	5768-5774	UBERON:0000479	denotes	tissue
T10337	5823-5830	CHEBI:60425	denotes	amyloid
T10338	5864-5873	CL:0000129	denotes	microglia
T10339	5886-5893	CHEBI:60425	denotes	amyloid
T10340	5905-5910	NCBITaxon:9606	denotes	human
T10341	5911-5916	UBERON:0000955	denotes	brain
T10342	5969-5979	GO:0010467	denotes	expression
T10343	5983-6002	GO_EXT:0004875	denotes	complement receptor
T10344	6027-6036	CL:0000129	denotes	microglia
T10345	6040-6047	CHEBI:60425	denotes	amyloid
T10346	6048-6058	GO:0008152	denotes	metabolism
T10347	6071-6081	SO_EXT:transgenic_entity	denotes	transgenic
T10348	6105-6110	NCBITaxon:9606	denotes	human
T10349	6202-6225	CHEBI_EXT:35472	denotes	anti-inflammatory drugs
T10350	6207-6219	GO_PATO_EXT:inflammatory_process_or_quality	denotes	inflammatory
T10351	6236-6246	CL:0000129	denotes	microglial
T10352	6236-6257	GO:0001774	denotes	microglial activation
T10353	6274-6281	CHEBI:60425	denotes	amyloid
T10354	6290-6293	PR_EXT:000004168	denotes	APP
T10355	6294-6304	SO_EXT:transgenic_entity	denotes	transgenic
T10356	6305-6309	NCBITaxon:10088	denotes	mice
T10357	6333-6338	NCBITaxon:10088	denotes	mouse
T10358	6339-6348	CL:0000129	denotes	microglia
T10359	6385-6392	CHEBI:60425	denotes	amyloid
T10360	6492-6515	CHEBI_EXT:35472	denotes	anti-inflammatory drugs
T10361	6497-6509	GO_PATO_EXT:inflammatory_process_or_quality	denotes	inflammatory
T10362	6519-6530	GO:0070765	denotes	γ-secretase
T10363	6531-6539	MOP:0000780	denotes	cleavage
T10364	6574-6583	CL:0000129	denotes	microglia
T10365	6596-6601	NCBITaxon:9606	denotes	human
T10366	6620-6625	NCBITaxon:10088	denotes	mouse
T10367	6674-6684	CL:0000129	denotes	microglial
T10368	6747-6754	CHEBI:60425	denotes	amyloid
T10369	6772-6778	UBERON:0000955	denotes	brains
T10370	6830-6833	PR_EXT:000004168	denotes	APP
T10371	6834-6838	NCBITaxon:10088	denotes	mice
T10372	6882-6891	CL:0000129	denotes	microglia
T10373	6901-6906	NCBITaxon:10088	denotes	mouse
T10374	6962-6967	CL_GO_EXT:cell	denotes	cells
T10375	6996-7003	CHEBI:60425	denotes	amyloid
T10376	7029-7032	PR_EXT:000004168	denotes	APP
T10377	7033-7037	NCBITaxon:10088	denotes	mice
T10378	7091-7094	CHEBI:50845	denotes	dox
T10379	7146-7155	CL:0000129	denotes	microglia
T10380	7171-7175	NCBITaxon:10088	denotes	mice
T10381	7177-7180	CHEBI:50845	denotes	Dox
T10382	7208-7219	CHEBI:50694	denotes	minocycline
T10383	7232-7254	CHEBI_EXT:35472	denotes	anti-inflammatory drug
T10384	7237-7249	GO_PATO_EXT:inflammatory_process_or_quality	denotes	inflammatory
T10385	7259-7268	CHEBI_EXT:35222	denotes	inhibitor
T10386	7272-7282	CL:0000129	denotes	microglial
T10387	7272-7293	GO:0001774	denotes	microglial activation
T10388	7312-7315	CHEBI:50845	denotes	dox
T10389	7331-7343	GO_PATO_EXT:inflammatory_process_or_quality	denotes	inflammatory
T10390	7397-7416	CHEBI_EXT:67079	denotes	anti-inflammatories
T10392	7469-7472	CHEBI:50845	denotes	dox
T10393	7481-7488	NCBITaxon:33208	denotes	animals
T10394	7548-7551	CHEBI:50845	denotes	dox
T10395	7583-7590	CHEBI:60425	denotes	amyloid
T10396	7646-7656	CL:0000129	denotes	microglial
T10397	7657-7666	GO_EXT:reaction_or_response	denotes	responses
T10398	7692-7697	NCBITaxon:10088	denotes	mouse
T10399	7746-7749	CHEBI:50845	denotes	dox
T10400	7759-7769	CL:0000129	denotes	microglial
T10401	7849-7856	CHEBI:60425	denotes	amyloid
T10402	7921-7923	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10403	7956-7961	NCBITaxon:10088	denotes	mouse
T10404	8003-8005	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10405	8006-8016	GO:0042571	denotes	antibodies
T10406	8044-8049	UBERON:0000955	denotes	brain
T10407	8079-8086	CHEBI:60425	denotes	amyloid
T10408	8153-8161	GO:0042571	denotes	antibody
T10409	8182-8189	CHEBI:60425	denotes	amyloid
T10410	8304-8311	CHEBI:60425	denotes	amyloid
T10411	8413-8423	NCBITaxon:11646	denotes	lentiviral
T10412	8424-8432	GO_EXT:biological_movement_or_translocation_process	denotes	transfer
T10413	8436-8446	PR_EXT:000001898	denotes	neprilysin
T10414	8581-8589	GO:0042571	denotes	antibody
T10415	8628-8647	CL:0002629	denotes	activated microglia
T10416	8770-8778	SO_EXT:sequence_deletion_entity_or_process	denotes	deletion
T10417	8786-8797	GO_EXT:0019763	denotes	Fc receptor
T10418	8811-8819	GO_EXT:0004872	denotes	receptor
T10419	8824-8834	CL:0000129	denotes	microglial
T10420	8851-8859	GO:0042571	denotes	antibody
T10421	8860-8867	CHEBI_EXT:59132	denotes	antigen
T10422	8868-8877	GO:0032991	denotes	complexes
T10423	8882-8885	PR_EXT:000004168	denotes	APP
T10424	8886-8896	SO_EXT:transgenic_entity	denotes	transgenic
T10425	8897-8902	NCBITaxon:10088	denotes	mouse
T10426	8948-8956	GO:0042571	denotes	antibody
T10427	9026-9035	CL:0000129	denotes	microglia
T10428	9026-9046	GO:0001774	denotes	microglia activation
T10429	9143-9156	UBERON:0002405	denotes	immune system
T10430	9225-9233	GO:0042571	denotes	antibody
T10431	9237-9242	NCBITaxon:10239	denotes	viral
T10432	9273-9296	GO:0001774	denotes	activation of microglia
T10433	9287-9296	CL:0000129	denotes	microglia
T10434	9375-9387	GO:0006909	denotes	phagocytosis
T10435	9415-9417	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10436	9442-9452	PR_EXT:000001898	denotes	neprilysin
T10437	9456-9458	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10438	9468-9478	GO:0042571	denotes	antibodies
T10439	9517-9524	CHEBI_SO_EXT:peptide_or_peptide_region	denotes	peptide
T10440	9575-9598	GO:0001774	denotes	activation of microglia
T10441	9589-9598	CL:0000129	denotes	microglia
T10442	9607-9617	SO_EXT:transgenic_entity	denotes	transgenic
T10443	9618-9628	GO:0010467	denotes	expression
T10444	9632-9636	PR_EXT:000000046	denotes	TGFβ
T10445	9666-9684	CHEBI:16412	denotes	lipopolysaccharide
T10446	9745-9748	PR_EXT:000004168	denotes	APP
T10447	9749-9759	SO_EXT:transgenic_entity	denotes	transgenic
T10448	9760-9764	NCBITaxon:10088	denotes	mice
T10449	9791-9799	GO:0042571	denotes	antibody
T10450	9845-9857	GO_PATO_EXT:inflammatory_process_or_quality	denotes	inflammation
T10451	9878-9886	GO:0042571	denotes	antibody
T10452	9891-9896	CHEMINF_GO_EXT:chemical_binding_or_bond_formation	denotes	bound
T10453	9897-9904	CHEBI_SO_EXT:peptide_or_peptide_region	denotes	peptide
T10454	9951-9953	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10455	9979-9986	CHEBI:60425	denotes	amyloid
T10456	10091-10100	CL:0000129	denotes	microglia
T10457	10104-10109	NCBITaxon:10088	denotes	mouse
T10458	10190-10196	NCBITaxon:9606	denotes	humans
T10459	10245-10249	NCBITaxon:10088	denotes	mice
T10460	10255-10262	GO:0010467	denotes	express
T10461	10269-10274	NCBITaxon:9606	denotes	human
T10462	10275-10278	PR_EXT:000010173	denotes	tau
T10463	10293-10299	SO_EXT:0000440	denotes	vector
T10464	10331-10334	PR_EXT:000004168	denotes	APP
T10465	10335-10339	NCBITaxon:10088	denotes	mice
T10466	10369-10372	PR_EXT:000010173	denotes	tau
T10467	10369-10396	GO:0097418	denotes	tau neurofibrillary tangles
T10468	10403-10410	CHEBI:60425	denotes	amyloid
T10469	10458-10467	SO_EXT:0000902	denotes	transgene
T10470	10584-10591	CHEBI_PR_EXT:protein	denotes	protein
T10471	10628-10633	NCBITaxon:10088	denotes	mouse
T10472	10754-10757	CHEBI:50845	denotes	dox
T10473	10767-10776	SO_EXT:0000902	denotes	transgene
T10474	10826-10833	CHEBI_PR_EXT:protein	denotes	protein
T10475	10911-10918	CHEBI_PR_EXT:protein	denotes	protein
T10476	11026-11028	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10477	11082-11089	CHEBI_PR_EXT:protein	denotes	protein
T10478	11122-11128	_FRAGMENT	denotes	intra-
T10479	11138-11146	GO:0005622	denotes	cellular
T10480	11133-11146	GO:0005576	denotes	extracellular
T10481	11138-11146	CL_GO_EXT:cell	denotes	cellular
T10482	11246-11258	_FRAGMENT	denotes	synthesis of
T10483	11263-11265	GO:0034205	denotes	Aβ
T10484	11263-11265	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10485	11291-11300	GO:0050890	denotes	cognitive
T10486	11335-11338	PR_EXT:000010173	denotes	tau
T10487	11339-11343	NCBITaxon:10088	denotes	mice
T10488	11357-11364	CHEBI_PR_EXT:protein	denotes	protein
T10489	11407-11416	GO:0050890	denotes	cognitive
T10490	11439-11448	SO_EXT:0000902	denotes	transgene
T10491	11504-11513	GO:0050890	denotes	cognitive
T10492	11514-11524	GO_PATO_EXT:biological_behavior	denotes	behavioral
T10493	11576-11579	PR_EXT:000004168	denotes	APP
T10494	11580-11584	NCBITaxon:10088	denotes	mice
T10495	11644-11651	CHEBI:60425	denotes	amyloid
T10496	11681-11684	PR_EXT:000004168	denotes	APP
T10497	11685-11689	NCBITaxon:10088	denotes	mice
T10498	11834-11844	SO_EXT:transgenic_entity	denotes	transgenic
T10499	11845-11849	NCBITaxon:10088	denotes	mice
T10500	11886-11894	GO:0036268	denotes	swimming
T10501	11947-11952	CHEBI:15377	denotes	water
T10502	12012-12020	GO:0007612	denotes	learning
T10503	12025-12031	GO:0007613	denotes	memory
T10504	12113-12121	GO_EXT:biological_movement_or_translocation_process	denotes	movement
T10505	12150-12159	GO:0050890	denotes	cognitive
T10506	12160-12170	GO_PATO_EXT:biological_behavior	denotes	behavioral
T10507	12258-12268	GO:0010467	denotes	expression
T10508	12306-12317	GO:0006508	denotes	proteolytic
T10509	12407-12410	CHEBI:50845	denotes	dox
T10510	12418-12422	NCBITaxon:10088	denotes	mice
T10511	12573-12583	SO_EXT:transgenic_entity	denotes	transgenic
T10512	12584-12587	PR_EXT:000004168	denotes	APP
T10513	12584-12597	GO:0042983	denotes	APP synthesis
T10514	12699-12707	CL:0000540	denotes	neuronal
T10515	12727-12736	SO_EXT:0000902	denotes	transgene
T10516	12737-12747	GO:0010467	denotes	expression
T10517	12765-12770	GO:0007567	denotes	natal
T10518	12902-12904	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10519	12902-12915	GO:0034205	denotes	Aβ production
T10520	12965-12975	SO_EXT:transgenic_entity	denotes	transgenic
T10521	12976-12981	NCBITaxon:10088	denotes	mouse
T10522	13059-13061	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10523	13059-13071	GO:0034205	denotes	Aβ synthesis
T10524	13073-13081	GO:0043005	denotes	neuritic
T10525	13210-13212	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10526	13210-13223	GO:0034205	denotes	Aβ production
T10527	13234-13236	CHEBI_PR_EXT:amyloid_beta	denotes	Aβ
T10528	13262-13274	GO:0006909	denotes	phagocytosis
T10529	13288-13295	CHEBI:60425	denotes	amyloid
T10530	13419-13429	CHEBI_EXT:35222	denotes	inhibitors
T10531	13512-13519	CHEBI:60425	denotes	amyloid
T10532	13597-13607	CL:0000129	denotes	microglial
T10533	13597-13618	GO:0001774	denotes	microglial activation
T10534	13622-13627	NCBITaxon:9606	denotes	human
T10535	13686-13693	CHEBI:60425	denotes	amyloid
T10536	13721-13733	GO:0006909	denotes	phagocytosis
T10537	13824-13834	CHEBI_EXT:35222	denotes	inhibitors
T10538	13888-13893	NCBITaxon:9606	denotes	human
T10539	13894-13899	UBERON:0000955	denotes	brain
T10540	13927-13934	CHEBI:60425	denotes	amyloid
T10302	4700-4707	CHEBI:60425	denotes	amyloid
T10391	7454-7461	CHEBI:60425	denotes	amyloid
R6983	T10313	T10312	_lexicallyChainedTo	synthetic,APP
R6984	T10479	T10478	_lexicallyChainedTo	cellular,intra-
R6985	T10483	T10482	_lexicallyChainedTo	Aβ,synthesis of

craft-ca-core-dev

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id	Subject	Object	Predicate	Lexical cue
T9940	28-33	NCBITaxon:10088	denotes	mouse
T9941	104-117	GO:0034205	denotes	Aβ production
T9942	137-144	CHEBI:60425	denotes	amyloid
T9943	180-184	NCBITaxon:10088	denotes	mice
T9944	220-227	GO:0010467	denotes	express
T9945	264-271	GO:0065007	denotes	control
T9946	277-289	CHEBI:27902	denotes	tetracycline
T9947	301-309	SO:0000167	denotes	promoter
T9948	346-349	CHEBI:50845	denotes	dox
T9949	520-530	GO:0010467	denotes	expression
T9950	601-608	CHEBI:60425	denotes	amyloid
T9951	633-637	NCBITaxon:10088	denotes	mice
T9952	689-696	CHEBI:60425	denotes	Amyloid
T9953	769-775	UBERON:0001851	denotes	cortex
T9954	789-793	NCBITaxon:10088	denotes	mice
T9955	877-880	PR:000004168	denotes	APP
T9956	932-939	CHEBI:60425	denotes	amyloid
T9957	987-994	NCBITaxon:33208	denotes	animals
T9958	1026-1033	CHEBI:60425	denotes	amyloid
T9959	1132-1142	CHEBI:35222	denotes	inhibitors
T9960	1216-1223	CHEBI:60425	denotes	amyloid
T9961	1250-1259	SO:0000902	denotes	transgene
T9962	1423-1433	PR:000008840	denotes	huntingtin
T9963	1493-1506	GO:0005576	denotes	extracellular
T9964	1507-1514	CHEBI:60425	denotes	amyloid
T9965	1544-1558	CHEBI:52217	denotes	pharmaceutical
T9966	1559-1570	GO:0070765	denotes	γ-secretase
T9967	1571-1581	CHEBI:35222	denotes	inhibitors
T9968	1617-1644	GO:1902003	denotes	regulation of Aβ production
T9969	1722-1731	CHEBI:36357	denotes	compounds
T9970	1782-1786	NCBITaxon:10088	denotes	mice
T9971	1964-1967	PR:000004168	denotes	APP
T9972	1968-1978	GO:0010467	denotes	expression
T9973	1993-1997	NCBITaxon:10088	denotes	mice
T9974	2084-2097	GO:0034205	denotes	Aβ production
T9975	2164-2175	GO:0070765	denotes	γ-secretase
T9976	2176-2186	CHEBI:35222	denotes	inhibitors
T9977	2224-2245	CHEBI:52217	denotes	pharmaceutical agents
T9978	2283-2307	GO:1902003	denotes	control of Aβ production
T9979	2409-2418	CHEBI:36357	denotes	compounds
T9980	2448-2455	CHEBI:60425	denotes	amyloid
T9981	2534-2541	CHEBI:60425	denotes	amyloid
T9982	2585-2594	SO:0000902	denotes	transgene
T9983	2638-2645	NCBITaxon:33208	denotes	animals
T9984	2661-2664	CHEBI:50845	denotes	dox
T9985	2718-2725	CHEBI:60425	denotes	amyloid
T9986	2863-2870	NCBITaxon:33208	denotes	animals
T9987	2884-2887	CHEBI:50845	denotes	dox
T9988	3133-3146	GO:0034205	denotes	Aβ production
T9989	3210-3217	CHEBI:60425	denotes	amyloid
T9990	3261-3270	UBERON:0000104	denotes	life span
T9991	3340-3346	NCBITaxon:9606	denotes	humans
T9992	3415-3424	UBERON:0000104	denotes	life span
T9993	3428-3434	NCBITaxon:9989	denotes	rodent
T9994	3636-3652	GO:0034205	denotes	production of Aβ
T9995	3708-3711	PR:000004168	denotes	APP
T9996	3712-3722	GO:0010467	denotes	expression
T9997	3821-3828	CHEBI:60425	denotes	amyloid
T9998	3926-3930	NCBITaxon:10088	denotes	mice
T9999	3943-3946	PR:000004168	denotes	APP
T10000	4133-4138	NCBITaxon:9606	denotes	human
T10001	4221-4225	NCBITaxon:10088	denotes	mice
T10002	4376-4385	SO:0000902	denotes	transgene
T10003	4386-4396	GO:0010467	denotes	expression
T10004	4426-4429	CHEBI:50845	denotes	dox
T10005	4450-4455	NCBITaxon:10088	denotes	mouse
T10006	4543-4548	NCBITaxon:10088	denotes	mouse
T10007	4570-4575	NCBITaxon:9606	denotes	human
T10008	4700-4707	CHEBI:60425	denotes	amyloid
T10009	4722-4729	PR:000003199	denotes	CaMKIIα
T10010	4750-4754	NCBITaxon:10088	denotes	mice
T10011	4765-4768	CHEBI:50845	denotes	dox
T10012	4801-4808	CHEBI:60425	denotes	amyloid
T10013	4865-4872	SO:0000704	denotes	genetic
T10014	4900-4916	GO:0034205	denotes	production of Aβ
T10015	4940-4946	NCBITaxon:9606	denotes	humans
T10016	5094-5097	PR:000004168	denotes	APP
T10017	5094-5097	_FRAGMENT	denotes	APP
T10018	5101-5110	GO:0042983	denotes	synthetic
T10019	5098-5110	GO:0034205	denotes	Aβ synthetic
T10020	5256-5263	CHEBI:60425	denotes	amyloid
T10021	5313-5320	CHEBI:60425	denotes	amyloid
T10022	5333-5338	NCBITaxon:9606	denotes	human
T10023	5339-5344	UBERON:0000955	denotes	brain
T10024	5402-5407	NCBITaxon:10088	denotes	mouse
T10025	5408-5413	UBERON:0000955	denotes	brain
T10026	5428-5433	NCBITaxon:9606	denotes	human
T10027	5434-5439	UBERON:0000955	denotes	brain
T10028	5486-5490	NCBITaxon:10088	denotes	mice
T10029	5546-5553	CHEBI:60425	denotes	amyloid
T10030	5588-5595	CHEBI:60425	denotes	amyloid
T10031	5635-5640	NCBITaxon:9606	denotes	human
T10032	5661-5666	NCBITaxon:10088	denotes	mouse
T10033	5685-5695	CL:0000129	denotes	microglial
T10034	5696-5708	GO:0006909	denotes	phagocytosis
T10035	5719-5728	CL:0000129	denotes	microglia
T10036	5743-5748	NCBITaxon:10088	denotes	mouse
T10037	5768-5774	UBERON:0000479	denotes	tissue
T10038	5823-5830	CHEBI:60425	denotes	amyloid
T10039	5864-5873	CL:0000129	denotes	microglia
T10040	5886-5893	CHEBI:60425	denotes	amyloid
T10041	5905-5910	NCBITaxon:9606	denotes	human
T10042	5911-5916	UBERON:0000955	denotes	brain
T10043	5969-5979	GO:0010467	denotes	expression
T10044	6027-6036	CL:0000129	denotes	microglia
T10045	6040-6047	CHEBI:60425	denotes	amyloid
T10046	6048-6058	GO:0008152	denotes	metabolism
T10047	6105-6110	NCBITaxon:9606	denotes	human
T10048	6202-6225	CHEBI:35472	denotes	anti-inflammatory drugs
T10049	6236-6246	CL:0000129	denotes	microglial
T10050	6236-6257	GO:0001774	denotes	microglial activation
T10051	6274-6281	CHEBI:60425	denotes	amyloid
T10052	6290-6293	PR:000004168	denotes	APP
T10053	6305-6309	NCBITaxon:10088	denotes	mice
T10054	6333-6338	NCBITaxon:10088	denotes	mouse
T10055	6339-6348	CL:0000129	denotes	microglia
T10056	6385-6392	CHEBI:60425	denotes	amyloid
T10057	6492-6515	CHEBI:35472	denotes	anti-inflammatory drugs
T10058	6519-6530	GO:0070765	denotes	γ-secretase
T10059	6531-6539	MOP:0000780	denotes	cleavage
T10060	6574-6583	CL:0000129	denotes	microglia
T10061	6596-6601	NCBITaxon:9606	denotes	human
T10062	6620-6625	NCBITaxon:10088	denotes	mouse
T10063	6674-6684	CL:0000129	denotes	microglial
T10064	6747-6754	CHEBI:60425	denotes	amyloid
T10065	6772-6778	UBERON:0000955	denotes	brains
T10066	6830-6833	PR:000004168	denotes	APP
T10067	6834-6838	NCBITaxon:10088	denotes	mice
T10068	6882-6891	CL:0000129	denotes	microglia
T10069	6901-6906	NCBITaxon:10088	denotes	mouse
T10070	6996-7003	CHEBI:60425	denotes	amyloid
T10071	7029-7032	PR:000004168	denotes	APP
T10072	7033-7037	NCBITaxon:10088	denotes	mice
T10073	7091-7094	CHEBI:50845	denotes	dox
T10074	7146-7155	CL:0000129	denotes	microglia
T10075	7171-7175	NCBITaxon:10088	denotes	mice
T10076	7177-7180	CHEBI:50845	denotes	Dox
T10077	7208-7219	CHEBI:50694	denotes	minocycline
T10078	7232-7254	CHEBI:35472	denotes	anti-inflammatory drug
T10079	7259-7268	CHEBI:35222	denotes	inhibitor
T10080	7272-7282	CL:0000129	denotes	microglial
T10081	7272-7293	GO:0001774	denotes	microglial activation
T10082	7312-7315	CHEBI:50845	denotes	dox
T10083	7397-7416	CHEBI:67079	denotes	anti-inflammatories
T10084	7454-7461	CHEBI:60425	denotes	amyloid
T10085	7469-7472	CHEBI:50845	denotes	dox
T10086	7481-7488	NCBITaxon:33208	denotes	animals
T10087	7548-7551	CHEBI:50845	denotes	dox
T10088	7583-7590	CHEBI:60425	denotes	amyloid
T10089	7646-7656	CL:0000129	denotes	microglial
T10090	7692-7697	NCBITaxon:10088	denotes	mouse
T10091	7746-7749	CHEBI:50845	denotes	dox
T10092	7759-7769	CL:0000129	denotes	microglial
T10093	7849-7856	CHEBI:60425	denotes	amyloid
T10094	7956-7961	NCBITaxon:10088	denotes	mouse
T10095	8006-8016	GO:0042571	denotes	antibodies
T10096	8044-8049	UBERON:0000955	denotes	brain
T10097	8079-8086	CHEBI:60425	denotes	amyloid
T10098	8153-8161	GO:0042571	denotes	antibody
T10099	8182-8189	CHEBI:60425	denotes	amyloid
T10100	8304-8311	CHEBI:60425	denotes	amyloid
T10101	8413-8423	NCBITaxon:11646	denotes	lentiviral
T10102	8436-8446	PR:000001898	denotes	neprilysin
T10103	8581-8589	GO:0042571	denotes	antibody
T10104	8628-8647	CL:0002629	denotes	activated microglia
T10105	8824-8834	CL:0000129	denotes	microglial
T10106	8851-8859	GO:0042571	denotes	antibody
T10107	8860-8867	CHEBI:59132	denotes	antigen
T10108	8868-8877	GO:0032991	denotes	complexes
T10109	8882-8885	PR:000004168	denotes	APP
T10110	8897-8902	NCBITaxon:10088	denotes	mouse
T10111	8948-8956	GO:0042571	denotes	antibody
T10112	9026-9035	CL:0000129	denotes	microglia
T10113	9026-9046	GO:0001774	denotes	microglia activation
T10114	9143-9156	UBERON:0002405	denotes	immune system
T10115	9225-9233	GO:0042571	denotes	antibody
T10116	9237-9242	NCBITaxon:10239	denotes	viral
T10117	9273-9296	GO:0001774	denotes	activation of microglia
T10118	9287-9296	CL:0000129	denotes	microglia
T10119	9375-9387	GO:0006909	denotes	phagocytosis
T10120	9442-9452	PR:000001898	denotes	neprilysin
T10121	9468-9478	GO:0042571	denotes	antibodies
T10122	9575-9598	GO:0001774	denotes	activation of microglia
T10123	9589-9598	CL:0000129	denotes	microglia
T10124	9618-9628	GO:0010467	denotes	expression
T10125	9632-9636	PR:000000046	denotes	TGFβ
T10126	9666-9684	CHEBI:16412	denotes	lipopolysaccharide
T10127	9745-9748	PR:000004168	denotes	APP
T10128	9760-9764	NCBITaxon:10088	denotes	mice
T10129	9791-9799	GO:0042571	denotes	antibody
T10130	9878-9886	GO:0042571	denotes	antibody
T10131	9979-9986	CHEBI:60425	denotes	amyloid
T10132	10091-10100	CL:0000129	denotes	microglia
T10133	10104-10109	NCBITaxon:10088	denotes	mouse
T10134	10190-10196	NCBITaxon:9606	denotes	humans
T10135	10245-10249	NCBITaxon:10088	denotes	mice
T10136	10255-10262	GO:0010467	denotes	express
T10137	10269-10274	NCBITaxon:9606	denotes	human
T10138	10275-10278	PR:000010173	denotes	tau
T10139	10293-10299	SO:0000440	denotes	vector
T10140	10331-10334	PR:000004168	denotes	APP
T10141	10335-10339	NCBITaxon:10088	denotes	mice
T10142	10369-10372	PR:000010173	denotes	tau
T10143	10369-10396	GO:0097418	denotes	tau neurofibrillary tangles
T10144	10403-10410	CHEBI:60425	denotes	amyloid
T10145	10458-10467	SO:0000902	denotes	transgene
T10146	10628-10633	NCBITaxon:10088	denotes	mouse
T10147	10754-10757	CHEBI:50845	denotes	dox
T10148	10767-10776	SO:0000902	denotes	transgene
T10149	11033-11036	PR:000010173	denotes	tau
T10150	11122-11128	_FRAGMENT	denotes	intra-
T10151	11138-11146	GO:0005622	denotes	cellular
T10152	11133-11146	GO:0005576	denotes	extracellular
T10153	11246-11258	_FRAGMENT	denotes	synthesis of
T10154	11263-11265	GO:0034205	denotes	Aβ
T10155	11291-11300	GO:0050890	denotes	cognitive
T10156	11335-11338	PR:000010173	denotes	tau
T10157	11339-11343	NCBITaxon:10088	denotes	mice
T10158	11407-11416	GO:0050890	denotes	cognitive
T10159	11439-11448	SO:0000902	denotes	transgene
T10160	11504-11513	GO:0050890	denotes	cognitive
T10161	11576-11579	PR:000004168	denotes	APP
T10162	11580-11584	NCBITaxon:10088	denotes	mice
T10163	11644-11651	CHEBI:60425	denotes	amyloid
T10164	11681-11684	PR:000004168	denotes	APP
T10165	11685-11689	NCBITaxon:10088	denotes	mice
T10166	11845-11849	NCBITaxon:10088	denotes	mice
T10167	11886-11894	GO:0036268	denotes	swimming
T10168	11947-11952	CHEBI:15377	denotes	water
T10169	12012-12020	GO:0007612	denotes	learning
T10170	12025-12031	GO:0007613	denotes	memory
T10171	12150-12159	GO:0050890	denotes	cognitive
T10172	12258-12268	GO:0010467	denotes	expression
T10173	12306-12317	GO:0006508	denotes	proteolytic
T10174	12407-12410	CHEBI:50845	denotes	dox
T10175	12418-12422	NCBITaxon:10088	denotes	mice
T10176	12584-12587	PR:000004168	denotes	APP
T10177	12584-12597	GO:0042983	denotes	APP synthesis
T10178	12699-12707	CL:0000540	denotes	neuronal
T10179	12727-12736	SO:0000902	denotes	transgene
T10180	12737-12747	GO:0010467	denotes	expression
T10181	12765-12770	GO:0007567	denotes	natal
T10182	12902-12915	GO:0034205	denotes	Aβ production
T10183	12976-12981	NCBITaxon:10088	denotes	mouse
T10184	13059-13071	GO:0034205	denotes	Aβ synthesis
T10185	13073-13081	GO:0043005	denotes	neuritic
T10186	13210-13223	GO:0034205	denotes	Aβ production
T10187	13262-13274	GO:0006909	denotes	phagocytosis
T10188	13288-13295	CHEBI:60425	denotes	amyloid
T10189	13419-13429	CHEBI:35222	denotes	inhibitors
T10190	13512-13519	CHEBI:60425	denotes	amyloid
T10191	13597-13607	CL:0000129	denotes	microglial
T10192	13597-13618	GO:0001774	denotes	microglial activation
T10193	13622-13627	NCBITaxon:9606	denotes	human
T10194	13686-13693	CHEBI:60425	denotes	amyloid
T10195	13721-13733	GO:0006909	denotes	phagocytosis
T10196	13824-13834	CHEBI:35222	denotes	inhibitors
T10197	13888-13893	NCBITaxon:9606	denotes	human
T10198	13894-13899	UBERON:0000955	denotes	brain
T10199	13927-13934	CHEBI:60425	denotes	amyloid
R6980	T10018	T10017	_lexicallyChainedTo	synthetic,APP
R6981	T10151	T10150	_lexicallyChainedTo	cellular,intra-
R6982	T10154	T10153	_lexicallyChainedTo	Aβ,synthesis of

PMC:1283364 / 48153-62158 JSONTXT

Annnotations TAB JSON ListView MergeView

craft-sa-dev

2_test

craft-ca-core-ex-dev

craft-ca-core-dev

PMC:1283364 / 48153-62158 JSON TXT